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Abstract 
Background . 
Falls in older people result in harm for individuals and are a major public 
health problem, but there is little published data on the recording and 
incidence of falls seen in primary care, with which to consider the implications 
of recent policy initiatives. A range of factors contribute to falls risk. 
Amongst these, the role of some medications is well established, but the 
evidence base regarding the effects of some of the most commonly 
prescribed medications remains meagre and inconsistent. 
Aims 
The project aims to quantify the overall incidence and distribution of recorded 
falls among older people in primary care in the UK, and the associated risk of 
death. The falls risk profile of more recently introduced serotonin 
noradrenalin reuptake inhibitors (SNRls) is explored to assess whether it is 
more favourable than that of selective serotonin reuptake inhibitors (SSRls). 
Similarly, prescribing of subclasses of antihypertensive medication is 
explored to establish whether any of them modify risk of falling. Finally, other 
classes or sub-classes of medication prescribed in primary care are identified 
whose apparent falls risk warrants further investigation. 
Methods 
Analysis of falls and prescribing history in the electronic records of patients 
aged 60 years and over from The Health Improvement Network (THIN) using 
cohort, survival, case-control and case series study designs. 
Results 
Amongst people aged >60 years the overall crude incidence rate of recorded 
falls was 3.58/100 person-years (3.56-3.61), higher in older age groups, in 
women and least advantaged social groups, and was constant in the period 
2003-2006. Fallers experienced a substantial increase in mortality (two-fold 
increase for recurrent fallers, and more than five-fold for those aged 60-74 
years). This increase is independent of fractures recorded at the time of the 
fall or subsequently. People who fall have an increased rate of subsequent 
fracture (approximately three-fold and, for recurrent fallers aged 60-74 years 
more than eight-fold). 
There was an increased risk of current prescribing of SNRls (adjusted OR 
1.79, 1.42 - 2.25) in first fall cases compared with controls. This was similar 
in magnitude to that seen with tricyclic antidepressants and SSRls. The 
increase in risk was apparent within the first 28 days after first prescription. 
The effects were also apparent in the self-controlled case series analysis: the 
incidence risk ratio for the period 1-28 days after initiation of treatment 
compared with unexposed periods was 1.49 (1.15 - 1.93) . 
. 
There was an increased risk of current prescribing of thiazides (adjusted OR 
1.28, 1.16-1.42). At 3 weeks after first prescribing the adjusted risk remained 
4.28 (1.19-15.42). In the case series analysis the incidence risk ratio for the 
period 21 days after first prescription was 2.80 (1.7 - 4.57). We found a 
reduced risk for current prescribing of beta blockers (adjusted OR 0.90; 0.85-
0.96), but a weakly positive effect in the case series analysis for the 
corresponding period IRR 1.23 (1.02-1.48). 
Taken together, the case-control and case series analyses of other 
subclasses of antihypertensives provided weak or no evidence for an effect 
on falls. 
In the hypothesis generating case-control analysis of other medication 
classes, unadjusted odds ratios of greater than 1.7 were found in a number 
of classes of medication including: laxatives, antifungals, corticosteroids, 
insulin, antibiotics for mild to moderate acne, and vaccines for influenza and 
other infections. 
ii 
Conclusions 
Older people with a recorded fall represent a group who are at increased risk 
of death, irrespective of whether they have a subsequent fracture. 
Nevertheless the incidence of falls recorded in primary care suggests that 
guidance about asking patients if they have fallen in the last year appears not 
to have been followed during the study period. The fact that the incidence 
rate of falls is strongly associated with social disadvantage suggests the 
need to target the design and delivery of interventions accordingly. 
The falls risk profile of SNRls, which is similar to that of SSRls and TCAs, 
suggests that clinicians initiating prescribing of SNRls should be alert to the 
. 
increased risk of falls. 
Similarly, clinicians initiating prescribing of thiazides in older people, which 
has generally been considered a 'safe' option for older patients, should be 
alert to the possibility of an increased risk of falls in the first three weeks of 
prescribing. 
Case series analysis of recurrent periodic exposures can elucidate bias in 
classis case-control analysis of the same data, and will be useful in 
assessing the falls risk profile of other medications such as insulin. 
Given the small size of sources of detailed data about older people who fall 
and the imprecision in their measurement of exposure to medications and 
potential confounders, case-control and case series analysis of first falls in 
THIN represents a valuable source of new evidence about medication risk 
factors. 
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1 Introduction 
Falls represent a major public health problem and the leading cause of injury-
related hospitalisation in older people, with significant consequences for the 
individual, carers and wider society. For countries like the United Kingdom 
whose populations are ageing, its scale is set to increase. 
In this first chapter, some key definitions relating to the study of falls are 
outlined to provide a frame of reference within which to consider evidence of 
causation. The chapter goes on to set out what is known from the 
literatureaabout: the measurement, incidence and consequences of falls 
amongst cOmmunity dwelling older people, the evidence of an association 
with various medications with particular reference to commonly prescribed 
cardiovascular and central acting medications, and contemporary . 
approaches to the management of falls in the UK. It will highlight that: 
• There is little published data on the recording and incidence of falls 
seen in primary care, with which to consider the implications of recent 
policy initiatives which envisage an important role for general 
practitioners and primary care within the care pathway for the 
prevention and treatment of falls 
• The evidence base for the effect on falls in older people of some of the 
most commonly prescribed medications, including antihypertensive 
medications, is meagre and inconsistent 
• There is a gap in the evidence concerning SNRls, which some have 
suggested may be safer than SSRls 
Against this background, the chapter sets out the specific aims and 
objectives of the study, and the approval and funding secured. The chapter 
closes by mapping out the structure and flow of the thesis. 
a The search criteria for the literature review are set out in Appendix A 
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1.1 Definitions 
1.1.1 Falls and recurrent falls 
The World Health Organisation (WHO) defines a fall as "an event which 
results in a person coming to rest inadvertently on the ground or floor or other 
lower level" and specifically excludes falls from animals, burning buildings 
and transport vehicles, and falls into fire, water and machinery 1• This WHO 
definition closely follows the consensus definition developed in 2005 by 
collaborators in the Prevention of Falls Network Europe (ProFaNE)2. These 
definitions are considered to be appropriate for studies addressing a broad 
range of risk factors for falls, including cardiovascular and neurological 
causes3. Other definitions appearing in the literature include that developed 
by the Kellogg International Working Group on the Prevention of Falls in the 
Elderly, which specifically excludes events which are the consequence of 
"sustaining a violent blow, loss of consciousness, sudden onset of paralysis 
as in stroke or epileptic seizure,,4. 
These standards all define a fall in terms of an event which is the result of 
some other environmental or clinical factor. However, Grimley Evans5 
undertook secondary analysis of data frorn a contemporary falls study which 
demonstrated support for the hypothesis that people who fall comprise two 
distinct subgroups: one of people who are susceptible to falling (by virtue of 
exposure to a risk factor), and one of people whose fall can be more properly 
described a random event. On this basis, it is contested that there are some 
people who fall for whom it may be inaccurate (or at least premature) to 
consider the event as a symptom. 
Amongst people who fall morethan once, Grimley Evans found that the 
Proportion whose fall event is a random event is much lower5• For this 
reason, a number of studies have been designed to measure recurrent rather 
than single falls events. More commonly now, a fall event is regarded as a 
product of risk factors and precipitating factors. This conceptualisation is set 
out in 1.2. 
2 
Definitions of recurrence vary, but many consider a second or subsequent fall 
within a 12 month period to be a recurrent event. Related to this is the 
consideration given by Cummings et al6 to whether the relevant outcome 
measure in falls studies should be the instantaneous occurrence of a fall 
event (initial or recurrent), or the state of being a faller. 
In some studies, the definition of fall is not specified. In many, including 
those based on routine data from surveillance and healthcare systems, the 
definition reflects whatever categories are available to those entering 
information to the source system (and the quality and consistency of the 
coding they apply). 
1.1.2 Older person 
The age at which studies consider an individual to be an 'older person' also 
varies. Many studies focus on falls subsequent to the date or year in which 
the subject is aged 65 years. Several studies of older people set a lower age 
threshold of 60 years and a few even lower than this. A number of studies 
stratify older people further into subgroups denoting the 'oldest old'. Reliable 
interpretation of such studies should take account of the subjectivity involved 
in applying these categories to the age of participants, which is a continuous 
(not categorical) variable. 
1.2 Frame of reference for considering causation 
Subsequent sections of this chapter will set out the evidence for the causal 
relationship between falls and medications. This is best considered within a 
wider frame of reference which identifies falls as the result of an interaction 
between a potential challenge to an individual's stability and their ability to 
mount an integrated reflex response to visual, vestibular and proprioceptive 
information7. This ability can be conceptualised as a "balance system". 
Ageing is associated with a degradation of the components of this system, 
which may render individuals progressively more susceptible to challenges to 
their stability. The system may allow an individual to compensate to some 
degree for a single deficit, but will become progressively more vulnerable to 
3 
multiple deficits. It is in the context of this complex system and the wide 
range of age-related and other factors impacting its performance that 
evidence about the aetiology of falls must be considered. 
1.3 Design and methodology of studies measuring falls 
1.3.1 Objectives and scope of studies in which the occurrence of 
falls is measured 
In the three decades since Gryfe et al8 published the first prospective study 
of falls based on standardised reporting and fOllow-up, there have been more 
than a hundred studies reporting the occurrence of falls as a primary 
" outcome measure. 
Many of these were trials and reviews910 of the relative effectiveness of 
interventions, their significance to this review being the rates of occurrence 
they report in their control arms. Some of these trials were larger scale and 
were located in community settings 11, but most were based on small 
numbers, were located in institutionalised settings 12, or focused on subjects 
unlikely to be representative of the older population in general13. 
A smaller number of studies were designed with the primary objective of 
measuring the occurrence of falls or their risk factors in a population. Again, 
many of these studies were small-scale 14-29, or they studied settings or 
subjects unlikely to be representative of the general popuiation2330-44 
(because their focus was the institutionalised elderly or those attending a 
healthcare setting for reasons unrelated to their fall, for example). 
Other studies focused on a subset of falls, e.g. those resulting in various 
degrees of injury45-49 or hospitalisation50-62. Some studies based on 
surveillance or survey data focused on accidental injury in general (and often 
in all ages), of which injury attributed to falls or falls in older people is only 
one part4963-70. 
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1.3.2 Different approaches to detecting falls 
Studies in the literature employ different approaches to detecting falls 
according to their design and logistical constraints. More recent studies have 
used prospective designs, employing self-completed questionnaires or 
interviews at regular intervals. The standard recommended by ProFaNE 
collaborators is prospective daily recording of fall events, with notification at 
least once a month backed up by telephone interviewing to secure missing 
retums2 . Key constraints in this approach are the expense involved in 
securing daily recording from sufficient participants to achieve the necessary 
statistical power, and difficulties amongst participants who may have 
impaired rt§call. Currently, sensor technologies remain insufficiently 
developed to offer a reliable, practicable, non-intrusive means of measuring 
falls.71 
In observational studies the occurrence of fall events is generally self-
reported using some kind of questionnaire, which means the measurements 
may be affected by recall bias. Cummings et al found that amongst their 304 
participants aged 60 years or over between 13-32% of prospectively 
recorded falls were not recalled subsequently. Rates of recall were lower for 
participants with lower score on the mini Mental State Examination72. In this 
sample, recall at 12 months was better than at 3 or 6 months, and was not 
associated with the actual number of fall events. One study in an Australian 
intermediate care setting found that systematic recording of falls by nurses 
increased the number of falls reported by one third 73. 
Recognising the problems of recall bias and the expense of securing daily 
recording, Lachenbruch et al sought to quantify the role of recall bias in the 
under-reporting of falls, and proposed an approach to adjust for it using 
proportional hazards modelling74. Several studies75-77 have investigated the 
e x t ~ n t t to which different follow-up intervals optimise the level of recall 
amongst elderly participants, and the extent to which a "better" estimate of 
actual falls can be derived by compensating for length of recall78• 
Nevertheless, these approaches remain dependent on inferences made from 
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a subset or comparator for whom prospectively collected falls data is 
available. Furthermore, there may be other factors related to recall and 
reporting which need to be compensated for (e.g. socio-economic status and 
health beliefs in different groups: "only old people fall - I'm not 0Id,,74) for 
which it is problematic to collate data for a subset large enough to support 
valid inferences. 
Other studies detect fall events resulting in healthcare activity, e.g. 
admissions or attendances. Such measures are variable in terms of their 
completeness (e.g. not all falls result in attendance) or consistency 
(thresholds-for admission may vary between institutions and over time, 
independently of any underlying variation in incidence). 
1.3.3 Measures of occurrence of fall 
A variety of measures are used to quantify the occurrence of falls. 
Population studies generally measure occurrence of falls in terms of 
incidence and incidence rate. Some studies report these rates as a crude 
rate, but usually it is age- or age-sex specific. In a number of studies, 
Occurrence is stated in terms of a proportion who experience a fall or, to be 
precise, who have experienced a fall during a defined period (usually one 
year)79. In studies based in institutional settings, the denominator for the rate 
may be given in terms of bed-time, e.g. fall events per bed-month. 
1.3.4 Differences in setting 
Most studies reporting the occurrence of falls are set outside of the UK. 
Many of them are set in the industrialised economies of Western Europe, 
North America, Australia and the wealthier parts of Asia. The literature also 
comprises studies based in countries with diverse economies or less 
developed healthcare infrastructures including Egypt, Iran, Pakistan, 
Thailand, China, Latin America and the Caribbean. The validity of 
generalisations from these countries to the UK depends, in part, on the 
degree of similarity in contextual factors, including health and social care 
arrangements, climate, and culture as well as more obvious differences in the 
respective demographics of study part,cipants. 
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1.3.5 Summary of the strength of evidence 
In summary, the data on the occurrence of falls in community dwelling older 
people in the UK is sparse. It is derived from surveys of self-reported falls 14 
79-81, small-scale studies1718, or relates to institutional4o and acute healthcare 
settings57 58. It is supplemented by a more substantial body of literature 
relating to other countries. 
1.4 What is known about the incidence of falls in older 
people 
1.4.1 Development of the literature 
Current knowledge about the epidemiology of falls in older people builds on a 
body of literature that dates back to the middle of the last century. Although 
falls in older people were recognised as a frequent occurrence and as a 
cause of significant morbidity, research into falls had been, prior to 1977, 
restricted to a few studies of falls resulting in serious injury (for example,82-85). 
Gryfe et al claimed that their five year longitudinal study of older people living 
in an institutionalised setting8 was the first prospective study of falls of any 
severity, with standardised reporting and follow-up. Since the late 1970s, 
retrospective and prospective studies have reported the incidence of falls in a 
range of settings and populations. Increasingly over time, publications 
reporting incidence of falls have been based on intervention studies, as 
opposed to observational studies of basic epidemiology. 
1.4.2 Overall occurrence in populations 
Findings from studies of the annual prevalence rate of falls in older people in 
the UK vary from 15% to over 40%. For example, amongst people aged 65 
years or over, the Health Survey for England 2005 found that 23% of men 
and 29% of women recalled having fallen one or more times in the previous 
12 months81 . Amongst the 2793 respondents aged over 65 years in an early 
community-based study in the UK, the annual prevalence rate of one or more 
falls was 28%79. Amongst 1042 older people surveyed by Blake et al80 there 
was an annual prevalence rate of 34%. A smaller study in Manchester of 
203 people aged over 75 years found that 42% had suffered at least one fall 
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in the previous 12 months 17. Amongst 100 self-selected participants in 
Birmingham aged over 65 years, 15% had sustained at least one fall in the 
previous year18. A longitudinal study of older people in Nottingham found 
that 26.5% had experienced one or more falls in the previous year14 (N.B. the 
overall incidence described in the abstract for this paper includes recurrent 
falls). 
Almost all of the studies in various urban and rural, institutionalised and non-
institutionalised settings across all continents reported findings across a 
similar range to studies in UK settings. A number of studies in Japanese 1686-
89, other Asian settings90-93 and one Spanish studl4 report prevalence rates 
towards the lower end of this range (Le. rates ranging from 14-20%). 
A few studies also report rates for recurrent falls. A longitudinal study of 1517 
ambulatory older people in Hong Kong found an overall annual prevalence of 
recurrent falling of 5% (compared to 19% for once-only fallers) 91 92. A survey 
of 921 older people in Switzerland found that 10% had fallen more than once 
in the previous year (compared to 17% for once-only fallers)95. A Finnish 
longitudinal study of 1159 people aged 70 years or over found that 11 % fell 
more than once (compared to 30% who fell once-only)96. In an Australian 
study of 704 community dwelling women aged 65 years or over97, 20% were 
found to have fallen once in the previous year and a further 14% to have 
fallen on two or more occasions. 
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Figure 1-1 Chart showing how proportion of older people reporting a fall increases 
with age 
Percentages with at least one fall in last 12 months, 
by age and sex 
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1.4.3 Variations in occurrence by sex and age 
There is consistent evidence from most studies in the UK7980 and other 
countries that the rate of incidence of falls among women is higher than in 
men (see Figure 1-1 for example). With very few exceptions816 20, the 
literature also shows an increase in the incidence rate of falls or fall-related 
injuries with increasing age, until the very oldest age groups amongst whom 
incidence rates are constant. There is consistent evidence that this age-
related increase in incidence is steeper amongst men7980. In England, rates 
of self-reported falls amongst those aged 85 and over are the same for men 
and women81 . Gryfe et al8 found some clustering of falls prior to death. 
1.4.4 Variations in occurrence by country/region 
Ev'idence of regional variations in the occurrence of falls within the UK is 
limited. The best regional comparisons available are those published in the 
Health Survey for England 2005 which shows that the East Midlands region 
had the highest age-standardised prey,alence of reported falls for older 
9 
" 
people (approximately 30%) and East of England the lowest (approximately 
20%) - see Figure 1-2. This apparent variation remains unexplained. 
Figure 1-2 Table showing how prevalence of falls varies by region within England 
Prevalence and number of falls (observed and age-standardised), 
b ~ ~Government Office Region/Strategic Health Authority and sexa 
Aged 65 and Oller 2005 
Number ollalls Government Office Region Strategic Health 
In previous 12 Authority 
months North North Yorkshilll East West East Laldon South Stuth South 
Easl Wast &th& Midlands Midlands of W&SI East East 
Humber England Coast 
% % % % % % % % % % 
t.,j 
Observed 
Nolalls 
'" 77 76 77 70 79 83 78 76 80 80 
Hall 15 15 15 15 15 15 15 15 15 14 
21alls 5 7 6 7 4 2 2 5 3 3 
3+ lalls 4 5 7 8 5 4 6 4 4 4 
One or mOfll tal 23 24 23 30 21 17 22 24 20 20 
Standardised 
Nolalls 76 76 76 71 78 83 78 76 80 80 
l1all 15 12 11 15 12 10 14 16 14 14 
21alls 5 7 7 7 4 3 2 5 3 3 
3+ lalls 4 5 7 7 5 4 6 4 4 3 
One ormOfll toll 24 24 24 29 22 17 22 24 20 20 
on •• tll 
Observed 
No lalla 70 72 69 69 70 75 71 66 72 73 
Hall 16 16 18 16 17 14 16 20 15 16 
21alls 6 7 7 7 7 7 6 5 7 6 
3+ lalls 9 5 5 8 6 5 6 6 5 5 
One· or more toll 30 28 31 31 30 25 29 32 28 27 
Standardised 
Nolalls 68 73 69 68 71 75 71 66 72 74 
11811 17 15 18 16 17 13 17 20 15 15 
21811$ 6 7 8 7 7 7 6 6 7 6 
3+ lalls 9 5 5 8 6 4 6 6 5 5 
One O"1lOfII tal 32 27 31 32 29 25 29 32 28 26 
Bases (Unwelghted) 
Men 116 256 184 176 190 231 193 246 301 158 
Women 139 . 369 235 202 255 265 223 292 386 224 
Bases (weighted) 
Men 102 233 187 169 193 227 218 226 307 161 
Women 125 348 247 199 269 266 259 276 406 235 
Copyright © 2011, Re-used with the permission of The Health and Social Care 
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1.4.5 Variations in occurrence by deprivation 
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A Finnish study of falls resulting in medical attention found higher incidence 
rates of fall-related injuries in women and in people with only basic level 
education98 . This association with education was not significant in the men, 
the numbers in this strata being too small to demonstrate an effect. 
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Analysis of a survey of urban-living older people in British Columbia found 
that risk of falling for lower socio-economic status disappeared after adjusting 
for chronic illness, age and sex99 , which suggests that the association in this 
population between falls and socio-economic status may be a function of 
higher rates of fall-related chronic illness in this group. 
An ecological study of admissions data for falls-related injuries and hip 
fractures in people aged 70 years and over in England found evidence that 
relative deprivation is associated with higher fall rates, but not with rates of 
hip fracture58. On the other hand, Health Survey for England found no 
association between fall rates and PCT Spearhead-statusb , nor with quintile 
of household income81 . 
In summary, the evidence for an association with deprivation is mixed, and 
may reflect the measures of deprivation used. 
1.4.6 Variations in occurrence byethnicity 
There is some evidence from other countries that incidence rates vary by 
ethnicity. For example, Japanese living in Hawaii experience lower rates of 
falls than their white American counterparts, although the risk of serious 
injury between fallers in the two groups was not significantly different1oo. 
Another study comparing fall rates amongst these groups found that fall rates 
of older people in Japan were similar to Japanese-Americans in Hawaii, but 
about twice that of Caucasian groups87. 
In the US, elderly Mexican-Americans have a similar risk of falling as 
Caucasians 101. Another US-based study comparing incidence of falling in 
b Spearhead status is the label assigned by HM Government departments to denote high 
levels of deprivation and need 
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elderly women found no significant differences between the rate in African-
and Caucasian-American women 102. 
It remains unclear the extent to which specific differences may be attributed 
to lifestyle and environmental factors, or intrinsic factors (systematic 
differences in sensorimotor function, say), or to their interactions. 
1.4.7 Variations in occurrence by marital status 
Ryynanen et al found higher rates of incidence of fall-related injury in 
unmarried, divorced or widowed people compared to those who were 
., 
married, but in estimating the odds of falling amongst these groups no 
adjustment was made for age, sex, or other potential confounders such as 
the prevalence of co-morbidities98. 
1.4.8 Variations in occurrence by residence setting 
Luukinen et al96 found incidence rates of 2021 per 1000 person years in men 
and 1423 per 1000 person years in women living in institutions (compared to 
368 and 611 per 1000 person years in home-dwelling). In a further studl5 
they found similar rate ratios between home- and institutional-dwelling older 
people. Another study in institutional care settings in Finland found an 
incidence rate of 1398 falls per 1000 person years 103. 
A Swiss studl5 found that people aged 65 and over in nursing homes had a 
significantly higher risk of falling compared to home-dwelling people 
(adjusted OR 2.46, 1.04 - 5.78)c. Similarly, a comparison of fall rates in 
different residential settings in Sweden found that rates in an institutional 
setting (which cared for older people with dementia) were twice that found in 
a residential home and in apartments set aside for older people104. 
C Confidence interVals for estimates of effect are in all cases 95% confidence intervals 
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There is consistent evidence from studies such as these that the incidence of 
falls amongst people in institutional living arrangements is higher than 
amongst home-dwelling people, and that this is not explained by differences 
in age95• Since the prevalence of morbidities and frailty is higher amongst 
older people living in institutional care than amongst community dwellers, it is 
thought that this accounts for much of the difference, including the 
differences in type of injury sustained45• However, we cannot be certain of 
the extent to which observed differences in type of injury sustained and in 
diurnal distribution of falls are explained by extrinsic factors. 
1.4.9 Lo.ng term variations in occurrence 
There is some evidence that the incidence of falls has increased over time. 
Some of this evidence is relatively weak and may be due to changes in 
. t d d· 50 ascertalnmen an recor Ing . 
Evidence from Finland based on surveillance of hospital discharges for the 
whole Finnish population suggests that age-adjusted incidence rates of fall-
related injuries increased by about one quarter in the 24 years to 1995, but 
that there was no corresponding increase in fall-induced death 53. The same 
period also saw increases in falls-induced, fracture-associated spinal cord 
injuries54, but this may be due to factors relating to bone health rather than to 
falls. The observed trend in rates of injury resulting from falls in older people 
has persisted to 20046061 • The findings of a longitudinal study also found an 
increase in the incidence of major soft tissue injury from falls from start to end 
of the study period lasting 9 years (adjusted OR 1.08, 1.03 - 1.12), but no 
increase in the rate of incidence of hip fractures 105. Neither did the study find 
an increase in the rate of falls. ,These findings suggest that observed 
increases in injuries are not due to an increased tendency to fall, but could be 
due to an increase in severity, which the authors hypothesize to be a result of 
increaSing environmental, situational or behavioural hazards. However, 
elsewhere, analysis of rates of fatal and non-fatal falls in the US between 
1993-2003 shows that the rate of non-fatal injury has not changed48• 
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In England, a large study using hospital episode statistics found that age-
specific rates of admission for fractures of the hip had stabilised by 2001 106. 
Hip fracture is often taken to be a marker of falls in older people, but the 
extent to which the association between falls and hip fracture has remained 
constant over time is not clear. Therefore inferences made about trends in 
rate of falls must be tentative. 
Demographic changes in the UK and industrialised countries mean that 
unless there is a reduction in age specific rates, the actual number of falls is 
likely to increase. 
1.4.10 Short term variations in occurrence 
The evidence for seasonal variations in falls is mixed. A study of 761 people 
in New Zealand aged 70 years and over found that winter was associated 
with an excess of falls amongst women 107, but a survey of 1321 people aged 
65 and over from a rural Japanese community found no difference in the 
rates offalls by season108. Similarly, a 10 year longitudinal study of Finns 
aged 75 or 80 years at outset found no variation in fall incidence by season29• 
Analysis of national surveillance of falls in people aged 65 and over in the US 
found that neither fatal nor non-fatal falls showed any seasonal pattern, but 
that the frequency of fatal falls was on average 9% higher in colder 
climates 109. 
1.4.11 Summary 
The literature is rich in evidence for the public health significance of falls 
amongst older people in terms of its overall frequency, and its demographic, 
socio-economic and temporal distribution. 
Many peer-reviewed studies, review articles and standard textbooks about 
healthcare of the elderly state that up to a third of older people fall each year. 
Evidence underpinning these estimates arises from the analysis of cross-
sectional and longitudinal data generated in the course of observational 
studies (and some trials), and the analysis of routinely collected health data. 
Evidence of the frequency of attendan.ce in primary care for falls in 
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community-dwelling adults is sparse. In a UK setting it is limited to self-
reported data. 
1.5 Health consequences of falls in the community 
1.5.1 Falls associated mortality 
The literature quantifying mortality following a fall in a community setting is 
small compared to that for the frequency of falls. 
Amongst 339 older people attending an A&E department following a fall, 
Morfitt15 found an excess in one-year mortality which could not be attributed 
" 
to the injuries sustained in the fall. Another early UK study of 125 fallers 
aged 65 years and over living at home found a one year all-cause mortality 
five times that in their age-sex matched controls 110. This evidence'underlines 
the fact that fallers represent an important group of people in terms of 
mortality, irrespective of the severity of injury sustained during the fall. 
1.5.2 Variations in mortality by age and sex 
In their 1990 study, Sattin et al51 found that for males in the US the risk of 
death following a fall-related injury was double that for females. This is 
consistent with the findings of a Canadian study of falls in people aged 65 
and older, which found higher mortality rates and lower accident-related 
admission rates for men compared to women. Riley postulated that this was 
due to the possibility that while more women fall than men, more men incur 
serious injury52. This in turn might be because the normal ageing process in 
men has advanced further than in women by the time a fall is experienced, or 
because men experience more extreme challenges to their postural stability. 
In either case, falls are a stronger indicator of mortality risk in men than in 
women. 
1.5.3 Variations in mortality by fall history 
In their small longitudinal UK study, Bath and Morgan found that mortality for 
people experiencing 3 or more falls during 4 years of follow-up was about 
twice that of people who reported no falls (HR 2.22, 1.37 - 3.61 )14. Similarly, 
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analysis of people aged 70 or more from the US Longitudinal Study of 
Aging 111 showed that risk of death within 2 years was greater for people 
falling once (OR 1.5, 1.1 - 2.0) and for multiple fallers (OR 2.2, 1.7 - 2.8), 
compared to non-fallers. 
In the UK, a prospective cohort study in the UK of people aged over 75 years 
also found an increased risk of death for recurrent fallers at one year (OR 
2.6, 1.4 - 4.7) and three years (OR 1.9, 1.2 - 3.0), but found no such 
associations for single fallers112. 
1.5.4 Variations in mortality over time 
Analysis of mortality rates of fatal and non-fatal falls in the US between 1993-
2003 shows that the rate of non-fatal injury has not changed whilst the risk of 
death as an immediate result of falling has increased48. On the other hand, 
analysis of surveillance data from European countries suggests that recent 
years may have seen a small decline in fall-related injury mortalit/o. 
1.5.5 Physical injury and medical treatment following a fall 
There is evidence that for community dwelling older people in England the 
proportion of falls that require medical treatment is different for men and 
Women. The Household Survey for England found that the proportion of 
women requiring medical treatment following a fall varied from 29% for those 
aged 65-69 years to 42% for those aged 85 and over. Men accessed 
treatment in only 23% of falls, and this proportion did not vary with age81 . A 
UK study based in a residential care setting found that 82.5% of falls involved 
nil or negligible injury; only 17.5% were severe enough to be brought to 
immediate medical attention8. A large Finnish study found that the incidence 
rate of people requiring mediCal attention following a fall was 3.8 per 100 
person years (and 5.5 when recurrent events were included)98. Another 
Finnish study45 followed up 1169 people aged 70 or over and found a rate of 
fall-related injury requiring medical attention of 57 per 1000 person years for 
men and 113 per 1000 person years for women. A large population study in 
Singapore found a one year prevalence for falls of 17%, just under half of 
whom had sought medical attention9o. It is clear that the number of falls 
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requiring medical treatment is smaller than the total number of self-reported 
falls, but the relationship between these varies by sex and setting and, for 
women, by age. 
1.5.6 Other health consequences of falls 
Another significant outcome following a fall is admission to a nursing home. 
Analysis of surveillance data in Florida found that 50% of the people with 
falls-related injuries which were sustained at home and required admission to 
hospital were subsequently discharged to a nursing home. Similarly, a UK-
based study112 found that one year risk of admission to long-term care was 
increased for once-only (OR 3.8, 1.8 - 8.3) and recurrent fallers (OR 4.4, 1.7-
12) compared to non-fallers. 
There is also consistent evidence of restriction in activities of daily living, 
reduced quality of life, and loss of independence following a fall3. For 
example, Tinetti and Williams found a decline in activities of daily living in the 
3 years following a fall, for both non-injurious and injurious falls113. Amongst 
those suffering a fall without injury, they found reported declines in social 
activities. 
The fear of falling accompanied by a loss of mobility and independence has 
been described as 'post-fall syndrome,114. In many cases this fear may 
reflect a realistic appraisal of the individual's risk of falling. In others, it may 
be unrealistio, but is nevertheless associated with functional decline, reduced 
quality of life, and social isolation 115. In a small qualitative study Faes et al116 
noted the consequential emotional impact on the individual responsible for 
providing care to an older person who has fallen. 
Taken together these studies underline the fact that for many people, a fall is 
subsequently associated with changes to health and social relationships 
which endure long after the healing of any physical injury which may have 
been incurred. 
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1.5.7 Economic cost of falls 
The economic costs associated with falls in people aged over 60 years in the 
UK in 1999 was estimated to be £981m, based on unit costs in 200057• This 
estimate is derived from accident and emergency department attendance for 
injuries resulting from falls. It includes costs arising in healthcare including 
hospital and GP referrals, and some social care costs relating to long-stay 
nursing home care. However, it excludes costs of falls resulting in a visit to 
the GP. The overall cost to society of falls requiring medical attention of 
some sort may well be much higher. 
Similar calculations for the US found that the direct medical costs alone of 
falls amongst people aged over 65 were US$12.8 billion (based on units 
costs in 2000), but were more than US$19 billion when the costs of long-
stand nursing care and complications were included117. Contemporaneous 
data showed that up to 85% of injury-related hospital admissions in Canada 
were following a fa1l118. 
The ageing of populations in many countries is likely to result in a significant 
increase in the overall economic cost. For example, a report prepared for the 
Australian government in 2003 highlighted that the overall cost of fall related 
injuries in older people will increase threefold in the first half of the century, 
assuming that age-specific rate remain stable. 
1.5.8 Summary 
The literature quantifying the impact on individuals and on wider society is 
smaller than that concerning the frequency of falls, but consistently shows 
that older people who fall have an increased risk of death in the years 
following the event as well as in the immediate aftermath, and that falls 
amongst older people are associated with a loss of confidence, function and 
independence. 
In addition to the significant impact on individuals, there is an economic cost 
associated with falls which, even using unit costs from 2000, amount to 
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hundreds of millions annually. In the absence of intervention to reduce the 
rate of falls, the UK's changing demography means that these costs are likely 
to continue to increase. 
1.6 What is known about the role of medications in falls in 
older people 
Since the late 1970s, epidemiological studies have identified many risk 
factors for falls in older people including past history of falls, socio-
demographics (advanced age, mobility, female sex, ethnicity/race, living 
alone) and lifestyle (inactivity, use of walking aid, alcohol consumption), 
physiology and clinical conditions (postural instability, sensory and 
neuromuscular function, impaired cognition, stroke, Parkinson's disease, 
depression, neurological signs, incontinence, acute illness, arthritis, 
orthostatic hypotension, vestibular disorders) together with environment (poor 
footwear, inappropriate spectacles), psychology (fear of falling) and 
medication use119. 
Evidence from a range of studies for the iatrogenic effect of medications on 
falls in older people dates back more than a quarter of a century120. Reduced 
levels of mental alertness, impaired transmission within the central nervous 
system, sedation, confusion, reduced neuromuscular coordination and 
balance, and drug-induced parkinsonism are all plausible mechanisms by 
which various medications may degrade the balance system 121. However, 
commentators note that, in general, the pharmaceutical industry has not 
recorded falls or any intermediate measures of postural stability as an 
outcome measure during drug development121 . Consequently, despite the 
high prevalence of prescribing amongst older people, the majority of the 
evidence for the possible role of medications arises from observational 
stUdies. Many of these are small and subject to confounding or to other 
issues impacting their reliability. Confounding by indication and small study 
size is a feature of the literature in most of the following sections. 
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1.6.1 Centrally acting medication 
The association between prescribing of centrally acting medication and falls 
in older people has been examined in a large number of studies. Leipzig et 
al published a systematic review in 1999 which, based on the pooled odds 
ratios of the 40 studies which met their inclusion criteria, found a significant 
association with falls in older people for anti-psychotics (pooled OR 1.50, 
1.25 - 1.79), anxiolyticlhypnotics (pooled OR 1.54, 1.40 - 1.70), any 
antidepressant (pooled OR 1.66, 1.4 - 1.95), tricyclic antidepressants (pooled 
OR 1.51,1.14 - 2.00), and benzodiazepines (pooled OR 1.48,1.23 _1.77)122. 
They also found that these effects were independent of age of participants, 
their frequency of falling, and study setting. The authors noted that there was 
evidence of heterogeneity between studies of some medication classes and 
that the evidence was based entirely on data from observational studies 
whose design made little allowance for confounding, dosage or duration of 
therapy. In a placebo controlled trial, Campbell et al found that psychotropic 
medicine withdrawal led to a lower risk of falling in the intervention group 123. 
Based partly on this, England's National Institute for Health and Clinical 
Excellence has recommended that "older people on psychotropic 
medications should have their medication reviewed, with specialist input if 
appropriate, and discontinued if possible to reduce their risk of falling"124. 
In 2007, a review by Hartikainen et al125 included studies of pharmaceutical 
preparations coming on to the market since Leipzig et ai's earlier review, e.g. 
selective serotonin reuptake inhibitors, atypical antipsychotics. The review 
did not provide a pooled result using formal statistical methods but found that 
SSRls were associated with falls. No association with falls was found in the 
two studies investigating atypical antipsychotics. Kallin et ai's study in 
residential care settings suggests that SNRls may be safer than SSRls in 
terms of risk of falls 126, but at the start of this project there was no data on the 
risk of falls associated with SNRls in older people in a community setting. 
(Recently, Coupland et ai's study of the adverse effects of antidepressants 
inciuded some sub-analysis for Venlafaxine, for which the estimates of one 
year risk of falls was similar to that for SSRls 127.) 
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Woolcott et al undertook a meta-analysis of studies of falls associated with 
these medication classes 128. They used Bayesian techniques to incorporate 
the results of studies included in Leipzig et ai's meta-analysis with data from 
more recent studies. The Bayesian pooled estimates they derived for the 
main classes of centrally acting medication were very close to the pooled 
odds ratios of Leipzig's earlier studies. 
1.6.2 Analgesics 
A smaller number of studies examine possible associations for analgesic 
agents. Findings from these have been mixed and subject to confounding by 
the musculoskeletal conditions they are used to treat. A second systematic 
, 
review by Leipzig et al found no. significant association for NSAIDs, aspirin, 
narcotic nor non-narcotic analgesics 129. Woolcott et ai's Bayesian meta-
analysis produced a pooled estimate for NSAIDs, for which the point estimate 
was almost unchanged (Bayesian pooled estimate 1.21). 
1.6.3 Cardiovascular medication 
The literature on cardiovascular medication and falls in older people is also 
scant compared to that for centrally acting medication. Leipzig et ai's 1999 
review studied cardiac medications including any diuretic, thiazide diuretics, 
loop diuretics, beta-blockers, centrally acting antihypertensives, calcium 
channel blockers, angiotensin-converting enzyme (ACE) inhibitors, nitrates, 
type 1 A antiarrhythmics, and digoxin 129. There were no randomised control 
trials meeting their selection criteria. The meta-analysis of the observational 
studies found weak associations with one or more falls for digoxin (pooled 
OR 1.22, 1.05 - 1.42), type 1 A antiarrhythmics (pooled OR 1.59, 1.02 - 2.48) 
and use of any diuretic (pooled OR 1.08, 1.02 - 1.16). In his review of the 
epidemiology of medication related falls in older people, Cumming 130 
observed inconsistent and undiscriminating classification of cardiovascular 
medications in many studies. 
There have been a few studies published since the meta-analysis. Of these, 
several were included in the review by Hartikainen et al125, who reported that 
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nine36 126 131-137 of the twelve studies 138-140 addressing cardiovascular 
medication use and risk of falling found no association. More significantly, 
Woolcott et ai's recent meta-analysis derived a new frequentist odds ratio for 
beta blockers of 1.14 (0.91 - 1.33) and an updated Bayesian odds ratio (with 
95% credible interval) of 1.01 (0.86 - 1.17). Woolcott et al found that the 
difference compared to Leipzig's original estimate was close to statistical 
significance. 
Woolcott et al also included analysis of antihypertensives which were not 
addressed in Leipzig's earlier meta-analysis, for which they found a 
frequentist pooled estimate of 1.26 (1.08 - 1.46). However, as previously 
noted by C,umming in respect of other studies13o, the meta-analysis was not 
able to differentiate between sub-classes of antihypertensive. 
In common with Leipzig et al122 and others, Woolcott et al highlight the 
problem that estimates of effect in these studies may be confounded by a 
number of factors including by indication. They observed that many of the 
studies included in the meta-analysis reported adjusted odds ratios, and that 
the pooled adjusted odds ratios were similar to the pooled unadjusted odds 
ratios. On this basis, they concluded that the role of confounding "was quite 
small in this regard". 
Setting out to test the hypothesis that associations between medications and 
falls are confounded by medical conditions, Lee et al141 found no association 
with falls for most cardiovascular and non-cardiovascular drug groups 
(including psycholropics) after adjusting for medical conditions, except for 
nitrates. The study involved 4000 participants but it is not clear whether it 
was powered to identify a small effect size in the subgroups analysed. More 
recently still, Carbone et al found no association between loop diuretics and 
falls amongst 3411 female users and 130444 non-users of loop diuretics 142. 
Van der Velde et al cOnducted a cohort study in 139 older people to assess 
whether withdrawal of medication is associated with a reduction in the 
incidence of falls. They found that the withdrawal of cardiovascular 
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medication in particular was associated with a reduction in falls143. 
Unfortunately the study was not designed to differentiate the effects of 
different classes of cardiovascular medicine, which included (amongst 
others) adrenoceptor blockers, diuretics, calcium channel blockers, 
angiotensin converting enzyme inhibitors, angiotensin receptor blockers, 
nitrates, class III antiarrhythmics, and a nicotinic acid derivative. 
Nevertheless, the study is important in terms of the supporting evidence it 
provides of causality in the relationship between at least some cardiovascular 
medications and falls in older people. The lack of differentiation in the class 
attribution points to the role of polypharmacy (which is considered in the 
following section) alongside or instead of the role of specific medications. 
Overall the evidence is sparse and arises from small-scale studies, or studies 
that do not differentiate between different classes of cardiovascular 
medication144. In particular, there is recent evidence that antihypertensives 
are associated with falls in older people but it is not clear whether the 
generalisation applies to all sub-classes or the extent to which some of the 
observed associations are due to residual confounding. 
1.6.4 Polypharmacy 
Polypharmacy is common amongst older people and its prevalence 
continues to increase145. Various studies have demonstrated an increased 
risk of falling with multiple medication prescribing. For example, Cumming et 
al146 reported that the relative risk of falling was 1.4 for a single medication, 
rising to 2.2 for two medications and 2.4 for three or more. However, the 
apparent impact of polypharmacy may be due to underlying frailty or co-
morbidities. 
More recently, a cross-sectional study of more than 4000 older women found 
that, after adjusting for underlying co-morbidities, falls were no longer 
Significantly associated with the number of prescribed medications 137. 
Similarly, Lee et al found no association with polypharmacy141. In their 
recently updated joint guidelines, the British and American Geriatric Societies 
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summarised the evidence for the effect on falls of reducing polypharmacy as 
"fair"147. The guidelines emphasise the review of medications 
with a view to reducing a range of associated problems (e.g. confusion, 
constipation, nausea, continence problems, tiredness, insomnia, depression) 
but, in view of wider considerations about the balance of possible benefits 
and harms, were not in a position to make a general recommendation for or 
against routinely reducing polypharmacy in older people who have fallen. 
These studies provide further evidence that research to measure the possible 
impact of a particular medication must take account of the prescribing of 
other medications. Implications of this for study design include the need for 
accurate rT\easurement of exposure to a range of medications, sufficient 
power to detect modest differences in their effects, and strategies for 
differentiating the effects of multiple risk factors. 
1.6.5 Evidence of mechanisms by which medications cause falls 
For some medications, an association with falls has long been recognised 
and the mechanisms are relatively well established. For some other 
medications the mechanism by which they have an effect are more 
speculative. This section sets out some of this evidence, starting with those 
medication groups for which evidence about the mechanism is strongest. 
Lord et al outline the evidence for the mechanism by which central acting 
medications in general are causally linked with falls in the elderly 121. 
Evidence about possible mechanisms by which central acting medications 
are causally linked with falls in the elderly is strongest for benzodiazepines, 
which are associated with reduced reaction times and increased postural 
sway148-150. The relationship is modelled in Figure 1-3 which indicates that 
approximately half of the association between psychoactive medication and 
falls is mediated via reduced stability151. 
24 
Figure 1-3 Path analytic model for the relationship between psychoactive medication 
use and falls from Lord et al 
The standardised relative strengths of the effects are indicate by the numbers above the 
path arrows. (Notes: Psychoactives: nil, one or two. Activity: hours per week. Age: age in 
years. Poor balance control: a composite measure incorporating measures of tactile 
sensitivity, vibration sense, quadriceps strength, reaction time, sway and clinical stability. 
Falls: two or more falls versus nil or one. Postural hypotension was found to be a statistically 
insignificant variable in the development of the final model. 
Psychoactives 
Instability 
Activity 
0.49 
FeUs 
Age 
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In their 2009 review Darowski et al summarise the evidence for mechanisms 
by which antidepressant medication may contribute to falls in older people 152. 
Causal links may be mediated through sedation and impaired premotor 
planning and reaction times, impaired balance, insomnia, alerting effects and 
deranged sleep architecture leading to daytime drowsiness and increased 
nocturia, orthostatic hypotension, cardiac conduction or rhythm disturbances, 
and a tendency to cause movement disorders (see Table 1-1). However, the 
authors noted that most of the evidence comes from studies based on 
participants with a younger age profile than typical fallers, and that evidence 
of no adverse effect in younger fallers is not the same as evidence of no 
association for older people. It might be speculated that similar mechanisms 
exist for SNRls, but the study found no data for the effect of SNRls on falls. 
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Table 1-1 Adverse effects of antidepressants which may contribute to falls, from 
Darowski et al 
Anldepresanl etan Inchldual Adverse effect 
anidepreaaanl tall OfIhoalelic MdIItion anhytlmlaa balance sleep 
hypotension lmpaiIment dstulbance 
Tricyclic anldep'enants Amilriptyllne +++ +++ .... + ++ +++ 
Clomipramine +++ +++ .... + No dale +++ 
DoNepln +++ +H +H No dale H' 
Doxepln ++t +H +++ + ++ +++ 
Imipramine +++ +++ +++ No dale +++ 
Lo!eplBmlrw +++ +++ .... No dale No dIU 
Nonrtplyline +++ ++ +++ No dale +++ 
Tnmlpl1lmine ++t +++ +++ + No dale 
Noradrenergic and spedfic Trazodorw +++ +++ +++ + No daIs + 
_olonqc anldep'elSSlll 
Tell1lcyclic anlldepl8nanls Mlanserin +++ +++ +++ + No data ++ 
MlItazaPne +++ +++ +++ + No dale 
Monoamine oxidase inhibitors Phenelzine No dale H+ No dale - No dale ++. 
IIIOC8IboIcazId No dale +++ No data 
-
No dale +++ 
Tl1Inylc)lprcmlne No dale +++ No data 
-
No dale +++ 
R_18lble Inhlbilor\ of MocIobamlde Noda. - No dale ++ 
monoamine oxldMe A 
Selective serotonin l8UJ:Uke CIlaIopram ++t, + + +++ +++ 
ImIbkors E ecilaIopram No data No dale No dale No dale No dale +++ 
Fluoxeline ++t + + + +++ 
Flwoxamine +++ ++ +++ 
P.OIl,tlne +++ ++ +++ 
Senrelne +++ + +++ (earty +++ 
Iranslent efIact) 
Selecllve serotorin and Venla/axlne No dale +++ + + No dale + 
noreplneplYlne reuptake 
ImIbHors 
DuIoJlltlne No data ++ + No data No data Nodala 
Selective norepinephrine ReboIcetine No dale ++ + No dale No dale +++ 
ntull\ake InhlbHol8 BI4)IOpIon No dale - + 
Hypericum (SI No data 
- No dale + 
John's wort) 
+ indica .. _ak corralallon betw.n the adv«ae effacl and drug; ++ lndIcatas intermediate correlation betw.n the ad_ efIact and drug: 
+++ Indicales slrong oorntlalon betwaen the ad __ effect and drug; -Indlcalas no correlation between the adllel1l8 effect and drug. 
@ 2009 Adis Data Information BV. All rights reserved. Reproduced with kind 
permission of Springer Science and Business Media. 
In the case of antihypertensives, although an association with falls via 
orthostatic hypotension has long been suspected153, the relationship with 
drug-related orthostatic hypotension remains unclear154155. In part, this is 
due to the volatility of orthostatic hypotension and the difficulty of assessing 
its severity. 
1.6.6 Genera/ising from evidence about impact of medications 
on fractures 
There is evidence about the impact of some of these medications on risk of 
fracture. Hip fracture provides a reliable recorded marker of when a fall has 
occurred, but also reflects other factors such as osteoporosis. Nevertheless, 
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it represents a subset of falls for which the consequence is specific and 
relatively severe. It carries public health implications which are 
correspondingly large including costs to the public purse which, for the NHS 
are estimated to be in the range £1.4 billion annually and as much as double 
this if all costs to society are included156. 
Takkouche et ai's meta-analysis of studies 157 measuring the effect of 
centrally acting medication and fractures found increased risk of fracture for 
benzodiazepines (pooled RR 1.34, 1.24 - 1.45), antipsychotics (pooled RR 
1.59, 1.27 - 1.98) and antidepressants (pooled RR 1.60 (1.38 - 1.86) which 
were similar to the pooled and Bayesian odds ratios in Leipzig et al and 
Woolcott et ai's meta-analyses of falls 128129. On the other hand, the pooled 
OR for hypnotics was not significant (pooled RR 1.15, 0.94 - 1.39). For non-
barbiturate antiepileptics the pooled RR was 1.54 (1.24 - 1.93) and 2.17 
(1.35 - 3.50) for barbiturate antiepileptics. In common with other meta-
analyses 122 129, the authors noted a concern about the degree to which these 
effects were subject to residual confounding, and also about publication bias. 
Exploring associations with SSRls in particular, Hubbard et al found that the 
increase in risk of fracture associated with antidepressant medication was 
greatest in the first 14 days following the initiation of prescribing (adjusted OR 
6.30,2.65- 14.97)158. In the same study, Hubbard et al undertook self-
controlled case series analysis by which they estimated that amongst people 
prescribed SSRls the relative incidence offracture in the first 14 days 
following first prescription compared to unexposed period was 1.96 (1.35 -
2.83). They interpreted these results as evidence of an acute adverse effect, 
and of a bias in the case-control study resulting in an overstatement of the 
size of the true effect. 
Vestergaard et al found dose-dependent odds ratios of between 1.4 and 2 for 
the most frequently prescribed SSRI (citalopram) and mostly non-significant 
effects in SSRls for which prescribing was less prevalent159. In a large 
pro·spective cohort study (n=5008) Richards et al also found a positive effect 
for SSRls and this effect persisted for the duration of the 5 years of follow-
Up160. 
Wiens et ai's meta-analysis of observational studies of antihypertensives and 
fractures 161 found a pooled relative risk of 0.86 (0.81 - 0.92) for thiazides, 
and 1.14 (0.84-1.54) for non-thiazide diuretics. For beta blockers there was 
a statistically significant reduction (pooled RR 0.86,0.70 - 0.98). They found 
no significant associations between fractures and exposure to alpha-blockers 
or calcium channel blockers, and there was only a single study which looked 
at ACE inhibitors for which the pooled relative risk was 0.86 (0.70 - 0.98). 
The apparent protective effect of thiazides and beta blockers suggests that 
patients prescribed these medications may experience a reduced risk of 
fracture. Nevertheless, leaving aside the possibility that the observed effect 
is attributable to some factor other than the medication itself, it is not clear 
whether a reduced risk of fracture is necessarily an indication that the same 
group experience a reduced risk of falling. 
One method by which a possible causal link between medications and 
fractures may be mediated is that of reduced bone mineral density 162. The 
degree to which reduced bone mineral density explains all of the observed 
association between a medication and fractures is uncertain, as is the 
mechanism by which reduced bone mineral density might be associated with 
falls. A link between exposure to a medication and an increased risk of 
fracture, causal or otherwise, does not provide good grounds for concluding 
that there is a corresponding increased risk of falls. 
This together with the fact that effects observed for fractures and falls for 
some medications are in opposite directions (e.g. beta blockers), limits the 
degree to which an understanding of the effect of medications on fractures 
will properly inform an understanding of medication and falls. 
1.6.7 Summary 
Much of the evidence for the effect of medications on falls is derived from 
observational studies, many of which are small and may be subject to 
confounding. The strongest evidence is for the effect of centrally acting 
medications. Reviews of the relatively scant evidence for the effect of 
cardiovascular medications indicate that the evidence base could be 
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strengthened by studies which differentiate more clearly between classes of 
cardiovascular medication and which adjust for the confounding effects of 
comorbidities and other prescribing. This gap in the evidence base is 
significant not only because of the prevalence of prescribing for 
cardiovascular disease medication, but also because of their possible role in 
polypharmacy which is increasing in prevalence, and is associated with falls. 
There is also a gap in the evidence base concerning the falls profile of 
SNRls. 
1.7 Arrangements for the management of falls in older 
people 
Improving 'the prevention and management of falls in older people has been 
a government priority for more than a decade. In England, this was given 
expression in one of a series of National Service Frameworks, which were 
published in the early years of the New Labour government to set out the 
actions for several areas of public health need. The National Service 
Framework (NSF) for Older People was published in 2001 with an intent to 
"reduce the number of falls which result in serious injury and ensure effective 
treatment and rehabilitation for those who have fallen,,163. The NSF 
envisaged GPs at the heart of the pathway (see Figure 1-4). 
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Figure 1-4 Falls pathway as envisaged by the National Service Framework for Older 
People163 
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Against this background the National Institute for Health and Clinical 
Excellence (NICE) commissioned a multidisciplinary group to develop a 
~ o o
comprehensive set of clinical guidelines for the assessment and prevention 
of falls in older people 124. 
The scope of the NICE guidelines include "methods of assessment and 
identification of older people at risk of falling, the most clinically and cost 
effective interventions and preventative strategies for the prevention of falls, 
the clinical effectiveness of hip protectors for the prevention of hip fracture, 
the most clinically and cost effective interventions and rehabilitation 
programmes for the prevention of further falls, [and] older peoples' views and 
experiences of falls prevention strategies and programmes"124. The main 
interventions for which there is good evidence are: exercise interventions for 
strength and balance, correction of visual abnormalities, modifications to the 
, 
environment and multifactorial combinations including a medical assessment. 
In addition, the recommendations set out in the guidelines articulated a 
multidisciplinary approach in which (amongst other things): 
"older people in contact with health care professionals should be 
asked routinely whether they have fallen in the past year and asked 
about the frequency, context and characteristics of the fa Ills" , and 
"all care should be documented in the patient's health care records" 
and, 
"all health care professionals dealing with patients known to be at risk 
of falling should develop and maintain basic professional competence 
in falls assessment and prevention." 
Whilst the guidelines envisage that the proper falls risk assessment for 
people who have suffered a f ~ 1 I I or a gait/balance abnormality will normally be 
conducted in the setting of a specialist falls service, the responsibility for 
making a referral is explicitly attributed to the professionals at the point of 
presentation which, for many people, is either their GP or a hospital accident 
and emergency department who, according to the NSF, are charged with 
informing the GP. 
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1.8 Justification and aims of thesis 
Falls in older people are a major public health challenge. As many as a third 
of older people experience a fall, with results for the individual ranging from 
the inconsequential through to hospital admission, loss of confidence or loss 
of independence. Wider impacts include the cost of health and social care 
associated with the consequences of the fall, together with the cost of 
informal care. For countries with ageing populations, these costs are 
forecasted to increase. 
Recent health service initiatives, including the National Service Framework 
for Older People 163 and national clinical guidelines for falls prevention and 
t r e a t m e n t 1 ~ 4 , , envisage an important role for general practitioners and primary 
care within the care pathway for the prevention and treatment of falls in 
England. Yet there is little published data on the recording and incidence of 
falls seen in primary care, with which to consider the implications of this 
approach. 
These policy responses to the scale and impact of falls in older people 
recognise evidence for the role of particular medications and polypharmacy 
in the multifactorial aetiology of falls. Nevertheless, the evidence base for 
the effect on falls in older people of some of the most commonly prescribed 
medications, including cardiovascular medications, is meagre and 
inconsistent. In particular, evidence for the possible effect of 
antihypertensive medications is inconsistent and is compromised by a poor 
differentiation between sub-classes of medication and uncertainty about the 
extent to which observed effects are subject to residual confounding. There is 
also a gap in the evidence concerning SNRls, which some have suggested 
may be safer than SSRls. 
Therefore a longitudinal database of general practice records is used to 
quantify the burden of falls in primary care in the UK, and to address gaps 
and shortcomings in the evidence base regarding medications commonly 
prescribed to older people. 
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Specifically, the aims are: 
• To quantify the overall incidence of recorded falls among older people in 
primary care in the UK, and to determine whether it varies over recent 
years or by socio-demographic attributes 
• To quantify risk of death associated with falls in older people in primary 
care 
• To establish whether the falls risk profile of more recently introduced 
serotonin noradrenalin reuptake inhibitors is more favourable than that of 
selective serotonin reuptake inhibitors 
• To establish whether being prescribed antihypertensive medication 
modifies the risk of falling in' older people, differentiating between specific 
sub-classes of medication, and assessing the extent of any confounding 
• To identify any other classes or sub-classes of medication prescribed in 
primary care whose apparent falls risk warrants investigation in future 
studies 
1.9 Ethical approval 
A request for ethical approval was submitted to Nottingham Research Ethics 
Committee under their reference 06/Q2403/15. Nottingham Research Ethics 
Committee granted their approval for this research project and confirmed it in 
writing on 12th October 2006. 
1.10 Funding for the study 
University of Nottingham research student fees have been generously funded 
by the East Midlands S t r a t e g i ~ ~ Health AuthOrity. 
1.11 Structure of the thesis 
The chapters following this introduction will describe the primary care 
database used to address the study aims, together with the evidence for its 
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validity, and the methods used to prepare it for detailed analysis in the 
subsequent cohort and aetiological studies. 
The main body of the thesis consists of several chapters describing the 
studies of incidence and of association with antidepressant and 
cardiovascular medications. The chapter containing a description of the 
cohort studies with their key results is preceded by a chapter setting out the 
methods used and their rationale. 
Similarly, the chapters which describe the studies of associations with 
antidepressant and cardiovascular medication are preceded by a second 
methods chapter. This sets out the case-control and self-controlled case 
, 
series methods in detail, including their potential shortcomings and 
underlying assumptions. 
The penultimate chapter reports the findings of a further study intended to 
identify other classes of medication which may be associated with falls in 
older people. 
The findings from all the studies are brought together in a conclusion which 
sets out their implications with recommendations for policy and practice. 
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2 Methods development: incidence and mortality 
The previous chapter reviewed the relevant literature relating to the field of 
study, and the aims and objectives for the project. This chapter describes 
the methods used to execute the study. It opens with a description of the 
source and structure of the data used to address the research questions, and 
the evidence for its validity. It then sets out a detailed description of the 
methods developed for the cohort and aetiological studies, so that in 
subsequent chapters the discussion can be focussed on the results of the 
analyses and their interpretation. 
2.1 The Health Improvement Network 
, 
Parts of this section draw from a review of evidence for the validity of THIN 
that is reported in a dissertation by the author submitted to the University of 
Nottingham for a Masters in Public Health 164. 
2.1.1 Background 
The Health Improvement Network (THIN) is a computerised longitudinal 
primary care database, containing patient records from general practices in 
the United Kingdom. It is the result of a collaboration between EPIC 
(www.epic-uk.com) which is a non-profit making organisation that facilitates 
access to electronic research data, and Cegedim (www.cegedim.com) who 
develop and supply the Vision general practice computer system to about 
2000 GP practices in the UK165. The THIN data are derived from general 
practices using Vision. In return for providing data, practices receive help 
with software training and audit. 
THIN was developed by Dr Alan Dean who played a leading role in the 
management and d e v e l o p m e ~ t t of the General Practice Research Database 
(GPRD) from 1994. THIN is modelled on GPRD and uses the same data 
structures. Many practices that contribute data to THIN also contribute data 
to GPRD. 
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The primary reason for using THIN in these studies (rather than GPRD) was 
because of the availability of a license to use the data within the Department 
of Epidemiology and Public Health at the University of Nottingham. 
2.1.2 Data anonymity 
To prevent the identification of individuals, patient data in THIN has been 
anonymised by removal of names and addresses of patients, names of 
practices, and the day of the month of birth. 
2.1.3 Coverage 
The version of THIN, from which the data for the studies of incidence and 
mortality were selected, represented records from 336 general practices up 
to July 2007. Later studies in the project used a more recent version of the 
database, which was able to draw on data from additional practices. 
2.2 The data 
2.2.1 Content & structure 
THIN contains diagnostic and prescribing data recorded by general 
practitioners as part of routine clinical care. It includes information from 
secondary hospital referrals and emergency admissions, and information 
about date and cause of death. These data are contained in several tables 
which are summarised in Table 2-1. 
Table 2-1 Description of the main tables of data In THIN 
Database Table 
Patient 
Medical 
Therapy 
Additional health 
data 
Description of data 
Demographic data, including year of birth, sex, and period 
in database 
Data on all illnesses diagnosed (Read coded), including 
emergency visits and hospital referrals 
. Details of each prescription (including drugs prescribed 
acutely) with name, form, strength and dose (multilex 
coding system) 
Data on height, weight, smoking habit and blood pressure. 
THIN also holds information about the health authority region in which the 
patient was last resident and quintile of Townsend score, which is a marker 
of deprivation for the small geographical area comprising the patient's 
residence and approximately 150 households. It is derived from 2001 
census data comprising prevalence of household access to a car, owner 
occupation, overcrowding, and unemployment166. 
2.3 Validity 
The weight that is attributed to findings from these studies depends in part on 
the validity of the measures of outcomes and exposures recorded in THIN. 
The most compelling evidence for the validity of THIN includes peer-reviewed 
findings of'validation studies of THIN. It is also supported by validation 
studies of GPRD, which derives its data from the same network of practices. 
2.3.1 Validation studies 
There are a growing number of published validation studies of THIN. For 
example, Lewis et al conducted a series of case-control studies in THIN to 
explore known disease associations 167. For the vast majority of hypotheses 
they found associations consistent with those reported in the published 
literature. Lo Re et al undertook a formal validation of recorded diagnoses of 
Hepatitis C virus (HCV). They found that that among the 74 patients who 
had a specific HCV diagnosis, HCV was confirmed in 64 giving a positive 
predictive value of 86% (77% - 93%)168. Others have looked at events as 
diverse as smoking cessation prescriptions169, diagnoses of psoriasis 170, non-
melanoma skin cancer171 and found that the information in THIN supports 
research objectives. In addition to peer reviewed studies, a number of 
validation studies are reported in conference proceedings 172. The validity of 
THIN for the study of mortality is demonstrated by Hall who investigated the 
recording of deaths and suicides and found that a record of death in THIN 
has a positive predictive value of 99.6% 173. In 95% of the deaths the 
recorded date of death was within 1 day of the actual date of death. 
2.3.2 Validation studies of GPRD 
Approximately half of the practices contributing to GPRD also contribute data 
to THIN169. Therefore evidence for the validity of GPRD is a relevant 
consideration. Lewis et ai's study of known disease associations 167 found 
almost identical results irrespective of whether the practice concerned 
contributed to GPRD or only to THIN. In other words they found no evidence 
that the reliability of data in THIN is different to that in GPRD. 
Amongst more than 500 peer-reviewed studies based on GPRD, there are 
several which relate to its validity 174. For example, Jick et al175 176 validated 
the recording of medical information in GPRD from primary and secondary 
care and found it to be near complete. The literature also contains reviews of 
studies evaluating the quality of-other aspects of GPRD 177 178, much of which 
relates to pharmaco-epidemiological aspects of the data. 
2.3.3 Other considerations regarding the reliability of THIN 
Additional factors point towards the credibility of THIN as a reliable record of 
patient details and health events. 
Firstly, THIN represents an investment from which the owners (EPIC) derive 
a stream of revenue from licensing fees paid by the pharmaceutical and other 
organisations wishing to undertake research using primary care data. 
Furthermore, EPIC's business model involves providing management reports 
to general practices who are contributing patient data to THIN. Together 
these show that it is critical to EPIC's commercial exploitation of THIN that 
the quality of the data is high. 
Secondly, EPIC publishes details of known quality issues relating to data 
within THIN165• The possible impact of these issues is discussed below, but 
the fact that EPIC are explicit about these limitations adds to the credibility of 
the argument for the general validity of THIN. 
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2.3.4 Management of data quality in THIN 
EPIC arrange periodic downloads of data from general practices and 
undertake basic checks on data integrity. Individual records with integrity 
errors are flagged so that they can be excluded from the analysis or be given 
other special treatment. Details of data quality issues identified include those 
where data is missing (e.g. the dates of certain events), inconsistent (e.g. an 
event appears to occur after the patient has been transferred out), or of 
uncertain reliability (e.g. differentiation of actual from attempted suicide) 177. 
In some instances, recognised issues of data quality or integrity are flagged 
on individual records. Patients with records that have been flagged in this 
way were excluded by the initial data extract routines which were executed 
according to the normal procedures of the research department. 
Theoretically, this may have resulted in the exclusion of people who would 
otherwise have been selected as cases. To quantify the possible impact, the 
reader is referred to the results of applying the same 'rules' to an earlier 
version of the dataset which resulted in the exclusion of about 10% of 
cases 179. If the prevalence of data quality issues is the same amongst fallers 
in this more recent version of the data, one might expect the estimates of 
incidence to be impacted by up to 10%. However, EPIC report that in 
general it is records relating to the earliest years of data collection (Le. years 
which precede the study period) that are incomplete. Records during the 
study period will be subject to a lower prevalence of integrity errors. 
Therefore the impact of data quality issues on estimates of incidence is likely 
to be less than 10%. 
2.3.5 Population coverage of THIN 
98% of the general population in the UK are registered with a general 
practitioner18o• All sections of the population are represented in the versions 
of THIN used in this study, which covered approximately 3% of the UK 
population 165. Szatkowski et al found that the demographic of THIN is 
"broadly nationally representative" when compared to data provided by the 
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Office of National Statistics 181. Similarty, Rodriguez and Gutthann cite work 
which allows for a comparison of the age and sex distribution of the GPRD 
population with that available for the general population from census data 
and has shown these to be "closely similar" 178. 
2.3.6 Conclusion about dataset 
Evidence from a number of sources indicate the validity of THIN (and of 
GPRD on which THIN is based) and that it provides a representative sample 
of those registered with general practitioners in the UK. Where there are 
known quality issues in the data their likely impact is small. 
2.4 Tqols for initial data extraction and statistical analysis 
2.4.1 Initial data extract 
Data were extracted from THIN using Microsoft Access routines executed 
according to the Department of Epidemiology and Public Health's normal 
procedures by Mr Christopher Smith (Senior Research Fellow). These 
procedures include logic to filter data which are known to be incomplete or to 
have errors. They also ensure that the selection of any controls is property 
randomised. All subsequent routines for managing the data, and for applying 
the statistical analysis, and its interpretation were developed and undertaken 
by the author. 
The specification of the initial extract required that the start date was defined 
as the later of their date of registration at the practice or the date of practice 
computerisation, and a stop date was defined as the eartier of either the last 
THIN data collection or the date of death. The data extract was provided to 
the author as a Microsoft Access .mdb file. 
2.4.2 Statistical analysis' 
The data extracts were converted to Stata formats using StatTransfer182• All 
statistical analysis was undertaken in Stata version 9183• 
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2.5 Analysis of incidence 
This section sets out the methods used to measure the incidence of falls and 
to model the effects of relevant demographic variables. Attention is given to 
some considerations which are particular to the THIN data, including 
approaches to dealing with the possibility of prevalent recording and of 
recurrent recording of the same event. 
2.5.1 Identifying the outcome of interest 
The key outcome of interest is a recorded fall. In this study, fall events were 
identified using Read codes. Read codes comprise the comprehensive set of 
symptoms and diagnoses available to primary care practitioners in the UK for 
recording t,he reason for a consultation or other event. 
Table 2-2 summarises analysis which shows that out of the wide range of 
Read codes available, more than 80% of events relating to falls were 
recorded using the term "Fall- accidental". This term and a further seven 
account for 99% of fall events recorded in THIN. 
Table 2·2 Frequency of the most commonly occurrIng Read codes related to falls 
(excluding codes related to Assessments or Referrals) 
Number of %oftotal 
FalllH'elated Read Code occurrences occurrences 
TC ... 11 Fall - accidental 314,409 82.61% 
160 .. 00 Falls 18,566 4.88% 
R200.12 [01 Geriatric fall 15,035 3.95% 
TC ... OO Accidental falls 15,028 3.95% 
TCz .. OO Accidental falls NOS 5,220 1.37% 
TCy .. oo O t h e r f a l l ~ ~ 2,794 0.73% 
1601.00 Recurrent falls 2,334 0.61% 
1602.00 Number of falls in last year 1,232 0.32% 
TC5 .. oo Fall on same level from slipping, tripping or stumbling 996 0.26% 
U10 .. 00 [Xl Falls 690 0.18% 
TCO .. OO Fall on or from stairs or steps 575 0.15% 
Further 159 codes, indi";dually comprising <500 (0.1%) of total 3,706 0.97% 
Total occurrences of falls-related read codes 380,585 100.00% 
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Some infrequently used codes for falls correspond to events during 
hazardous occupational activities (e.g. "fall from scaffolding"). In this study, 
these events were included in the definition of falls, noting that occurrences 
of these codes are rare. However, codes for falls risk assessments were 
excluded on the grounds that they signify a perception of risk on the part of 
the clinician which does not necessarily arise from an actual fall event. 
The fall codes used for calculating incidence and mortality patterns are listed 
in Appendix B. 
2.5.2 Differentiating between prevalent and incident recording 
2.5.2.1 General evidence of prevalent recording in THIN 
Lewis et al assessed the validity of using the first recorded diagnosis as the 
index date for calculating incidence 184. They compared variations in rates of 
incidence from time of patient registration for a range of acute, chronic and 
neoplastic diseases. They found that reported incidence rates are highest in 
the months after patient registration and that it takes as much as 12 months 
for them to return to baseline. They considered the rationale behind various 
possible explanations for this finding, and concluded that incidence is over-
reported in the first months after a patient registers with a practice as a result 
of prevalent cases being recorded as incident ones. 
2.5.2.2 Analysis of prevalent recording of falls 
The role of prevalent recording of falls was investigated in the THIN dataset 
by exploring the elapsed time between date of registration and date of first 
recorded fall. For periods close or very close to the date of registration, there 
was found to be a much higher frequency of falls than for other periods. This 
was most pronounced for the falls recorded on the same date as the date of 
registration. This is i n t e r p r e t e ~ ~ to be evidence of prevalent falling, i.e. 
recording that was contemporaneous with registration and for which the 
recorded date of the event is not reliable for the purposes of identifying 
incident events. 
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Figure 2-1 Chart showing the frequency distribution of time from registration to first 
recorded fall 
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In consideration of this, it was decided to adjust for prevalent recording of 
falls in the analysis on the basis that some of (but not necessarily all) the 
recorded falls in the first few days following registration represent prevalent 
recording. Therefore, for the cohort studies, the simplifying assumption was 
made that all falls recorded on the date of registration should be treated as 
prevalent falls (Le. they should be excluded from subsequent analysis), and 
to treat all falls on dates following registration as incident cases. 
A sensitivity analysis was undertaken by recalculating crude incidence rates 
under a series of different assumptions about the period of time during which 
recording is deemed to be prevalent. The results of this are provided in 
Table 2-2, which shows that the impact of this assumption on calculations of 
crude incidence rates is small. 
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Table 2-3 Analysis of sensitivity to different assumptions about the time period 
during which recording is deemed to be prevalent 
Period follov.;ng Crude incidence rate 
registration during v.hich 
recording is deemed to per 100 pyrs 
be prevalent (95% CI) 
1 day 3.58 ( 3.56 - 3.61 ) 
7 days 3.57 ( 3.55 - 3.60 ) 
32 days 3.55 ( 3.53 - 3.58 ) 
90 days 3.52 ( 3.49 - 3.54 ) 
180 days 3.47 ( 3.45 - 3.49 ) 
2.5.3 Distinguishing discrete events 
Early exploration of the data showed that approximately half of the recorded 
falls during the study period were recurrences. In some instances, these 
recurrences were at time intervals of less than a month. Further analysis of 
the distribution of these events over time was undertaken to investigate the 
extent to which some or all of these recorded events may be repeated 
recording of the same event. The distribution of the time intervals between 
apparently recurrent events was analysed and plotted on the histogram in 
Figure 2-2. 
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Figure 2-2 Frequency distribution of different time intervals between apparently 
recurrent fall events 
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The histogram shows a pattern of peaks at time intervals which are multiples 
of seven days. Recurrences at time intervals of greater than about ten days, 
were most likely to occur at an interval that is a multiple of seven days. It 
seems highly unlikely that such a pattern occurred by chance. 
2.5.3.1 Possible explanations for the temporal pattern of recorded falls 
One possible explanation is that the pattern reflects an underlying variation in 
actual events. Whilst it seems just plausible to attribute the timing of falls to 
an extrinsic event such as a weekly visit to the shops (say), it is not clear 
what kind of extrinsic or intrinsic factors could cause this pattern to persist 
over such long time intervals. 
An alternative explanation is that the pattern results from factors that 
controlled the timing of follow-up consultations. For example, particular 
individuals may have been invited for a follow-up appointment at "same time 
next week" or "same day in a fortnight". Arrangements of this sort could go 
some way to explaining recurrences that peak at 7, 14,21 and 28 days. But 
once again, it seems unlikely that follow-up appointments fully explain the 
persistence of 7 -day peaks so many weeks after the initial recorded event. 
It seems more likely that the persistence of the pattern beyond intervals of 28 
days reflects other factors. These could include the fact that particular 
patients were more likely to receive medical attention on a particular day of 
the week (when a doctor visits a nursing home, say, or when a patient's 
'favourite' doctor who may work part-time holds a surgery). Another 
contributory factor may have been the arrangements that determined the 
timing of the recording of the event within a general practice. For example, 
where there was a delay in recording patient consultations on a practice 
system (because the consultation took place at the patient's home, say, or 
when the system was not functioning) the healthcare professional or clerical 
staff responsible at a practice may have had a tendency to undertake the 
coding on a particular day of the week. 
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The conclusion drawn from this analysis of time intervals between apparent 
recurrences is that the temporal variation in incidence is likely to be a 
reflection of arrangements which affect the timing of consultations and 
recording. In other words, many of these recorded events do not represent 
recurrent falls but are simply repeated recording of a single fall event. An 
important implication of this was that a method was needed to reliably 
distinguish between successive records, which arose due to repeated 
recording of a single event and successive records which represent discrete 
events. 
2.5.3.2 Distinguishing discrete falls based on a minimum time that 
should elapse between events 
An alternative approach was adopted based on the sensitivity of incidence 
rates to some key assumptions made about the duration of time that must 
have elapsed after an initial fall event before a subsequent event can be 
counted as a discrete event. This involved recalculating the crude incidence 
for rate using a series of different assumptions about the duration of time that 
must elapse between discrete events. The shortest duration was 3 days, the 
longest plausible duration was assumed to be 90 days. 
It is unlikely that anyone of these assumptions is likely to be 'true' in the 
sense that the cut-off point will provide a 100% reliable means of 
distinguishing discrete events from repeat recorded events. But by testing 
the sensitivity of the resulting calculations of incidence, it is possible to 
quantify the impact of the likely inaccuracy of the assumption. 
It is to be expected that where the minimum duration of time that must elapse 
between events is short, then most of the recorded events will be counted as 
discrete events and thiswill result in an estimated incidence rate that is 
relatively high. Also, it is to be expected that where the minimum duration is 
longer, then fewer recorded events will be counted as discrete, and this will 
result in lower incidence rates. To the extent that recorded falls are 
independent events it is also reasonable to expect that the relationship 
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between the lengths of time used to identify discrete events and the resulting 
incidence rates is a linear function. 
Chart 2-2 shows the results of this sensitivity analysis. The incidence rates 
calculated using different minimum intervals vary by approximately 10% from 
about 3.4 to about 3.9 per 100 person-years. It also shows that the 
relationship between the minimum interval between discrete events and 
incidence rate is not linear for minimum intervals of less than 32 days. In 
other words, for minimum intervals of less than 32 days there is evidence of 
some clustering of recorded falls. This may be a reflection of the clustering 
of actual falls, or of repeat recording of the same fall, or of a combination of 
, 
these. 
Therefore, 32 days was identified as the minimum interval of time that must 
elapse between successive recorded falls for them to be counted as discrete 
events. It was chosen because there is a strong possibility that incidence 
rates derived using minimum intervals of less than 32 days may be inflated 
by repeat recording of the same event, but there is no evidence of repeat 
recording for minimum intervals of 32 days or longer. 
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Chart 2-2 Sensitivity of our estimate of crude incidence to assumptions about the 
minimum elapsed time interval between discrete fall events 
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2.5.4 Location of the consultation where the fall was recorded 
A field called 'locate' on the medical record contains information about the 
location in which the consultation took place165 (e.g. surgery consultation, 
casualty visit, attendance by out of hours GP service, phonecall, etc.). This 
was analysed to determine whether it might be used to assist in the 
differentiation of discrete fall events or in support of possible analysis of the 
sequelae of recorded falls. 
Analysis of fall events in the study period showed that 50% of events were 
coded as "surgery consultations" and a further 12% as "acute visit by GP to 
home". 4% were "phonecall from patient". As many as a dozen other codes 
were used less frequently, including "casualty attendance" (3.3%) and 
"hospital admission" (0.08%). 6% of events were coded as "other". 
It appears from this distribution that the majority of fall events relate to 
consultations taking place in the GP surgery or as a result of a visit to the 
patient's home by a GP. As few as 5% of the total number of fall events 
relate to notifications of consultations in a hospital setting. 
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Except for the very small number of falls recorded to identify a hospital 
admission, the values of 'locate' do not offer a simple basis for differentiating 
discrete events, nor for quantifying the severity or sequelae of a fall. 
Therefore, no further work was undertaken using the data in this field in 
subsequent anlyses. 
2.5.5 Case definitions 
Based on the analysis described above, incident cases of falls were defined 
as: 
An event recorded using one of the Read codes whose descriptor 
corresponds to a fall (see Appendix B), which occurs after the day of 
registration and more than 31 days after any previous fall. 
Recurrent falls were defined as: 
Second or subsequent events recorded using one of the Read Codes 
which corresponds to a fall (see Appendix B) which occurs between 1 
month and 1 year of the previous fall. This case definition was 
adopted to maintain alignment with other studies which commonly 
define recurrence as a second or subsequent fall within a 12 month 
period. 
2.5.6 Demographic variables 
THIN records demographic data relating to the actual individual (e.g. sex, 
year of birth), and to the geography of the last recorded residential address of 
the individual (e.g. regional health authority, and an indicator of the average 
socioeconomic status of residents of their neighbourhood). These data have 
been used as a basis for analysing falls by demography. 
It should be noted that in THIN the measurement of an individual's age is 
imprecise because only the year of birth is recorded and (for the purposes of 
calculating ages and mid year populations) it is assumed that everyone is 
born on 1 July in their year of birth. 
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The socio economic status of a patient in THIN is imputed from the quintile 
into which the Townsend score of their immediate neighbourhood falls. 
Townsend score is derived from 2001 census information which describes 
prevalence of household access to a car, owner occupation, overcrowding, 
and unemployment 166. 
Other datafields in THIN were also explored to assess their potential for 
supporting analysis related to the living arrangements of fallers. As detailed 
in the Introduction, the literature shows that incidence of recorded falls are 
generally higher in institutions than in the communitl5• This may reflect the 
relative co-morbidity and frailty of residents of institutions, as well as different 
recording 'behaviours36• Therefore, although anecdote suggests that GPs 
tend not to use read codes to identify patients from nursing or residential 
homes, work was undertaken to explore whether there is sufficient reliably 
recorded information in THIN by which to stratify the analysis of incidence in 
terms of living arrangements. 
2.5.6.1 Completeness and reliability of data about living arrangements 
There are two types of data which record information about living 
arrangements. Firstly, each individual was allocated a "family number" at the 
time of registration, to link together patients living at the same address. 
Secondly, the AHD and medical tables contain information about a patient's 
type of residence. The following section describes the steps taken to 
establish whether these data could be used to infer whether the patient was 
living in an institutional setting at the time of a recorded fall event. 
2.5.6.2 Family number 
Analysis of the all-age population in THIN established that about 60% of 
individuals are attributed a family number that is shared by more than four 
people, and that about 10% of individuals have a family number shared with 
more than seven people (see Figure 2-3). 
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Figure 2-3 Chart showing frequency distribution of occurrence of household in THIN 
" ;; u 
" ~ ~
.. 
.. 
u 
c 
.. 
~ ~
" u ~ ~
'5 
Z 
E 
" z 
10000000 
1000000 
100000 
10000 
1000 
100 
10 
1 10 19 28 37 46 55 64 73 82 91 100109 118 127 136 145 154 163 172 181 190199208217 226 235244 253 262 271 
- Household size- (based on occurrences of family number) 
Discussions with EPIC identified that although the default purpose of the field 
'family number' is to link patients living at the same address, it can also be 
used to link family members living at different addresses (for example, to link 
dependant parents to a patient living at a different address) 185. Since THIN 
does not contain address details it is not possible to quantify the prevalence 
of this use of family linkage. 
It is also unclear whether the family number assigned to a patient at 
registration is updated when a patient moves address. Unless the practice 
chooses to 'create a new family' or 'move to another family' a patient will 
retain the same number they were given at registration. Furthermore, 
another consideration is that people living at the same address may not have 
been registered with the same GP. 
These issues notwithstanding, a method was developed and tria lied to 
attribute "institutional living" on the basis that people with the same family 
number represent a single household, and that where the number of older 
52 
people in a single household is high this represents some kind of institutional 
living arrangement. This status relates to what is recorded at the time of 
registration. 
Therefore the following criteria were applied to identify whether a particular 
'family number' corresponds to an institutional living arrangement: 
Either 
Or, 
More than 50 occurrences of this family number (assumption is that in 
each practice, an institutional living arrangement for older people will 
result in >50 registrations against the same family number), and 
Average duration of registration is greater than 90 days (to exclude 
institutional settings that are acute hospitals), and 
Mean year of birth is earlier than 1947 (to exclude institutional living 
arrangements for children or younger adults) 
More than 3 occurrences of this family number (assumption is that in 
each practice, a small institution will result in >3 registrations against 
the same family number), and 
More than 75% of those registered against the family number were 
aged 60 years or over during the study period (to exclude institutional 
living arrangements for children or younger adults) 
2.5.6.3 Type of residence & housing arrangements 
Information about institutional living was also sought from data on the AHD 
and Medical tables. Information about the type of residence is recorded on 
the AHD table using a code "1091000000" along with a parameter which 
takes one of six values corresponding to: nursing home, rest home, warden 
supported, sheltered accommodation, own home, other. Housing 
arrangements may also be recorded on the Medical table using one or more 
of the medcodes listed in Table 2-3. Unlike the family number data which 
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has no date recorded with it, the events on the medical and AHD tables are 
date-coded, which means their timing relative to a history of fall events can 
be determined. 
Table 2-4 List of medcodes used to indicate Institutional living arrangements 
Medcode 
13F5.00 
13F5.11 
13F5100 
13F5111 
13F5200 
13F6.00 
13F6100 
13F7.00 
13F7100 ' 
13F7200 
13F8.00 
13F8.11 
13F8100 
13FK.OO 
13FS.OO 
13FT.OO 
13FX.OO 
Description 
Part III accommodation 
Part 3 accomodation 
Part III accomodation arranged 
Part 3 accomodation arranged 
Resident in part III accomodation 
Nursing/other home 
Lives in a nursing home 
Residential institution 
Lives in a welfare home 
Lives in an old peoples home 
Hospital patient 
Hospital inpatient 
Long stay hospital Inpatient 
Lives in a residential home 
Long stay hospital inpatient 
Lives in an old peoples home 
Lives in care home 
Occurrences of these medcodes on the medical table and events coded as 
"nursing home" or "rest home" from the AHD table were identified and treated 
as evidence of institutional living arrangements wherever they were recorded 
prior to the fall event. 
Another assumption underlying this approach to identifying living 
arrangements is that once a person is recorded as having one of these 
institutional living arrangements, they do not revert to independent living. 
2.5.6.4 Estimates of incidence by living arrangement 
Using the methods described in this chapter, crude incidence rate of falls was 
calculated for people with and without the institutional living arrangements 
described above. 
The estimated incidence for people ascribed with an institutional living 
arrangement was 1.30/100 person-years (1.22 - 1.39), compared to 3.86/100 
person years (3.84 - 3.89) for those in a non-institutional setting. 
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This finding is counter-intuitive and different to what was expected, based on 
prior knowledge that falls and falls recording are more common amongst the 
relatively frail population of residential and nursing homes4596 103. Based on 
this finding, and the fact that it was not possible to establish the validity of our 
criteria for identifying institutional living, it was decided that no further effort 
should be invested in this method of identifying living arrangements, and that 
it does not currently provide a reliable exposure on which to base other 
calculations. 
2.5.7 Calculating incidence rates 
2.5.7.1 Pbpulation at risk 
For the purposes of studying the incidence rate for falls, the population at risk 
was defined as people aged over 60 years who were registered with 
practices which contributed data to THIN for the entire period 2003-2006 
inclusive aged over 60 years. The start date of the period was set at 2003 to 
include data from before the publication of the NICE guidance for falls in 
older people 124 and to exclude older data which may be subject to different 
quality issues. The end date was set at 31 st December 2006 because this 
represented the most recent full year of data. The July 2007 release of THIN 
was used which was the latest version available at the start of the study. 
(For later studies a subsequent version of the THIN database was used 
which was released in October 2008). 
The lower age cut-off of 60 years was chosen to facilitate later comparison 
with other studies including this agegroup and, in the subsequent modelling 
of the effect of other factors, to provide a full picture of the effect of increasing 
age. For the purposes of maintaining anonymity, THIN does not record a 
patient's age. Therefore the age of each subject was estimated by assuming 
that their birth date was 1 July. 
Crude incidence rates were derived using total person-years at risk which 
was calculated using mid year population levels. 
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2.5.8 Modelling incidence 
Incidence rates were modelled in order to estimate the effect on falls of 
increasing age, fe":lale sex, geographical region, and socio-economic 
deprivation. The incidence of rare events is commonly modelled using 
Poisson regression. The proper use of the Poisson distribution assumes that 
the events of interest are occurring randomly in time and independently of 
one another186• 
However, it is frequently the case that recurrent events are not 
independent187• For example, in the case of falls amongst older people 
recurrences may be clustered around particular individuals5. A number of 
, 
alternative approaches have been put forward for modelling incidence rates 
in these situations and for deriving a better estimate of relative incidence than 
is possible with poisson regression 188. In many instances, negative binomial 
regression produces a better estimates 187. 
In a Poisson distribution the mean and the variance are equal; data whose 
variance is greater than the mean are said to be over-dispersed. Robertson 
et al describe a formal test for this in which a likelihood ratio test is performed 
to assess whether the data are over-dispersed and are better fitted to a 
negative binomial model188• This is the formal test employed in the study of 
incidence. 
2.6 Analysis of survival 
2.6.1 Case. definitions and comparator 
To compare the mortality of fallers and non-fallers, a cohort of 10,000 fallers 
were randomly sampled from all those who had at least one fall event, 
(defined according-to the case definition set out in Section 2.5.5) during 2003 
to 2006. A general population comparator cohort of non-fallers was randomly 
sampled using an index date which was taken as the date for the first fall. 
For this comparator cohort we matched individually by randomly selecting 
people of the same age and sex, and who had no falls in the study period, 
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and who were registered with the same general practice and which was 
contributing data for them at the index date. 
Up to six comparators were randomly matched for each case. This matching 
ratio was selected on the basis that it was the maximum that would ensure 
that in most practice-age-sex subgroups there were sufficient non-fallers from 
which to select the required number of comparators. 
A cohort of fallers and of non-faller comparators were also prepared to 
estimate mortality amongst recurrent fallers. Once again the cohort of 
10,000 fallers was randomly sampled, but using the definition of recurrent 
faller set out in Section 2.5.5. Another general population comparator cohort 
of non-fallers was developed using the same methods as described above, 
except that the index date was defined as the date of first recurrence. 
In this way a total of four cohorts were created: a cohort of fallers with a 
cohort of non-faller comparators, and a cohort of recurrent fallers with their 
own comparator cohort of non-fallers. 
2.6.2 Contemporaneous fracture 
Recorded fractures of the hip, wrist and foreann were also identified using 
the relevant Read codes to analyse whether survival of fallers and recurrent 
fallers is significantly associated with a contemporaneous fracture. 
2.6.3 Modelling survival 
We calculated the crude mortality rates for the cohorts and used Cox 
regression to compare mortality patterns between the cohorts of fallers and 
their controls, and between recurrent fallers and their controls, stratifying on 
their matched groups. The start point for fallers was the date of first fall; for 
recurrent fallers it was the date of the recurrent fall. The end point was the 
earliest of the following events: date of de-registration from the practice, or 
last recorded data download to THIN, or date of death (certification for which 
is fonnally notified to general practices by the statutory health authorities). 
We compared mortality patterns for fracture in the same way. 
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3 Incidence of falls amongst older people in primary 
care, and risk of death 
This chapter addresses the first two project aims: 
• to quantify the overall incidence of recorded falls among older people 
in primary care in the UK, and to determine whether it varies over 
recent years or by socio-demographic attributes, and 
• to quantify risk of death associated with falls in older people in primary 
care 
3.1 Introduction 
As previously noted, recent health service initiatives in England, including the 
National Service Framework for Older People 163 and national clinical 
guidelines for falls prevention and treatment124, envisage an important role 
for general practitioners and primary care within the care pathway for the 
prevention and treatment of falls. Yet there is little published data on the 
recording and incidence of falls seen in primary care, with which to consider 
the implications of this approach. 
Therefore a study was designed, whose methods are set out in the previous 
chapter, to quantify the extent of falls known to primary care in the UK in the 
period 2003-2006 in terms of overall incidence and distribution in different 
regions and socio-economic groups, and to estimate the relative risk of death 
for older people who fall or who are diagnosed with fractures to the hip, wrist 
and forearm. 
3.2 Results 
3.2.1 Incidence 
There were 79,295 recorded fall events in 61,248 individuals aged over 60 
years of age between 2003-2006 inclusive. These falls were recorded over a 
total time at risk of 2.2 million person-years, giving an overall crude incidence 
rate of 3.58 (3.56 - 3.61) recorded falls per 100 person-years (see Table 3-1). 
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Table 3·1 Crude incidence rate of falls and recurrent falls in people aged 60 years and 
over, in THIN 2003·2006 
F,. Recurrent fairs 
Person-
Crude Incidence rate Crude Incidence rate 
Events per 100pyrs Events per 100pyrs years (95% CI) (95%CI) 
Total 2214763 79295 3.58 ( 3.56 - 3.61 ) 14870 0.67 ( 0.66 - 0.68 ) 
Sex 
Women 1219628 56239 4.61 ( 4.57 - 4.65 ) 10843 0.89 ( 0.87 - 0.91 ) 
Men 995135 23056 2.32 ( 2.29 - 2.35 ) 4029 0.41 ( 0.39 - 0.42 ) 
Agegroup (years) 
60-64 620250 5844 0.94 ( 0.92 - 0.97 ) 474 0.08 ( 0.07 - 0.08 ) 
65-69 431643 7005 1.62 ( 1.59 - 1.66 ) 677 0.16 ( 0.15 - 0.17 ) 
70-74 374983 9948 2.65 ( 2.60 - 2.71 ) 1267 0.34 ( 0.32 - 0.36 ) 
75-79 313944 14070 4.48 ( 4.41 - 4.56 ) 2437 0.78 ( 0.75 - 0.81 ) 
80-84 285853 17694 6.19 ( 6.10 - 6.28 ) 3651 1.28 ( 1.24 - 1.32 ) 
85-89 115936 13734 11.85 ( 11.65 - 12.05) 3323 2.87 ( 2.77 - 2.97 ) 
90-94 55115 8393 15.23 ( 14.91 - 15.56 ) 2281 4.14 ( 3.97 - 4.31 ) 
95+ 17039 2607 15.30 ( 14.72 - 15.90 ) 760 4.46 ( 4.15 - 4.79 ) 
Region 
10644 3.88 ( 3.81 - 3.96 ) South Cenlr9l 274076 1882 0.69 ( 0.66 - 0.72 ) 
East Midlands 99637 3246 3.26 ( 3.15 - 3.37 ) 565 0.57 ( 0.52 - 0.62 ) 
East of England 190731 7111, 3.73 ( 3.64 - 3.82 ) 1654 0.87 ( 0.83 - 0.91 ) 
London 202536 8093 4.00 ( 3,91 - 4.08 ) 1571 0.78 ( 0.74 - 0.81 ) 
North East 78314 3191 4.08 ( 3.94 - 4.22 ) 821 1.05 ( 0.98 - 1.12 ) 
North West 234878 8805 3,75 ( 3.67 - 3.83 ) 1583 0.67 ( 0.64 - 0.71 ) 
Northern Ireland 66634 1978 2.97 ( 2.84 - 3.11 ) 472 0.71 ( 0.65 - 0.78 ) 
Scotland 142773 4802 3.36 ( 3.27 - 3.46 ) 869 0.61 ( 0.57 - 0.65 ) 
South East Coast 217486 7401 3.40 ( 3.33 - 3.48 ) 1278 0.59 ( 0.56 - 0.62 ) 
South West 262210 10577 4.03 ( 3.96 - 4,11 ) 2022 0.77 ( 0.74 - 0.81 ) 
Wales 114199 3255 2,85 ( 2,76 - 2.95 ) 505 0,44 ( 0.41 - 0.48 ) 
West Midlands 203081 6638 3.27 ( 3.19 - 3.35 ) 1104 0.54 ( 0.51 - 0.58 ) 
Yorkshire & Humber 128228 3555 2.77 ( 2,68 - 2.87 ) 544 0.42 ( 0.39 - 0.46 ) 
Townsend qulntlle 
2.92 1 (Least depriwd) 546843 15959 ( 2.87 - 2.96 ) 2740 0.50 ( 0.48 - 0.52 ) 
2 496642 16321 3.29 ( 3.24 - 3.34 ) 2938 0.59 ( 0.57 - 0.61 ) 
3 433517 15726 3.63 ( 3.57 - 3.69 ) 2728 0.63 ( 0.61 - 0.65 ) 
4 362623 15444 4.26 ( 4.19 - 4.33 ) 3000 0.83 ( 0.80 - 0.86 ) 
5 (Most deprill8d) 240940 11000 4.57 ( 4.48 - 4.65) 2210 0.92 ( 0.88 - 0.96 ) 
9 (Unavailable) 134198 4845 3.61 ( 3.51 - 3.71 ) 1254 0.93 ( 0.88 - 0.99 ) 
Year 
2003 539016 19249 3.57 ( 3.52 - 3.62 ) 3478 0.65 ( 0.62 - 0.67 ) 
2004 548966 19906 3.63 ( 3.58 - 3.68 ) 3605 0.66 ( 0.64 - 0.68 ) 
2005 556281 20009 3.60 ( 3,55 - 3.65 ) 3862 0.69 ( 0.67 - 0.72 ) 
2006 570500 20131 3.53 ( 3,48 - 3.58 ) 3925 0.69 ( 0.67 - 0.71 ) 
The crude incidence rate of recorded falls was 4.61 and 2.32 per 100 person-
years amongst women and men respectively. Crude incidence rose from 
0.94 per 100 person-years in those aged 60-64 to 15.30 per 100 person-
years in those aged 90 and over. For women and men the crude rate of 
recorded recurrent falls was 0.89 and 0.41 per 100 person-years 
respectively. The age-gradient was steeper in recurrent falls than in falls, 
rising from 0.08 per 100 person-years amongst the youngest, to 4.46 per 
100 person-years in the oldest. 
There was a strong socio-economic gradient in which the crude incidence of 
falls increased by over 50% from least to greatest quintile of deprivation. 
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This represents an absolute excess of 1.64 falls per 100 person-years in the 
most deprived quintile. For recurrent falls the crude rate increased by 80% in 
the same socio-economic groups. 
There were statistically significant differences in the crude incidence of falls 
and recurrent falls between some regions. These patterns remained 
significant after adjustment for sex, age, socio-economic status and year in 
multivariate analysis (Table 3-2). In crude or adjusted analysis, there were no 
significant changes in recorded incidence of falls in any of the years of the 
study period, and no clear trend in the occurrence of recurrent falls. 
Table 3-2 Adjusted incidence rate ratios for recorded falls and recurrent falls in 
people aged 60 years and over, in THIN 2003-2006 
F.ss Recumtnf ,.". 
Mutually adjusted Incldenca rate ratios Mutually adjusted incldenGe rate ratios 
(95" CI) (95" CI) 
Sex 
Women 1.00 1.00 
Men 0.67 ( 0.66 • 0.69 ) P <0.0001 0.66 ( 0.64 • 0.71 ) p<0.0001 
Agegroup (years) 
1.00 60 ·64 1.00 
65·69 1.66 ( 1.58 • 1.78 ) 1.90 ( 1.64 • 2.20 ) 
70·74 2.67 ( 2.53· 2.82 ) 4.08 ( 3.55· 4.64 ) 
75·79 4.34 ( 4.12· 4.58 ) 8.35 ( 7.36 • 9.47 ) 
80·64 5.71 ( 5.42· 6.01 ) 13.48 ( 11.94 - 15.22) 
85-89 10.24 ( 9.70· 10.81 ) 28.96 ( 25.59· 32.76 ) 
90-94 12.27 ( 11.55 - 13.04 ) 40.22 ( 35.38 - 45.73 ) 
95 + 12.44 ( 11.47· 13.49) P <0.0001 43.19 ( 37.16 - 50.20) p<0.0001 
Region 
1.00 South Central 1.00 
East Midlands 0.94 ( 0.88 • 1.01 ) 0.95 ( 0.64 • 1.09 ) 
East of England 0.99 ( 0.94 • 1.05 ) 1.13 ( 1.02· 1.25 ) 
London 1.01 ( 0.95· 1.06 ) 1.08 ( 0.96 - 1.18 ) 
North East 1.09 ( 1.01 - 1.17 ) 1.58 ( 1.40 • 1.77 ) 
NorthWest 1.00 ( 0.95 • 1.06 ) 1.04 ( 0.94 - 1.14 ) 
Northern Inlland 0.88 ( 0.81· 0.96 ) 1.10 ( 0.96 • 1.27 ) 
Scodand 0.90 ( 0.85 - 0.96 ) 0.93 ( 0.82 - 1.04 ) 
South East Coast . 0.87 ( 0.82· 0.92 ) 0.82 ( 0.74· 0.91 ) 
SouthWest 1.01 ( 0.96 • 1.06 ) 1.05 ( 0.95 • 1.15 ) 
Wales 0.81 ( 0.76· 0.87 ) 0.71 ( 0.62 - 0.82 ) 
West Midlands 0.91 ( 0.86 - 0.96 ) 0.88 ( 0.80 - 0.98 ) 
Yorkshire & Humber 0.75 ( 0.70· 0.80 ) P <0.0001 0.65 ( 0.57 - 0.74 ) p<0.0001 
SoclCHlCOnomlc status (Townsend quintile) 
1 (Least deprlwd) 1.00 1.00 
2 1.05 ( 1.01 • 1.09 ) 1.07 ( 0.99 • 1.15 ) 
3 1.13 ( 1.08· 1.17 ) 1.10 ( 1.02· 1.19 ) 
4 1.27 ( 1.22· 1.32 ) 1.33 ( 1.24· 1.44 ) 
5 (Most deprlwd) ~ . 3 5 5 ( 1.30 • 1.42 ) 1.45 ( 1.34 - 1.58 ) 
9 (Unawllable) 1.17 ( 1.10 • 1.24 ) P <0.0001 1.31 ( 1.18· 1.46 ) P<0.0001 
Year 
2003 1.00 1.00 
2004 0.98 ( 0.94 • 1.02 ) 0.97 ( 0.90 - 1.03 ) 
2005 1.01 ( 0.97· 1.04 ) 1.05 ( 0.98 • 1.12 ) 
2006 1.00 ( 0.97 - 1.04) p=0.390 1.04 ( 0.97· 1.11 ) P=0.051 
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By varying the time interval that must elapse before a consecutive fall-coded 
event is counted as a discrete event (rather than as a consultation associated 
with a previous fall event), the resulting crude incidence rate varied between 
3.84 and 3.40 per 100 person-years respectively. In other words, at worst 
case, our simplifying assumption that events recorded within a calendar 
month of each other should be counted as only a single fall impacted the size 
of the resulting incidence rate by less than 10%. 
3.2.2 Mortality 
There was an overall crude all-cause mortality rate of 1102 per 10,000 
person-years (1052 - 1153). The corresponding mortality rate for controls 
was 579 per 10,000 person-years (564 - 594). Amongst recurrent fallers the 
mortality rate was 1677 per 10,000 person-years (1610 - 1746). 
In Cox regression modelling (Table 3-3) the mortality rate ratio for older 
people who fall was 1.78 (1.68 - 1.88), and for recurrent fallers was 2.06 
(1.96 - 2.18), compared to those who do not fall. The rate ratio was almost 
unchanged when the analysis was repeated without people who had a 
recorded fracture of the hip, wrist or forearm contemporaneous to their fall. It 
was also almost unchanged when repeating the analysis excluding people 
who had a recorded fracture contemporaneous with or subsequent to the fall 
(also Table 3-3). The proportional hazards assumption was met in all 
instances. Compared to non-fallers, the hazard rate ratio of a subsequent 
fracture of hip, forearm or wrist in fallers is 3.00 (2.64 - 3.39) for fallers and 
3.52 (3.10 - 4.00) for recurrent fallers (data not shown), in whom it is as high 
as 8.43 (5.22- 13.61) amongst people aged 60-74 years. 
Table 3-3 Hazard ratios (for all cause death with/without fractures) for fallers and 
recurrent fallers compare d t f II o non- a ers 
Fall.,. (slngl_ and teCurrent) Recurrent fall.,. -
Event 
• compared to non-fall.,. compared to non-fallers 
Hazard rate ratios (95% CI) Hazard rate ratios (95% CI) 
Death 1.78 ( 1.68 - 1.68 ) 2.07 ( 1.96 - 2.18 ) 
Men 2.38 ( 2.17 - 2.62 ) Plnt<0.OOO1 3.05 ( 2.77 - 3.35) Plnt<0.OOO1 
Women 1.53 ( 1.43 - 1.65 ) 1.75 ( 1.65 - 1.87 ) 
Agecl60-74 2.91 ( 2.33 - 3.63 ) Plnt<0.OOO1 5.27 ( 3.95 - 7.03) Plnt<0.OOO1 
Aged 75-84 1.91 ( 1.77 - 2.06 ) 2.61 ( 2.42 - 2.82 ) 
Aged 85+ 1.52 ( 1.39 - 2.62 ) 1.57 ( 1.46 - 1.70 ) 
Death for people with no 
contemporaneous fracture 1.78 ( 1.69 - 1.89 ) 2.06 ( 1.95 - 2.17 ) 
Men 2.37 ( 2.16 - 2.62 ) Plnt<0.OOO1 3.00 ( 2.73 - 3.31 ) Plnt<0.OOO1 
Women , 1.54 ( 1.43 - 1.65 ) 1.74 ( 1.63 - 1.86 ) 
Aged 60-74 2.88 ( 2.30- 3.60 ) Plnt<0.OOO1 5.37 ( 4.02 - 7.19) Plnt<0.OOO1 
Agecl75-84 1.92 (' 1.78 - 2.08 ) 2.60 ( 2.41 - 2.81 ) 
Aged 85+ 1.52 ( 1.39 - 1.68 ) 1.56 ( 1.44 - 1.68 ) 
Death for people with no contemp-
oraneous or subsequent fracture 1.81 ( 1.71 - 1.92 ) 2.11 ( 2.00 - 2.23 ) 
Men 2.41 ( 2.19 - 2.68 ) Plnt<0.OOO1 3.09 ( 2.80 - 3.40) Plnt<0.OOO1 
Women 1.55 ( 1.44 - 1.68 ) 1.78 ( 1.86 - 1.91 ) 
Aged 60-74 2.82 ( 2.25 - 3.54 ) Plnt<0.OOO1 5.61 ( 4.15 - 7.58) Plnt<0.OOO1 
Aged 75-84 1.94 ( 1.79 - 2.11 ) 2.67 ( 2.46 - 2.89 ) 
Agecl85+ 1.55 ( 1.42 - 1.70 ) 1.60 ( 1.48 - 1.73 ) 
Pint is test for interaction between sex/agegroup and risk of death associated with failing 
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Figure 3-1. Kaplan Meier plot for fallers (compared to non-fallers) 
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Figure 3-2 Kaplan Meier plot for recurrent fallers (compared to non-fallers) 
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3.3 Discussion 
Amongst people in the UK aged over 60, the crude incidence rate of falls 
recorded in primary care was approximately 3.6 per 100 person years, and 
higher in women and in older age groups. The rate is strongly associated 
with social disadvantage. In a typical general practice with an all-age 
population of 10,000 this rate of incidence extrapolates to about 78 recorded 
fall events per year amongst its 2113 people aged 60 or over. Across the 
whole of the UK it equates to more than 475,000 recorded fall events per 
year. No evidence was found that this rate of incidence changed in the 
period 2003-2006. 
People who fell experienced a substantial increase in mortality (two-fold 
increase for recurrent fallers, and more than five-fold for those aged 60-74 
years). This increase in mortality was independent of fractures recorded at 
the time of the fall or subsequently. Furthermore people who fall have an 
increased rate of subsequent fracture (approximately three-fold and, for 
recurrent fallers aged 60-74 years more than eight-fold). 
3.3.1 Strengths and weaknesses 
This is the first study which provides a national picture of the incidence of 
falls in older people recorded in general practice in the UK and of their risk of 
death. The study population includes an average of more than half a million 
people aged sixty years and over with a period of follow-up that includes the 
years following the publication of the National Service Framework for Older 
People163, and the publication of NICE guidance124• The data includes 
patient records from practices across all regions of the UK and from all 
quintiles of socio-economic deprivation. The measure of deprivation 
available for the study population is derived at a small area level so 
minimizes the dilution effect of deprivation that impacts some studies. 
The main potential w ~ a k n e s s s relates to the reliability of recorded falls as a 
measure of falls seen in primary care. Although a comprehensive set of 
codes were used to identify recorded falls, it is likely that the estimates do not 
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include some of the fall cases attending primary care because, for example, 
the fall code has not been recorded in the notes, or was recorded as free 
text, or because the code for the medical consequence of the fall (hip 
fracture, say) has been recorded instead. As a result of these gaps in the 
data, the estimates of incidence will be underestimates of the true incidence 
of falls seen in primary care. Nevertheless, since being able to identify those 
who have had a fall or a recurrent fall is critical for managing this at-risk 
group, the rates derived in this study are important. 
The impact of these "gaps" on the estimates of mortality risk is less certain. 
It can be argued that such "gaps" in the data represent events with non-
significant' sequelae, and that events may be reasonably presumed to have a 
lower risk of subsequent mortality than events which warranted medical 
attention and recording. On the other hand, to the extent that the code for a 
fall is not used for those with more serious medical consequences requiring 
hospitalisation (e.g. hip fracture) or death, these mortality rate ratios may 
represent underestimates of the subsequent risk of death. In the absence of 
additional evidence about the true scale and profile of such gaps in the data, 
it is not possible to quantify with any certainty t h ~ ~ direction of any such bias. 
3.3.2 Other studies 
Previous studies have provided data on the incidence of falls in older people 
in different settings. The incidence of attendance relating to falls injury in 
people aged 60 years and over in a sample of 18 A&E departments was 
estimated to be 5 per 100 person-years in 1999, though the preCision of this 
estimate is not clear57• The same study reported the incidence of fall related 
hospital admissions at 1.7 per 100 person-years. Medical records in primary 
care should incorporate a record of consultations in secondary care, so these 
data are c o n s i s t e n ~ ~ with the possibility that our results underestimate the total 
number of falls that should be present in patient records. It is not possible to 
use these data to calculate a comparable estimate of the incidence of 
admission because cOding to show where a diagnosis was made is not 
complete in primary care records. In Finland, a study of falling injuries 
leading to medical treatment found an overall cumulative incidence rate of 
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5.5 per 100 person-years amongst people aged 65 years and over98, which is 
similar to the overall cumulative incidence rate of falls of 4.6 per 100 person-
years amongst people aged 65 and over found in this study (data not shown). 
All of these data from primary and secondary care report incidence rates that 
are much lower than that found in questionnaire surveys in community 
settings, which suggest that during a year 28-35% of people aged over 65 
have at least one fall and that approximately one third of these falls require 
medical attention. The most likely explanation for a disparity of this scale is 
that health professionals do not routinely ask about, or systematically record, 
recent falls. 
The associations with female sex and increasing age are consistent with 
studies based in the community setting. Regarding the effect of relative 
deprivation, the literature is inconsistent. West et al found that hospital 
admissions for fall-related injury and hip fractures in those aged 70 years and 
over in the Trent region of England were higher in relation to relative 
deprivation58• However, the Health Survey for England found no association 
between self-reported falls and deprivation, but used a much weaker marker 
of deprivation than that which is available in THIN81 • In this study there was 
a clear socio-economic gradient for recorded falls and recurrent falls for men 
and for women. It is not clear the degree to which this association is 
explained by co-morbidity. The differences in the adjusted incidence rate 
ratios between some regions may be due to underlying variations in the 
incidence of falls, differential recording behaviour in primary care, or to 
residual confounding by factors related to socio-economic status. 
The finding that recurrent fallers aged 60 and over have an overall risk of 
death about twice that of non-fallers is broadly consistent with the findings of 
. d· 14111-112 d fi communrty-based .stu les ,an con Irms that older people who fall 
represent a vulnerable group of patients. Furthermore these results suggest 
that this vulnerability is not simply a function of subsequent risk of fracture. 
3.3.3 Implications 
Identifying people who fall, and especially those who fall recurrently, provides 
an opportunity to intervene on a group who are vulnerable irrespective of 
whether they have a subsequent fracture. 
The falls standard of the National Service Framework (NSF) for older people 
and the NICE guidelines on the prevention of falls both highlighted the 
effectiveness of secondary prevention of falls, and the critical role of primary 
care professionals in identifying those who have had a fall, and referring to 
specialised falls prevention services those people whose falls history 
indicates they are at risk. To identify this group, NICE guidelines recommend 
, 
that older people in contact with, health professionals are asked routinely 
whether they have fallen in the past year. The gap between the incidence of 
falls recorded in primary records and that measured in the community, which 
has not changed over recent years, suggests that this has yet to become part 
of routine practice. According to NICE recommendations, people at risk who 
require referral to a falls service include all those who have received medical 
attention for a fall or have fallen more than once in a year. Estimates derived 
in this study give an indication of the numbers of such events that are 
identifiable in medical records, and these figures are much greater than the 
actual number of patients seen at falls clinics in 2006, which averaged at less 
than 0.5 per 100 person-years 189. The implication of these findings is that 
opportunities to identify patients at risk of falling, and to intervene in this 
vulnerable group, are currently being missed. 
The overall incidence of recorded falls, and the high mortality associated with 
those who fall, indicates the scale of the burden and its unequal distribution 
amongst different social g r o u p ~ . . The rate of recorded falls has remained 
unchanged in recent years. Greater emphasis on identifying and recording 
those who fall and delivering appropriate interventions are important for 
reducing the individual and societal costs of falling. 
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4 Methods development: aetiological studies 
Several of the project aims relate to establishing the falls risk profile of 
medications. This chapter describes the methods used to: 
• establish whether the falls risk profile of more recently introduced 
serotonin noradrenalin reuptake inhibitors (SNRls) is more favourable 
than that of selective serotonin reuptake inhibitors (SSRls), 
• quantify the extent to which being prescribed antihypertensive 
medication modifies the risk of falling in older people, and 
• identify any other classes or sub-classes of medication prescribed in 
primary care whose apparent falls risk warrants investigation in future 
stu,dies. 
The methods involve two distinct study designs: classic case control design, 
and self-controlled case series analysis. 
Subsequent chapters describe how these two study designs were used to 
estimate the risk of falling associated with two different exposures: firstly, 
antidepressant prescribing and, secondly, the risk associated with anti-
hypertensive prescribing. In addition, case-control analysis was used to 
estimate the risk of falling associated with prescribing of medication in each 
of the BNF subgroups. 
For the avoidance of repetition, the core methods for all these studies are set 
out in this chapter, so that in the subsequent chapters discussion can be 
focussed on the results of the analyses and their interpretation. 
4.1 Between-subject analysis to estimate risk of falls 
associated with prescribing exposures 
The necessary d e ~ i g n n for this analysis may be conceived as a nested case 
control within the previously described cohort study. This section sets out the 
design in detail, along with the considerations leading to its use. 
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4.1.1 Outcome of interest 
The introduction summarised evidence that there are some people who fall 
for whom it may be inaccurate (or at least premature) to consider the event 
as a symptom, because their distribution is characteristic of a random event. 
The same study also showed that amongst people who fall more than once, 
the proportion whose fall event is a random event is much lower. Therefore, 
in seeking to design a study to test the hypothesis that falls are associated 
with exposures to specific medications, attention turned to how best to frame 
the outcome of interest. 
Initially, consideration was given to whether the outcome should be 'recurrent 
, 
fall'. An advantage of this would be that cases defined using this outcome 
measure would contain relatively few people for whom the event could be 
regarded as the result of a random process. However, two issues emerged. 
Firstly, it is possible that in some or many patients receiving medication, 
prescribing may be changed as a result of the fall (Le. there may be a causal 
link in one direction between prescribing and a first fall, and a link in the other 
direction between the first fall and subsequent prescribing). On this basis, it 
was recognised that using recurrent fall as the outcome would be 
problematic. 
Secondly, prior knowledge from similar studies 158 suggested that (for SSRls) 
any temporal association between medication and falls would be strongest in 
the first few weeks following the onset of prescribing. Work completed earlier 
in the project on distinguishing between multiple discrete fall events and 
repeated recording of the same event resulted in an approach which defines 
a recurrent fall as one which 0?Curs at least a month after a previous 
recorded fall. In other words, the methods developed for this project do not 
enable recurrences to be reliably identified when they occur at intervals of 
less than one month. 
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Taking these two issues together, it was concluded that it would be 
problematic to use recurrent falls as an outcome against which to assess 
short term temporal associations with prescribing and that, in the interests of 
consistency and economy of effort, other options should be considered. 
Therefore attention tumed to how eases could be defined in terms of a first 
recorded fall. An advantage of using first fall is that it avoids the 
aforementioned problem associated with identifying recurrences, especially 
those occurring at short intervals. Furthermore it provides a simpler and 
more intuitive basis for defining the index date by which to identify potential 
controls. A disadvantage of using first fall is that, as noted above, many of 
these events may be the result of a random process with the result that the 
effect size for exposure to a putative risk factor will be weaker than if eases 
were defined in terms of recurrent falling. 
4.1.2 Case definition 
Cases were identified according to the following definition to ensure a proper 
consistency with the cohort study within which the ease control is nested. 
From a study population comprising the 386 primary eare practices who 
contributed data for the entire period 2003-2006 and only those patients aged 
60 years or over during this study period, eases were defined as those who 
experienced their first recorded fall during the study period (the index date) 
and who had at least 12 months of history in THIN prior to the fall. 
Falls were defined using the same set of Read codes as in the earlier study. 
In this definition, practices were also required to have contributed data for the 
entire period. This requirement relates to the cohort study and was 
introduced to ensure that changes in incidence over time may not be 
attributed to bias arising from the characteristics of practices joining or 
leaving THIN during the study period. 
Cases were required to have at least 12 months of history in THIN to ensure 
that each patient has a sufficient record of any prescribing in the period 
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leading up to the start of the study, and to limit the potential for a fall event to 
be misclassified as a first fall. 
4.1.3 Controls, matching ratio & sample size 
For each case, up to six general population controls were randomly sampled 
using an index date which was taken as the date for the first fall. These were 
matched on age, sex, and primary care practice, and had no recorded falls 
and were contributing data at the index date. As with the cases, controls 
were required to have at least 12 months of recorded history prior to the 
index date. 
This matching ratio was selected on the basis that it was the maximum that 
would ensure that in most practice-age-sex subgroups there were sufficient 
non-fallers from which to select sufficient comparators to deliver the required 
minimum statistical power. The sample size needed for 95% power to detect 
a risk ratio of 1.2 using a 5% significance level was estimated using Egret 
SiZ19o. Assuming that at least 5% of cases are exposed, and 6 controls per 
case, the number of case control sets needed is 9600. 
4.1.4 Primary care prescribing as exposure 
4.1.4.1 Identifying exposures 
In all of the studies the main exposures of interest were prescriptions prior to 
the index date (and in some cases subsequent to it) of particular dasses of 
medication. Prescriptions were identified by interrogating the Therapy table 
in THIN using the set of codes corresponding to the exposure of interest. For 
consistency and ease of interpretation medications were grouped according 
to their classification in the British National Formulary191. 
4.1.4.2 Temporality of exposure 
Temporality of the exposures was classified in two different ways. Firstly, 
exposures were classified in terms of the elapsed time between the index 
event and final preceding prescription, as follows: current (last prescription 
within 60 days of index event), recent (last prescription was within 60-120 
days of index event), previous (more than 120 days), never, or ever (any 
7 ~ ~
prescription prior to index event) prescribed. Ever prescribed was added in 
order to test the extent to which an apparent association between first fall 
and a medication may be due to the characteristics of the group of patients to 
whom the medication is prescribed, rather than a contemporaneous causal 
effect of the medication itself. 
Secondly, exposures were categorised in terms of the elapsed time from the 
time of the first prescription. In the study of SNRls, these categories were 
defined as follows: 0 days (the same day as the prescription), 1-28 days, 29-
56 days and greater than 56 days. These categories were selected with 
reference to Hubbard et ai's study of the association between SSRI 
prescribing and hip fracture, from which it may be inferred that any effect of 
this group of medications on falls may be strongest in the first month after the 
start of prescribing. The relatively low prevalence of SNRI prescribing means 
that further subdivision of these time-bands would be likely to result in odds 
ratios with very wide confidence intervals. In the study of antihypertensives, 
for which the prevalence rate of prescribing is higher, narrower time-bands 
were defined: 0 days, 1-7 days, 8-14,15-21,22-28, and greater than 28 
days. 
For the analyses of both antidepressants and antihypertensives, the day of 
prescription (day 0) was separated from subsequent periods of elapsed time 
in order to quantify risk in the period following first preSCription, without the 
ascertainment bias that would result from falls recorded on the day of the first 
prescription. 
4.1.5 Choice of confounders 
Adjustment for age, sex and practice-related factors (e.g. deprivation, or 
behaviour with regard to recording) was accommodated by sampling controls 
matched on these variables. Other potential confounders were identified by 
reference to the literature. 
For estimating risk associated with antidepressants, potential confounders 
identified included: pre-existing diagnosis of coronary heart disease, diabetes 
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mellitus, cardiovascular disease, and prescribing of antipsychotics, 
hypnotics-anxiolytics, diuretics, digoxin or antiarrhythmics. For the study of 
antihypertensives, potential confounders included: pre-existing diagnosis of 
coronary heart disease, heart failure, atrial fibrillation, diabetes mellitus, and 
prescribing of other antihypertensives or antipsychotics. 
Data for these was extracted from the Medical table in THIN using the 
relevant Read Codes to identify diagnoses of those diseases for each case 
and control. Similarly, potential confounding by prescribing of other 
medications was addressed by interrogating the Therapy table using the 
relevant medication codes to identify prescriptions of that medication for that 
patient. The impact of each variable identified as a potential confounder was 
assessed according to the rules set out in the next section. 
In addition to the specific co-morbidities and prescribing which the literature 
highlighted as potential confounders, the need to take account of general 
frailty reflecting the cumulative effect of various co-morbidities was also 
identified. To achieve this, an adaption of Charlson index was used as a 
proxy for general frailty associated with proximity to death. Charlson index is 
a marker of one-year mortality based on previous diagnoses of 17 diseases, 
including myocardial infarction, congestive heart failure, peripheral vascular 
disease, diabetes, and cerebrovascular disease192. The algorithm for 
calculating the index was copied with permission from a postgraduate 
student in the department193• 
4.1.6 Estimation of odds ratio for exposure 
Estimates of the odds ratio for exposure were derived using conditional 
logistiC regression which accommodates the binary nature of the outcome 
(subjects have either fallen or not fallen) and the matched design (which 
requires an analysiS which is conditional on the factors used for the 
matching). 
In each study, a series of univariate models was used to test whether 
potential confounders were associated both with first fall and with the 
73 
exposure of interest, by comparing people who had ever/never been 
prescribed each of the medications. Amongst those people ever-prescribed, 
odds ratios were also calculated for current / recent and previously 
prescribed medication compared to those never prescribed. 
For each class of medication, the influence of confounders was assessed via 
bivariate models, in which the odds ratio for exposure was monitored for a 
change of 10% or more with the addition to the model of the putative 
confounder. Confounders whose impact was 10% or more were inc/uded in 
a final multivariate model. 
Technically, the estimation of an effect size which is controlled for 
confounders is based on an assumption that the exposure effect is the same 
across all values of the confounder. The extent to which there is evidence of 
a modified effect for different values of the confounder can be tested formally 
by including an interaction term and using the likelihood ratio test. In these 
studies it was identified a priori that age may modify the effect of a 
medication. Therefore the likelihood ratio test was used to assess the 
strength of evidence for a possible interaction between age and ever 
prescribed .. A p-value for the likelihood ration test of less than 0.05 was 
interpreted to be weak evidence of interaction. 
4.1.7 Estimation of population attributable risk proportion 
For exposures of specific interest, the population attributable risk Proportion, 
which is 'an estimate of the proportion of an outcome (namely, first fall), was 
estimated using the formula described by Cole and McMahon 194. The 
formula rests on assumptions that the controls are representative of the 
overall population, and the adjusted odds ratio is a good approximation of the 
relative risk, and the confounders are adequately controlled for. 
4.1.8 Limitations of the method 
One of the limitations of this method is that it remains unclear whether an 
observed effect is attributable to some extent to residual confounding, i.e. a 
level of confounding which' remains after attempts to control for confounders. 
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Residual confounding may arise where the data do not contain adequate 
recording of variables which are likely to confound the association in 
question, and so cannot be adjusted for. For example, in this study, there 
may be residual confounding due to a greater degree of unmeasured frailty in 
cases compared to their controls, which contributes to an increased 
incidence of first falls irrespective of their exposure status. In the absence of 
a direct measurement or adequate proxy of the putative confounder (frailty), 
the effect of the confounder cannot be assessed or controlled for in the 
between-person analysis of the case-control design. 
Therefore-a further methodwas used to address the possibility of residual 
confounding. The design and its methodology is known as self-controlled 
case series, and involves a within-person analysis. Using this complementary 
approach the extent of possible residual confounding due to non-time varying 
factors in the between-person analysis of the case control method was 
quantified. 
4.2 Within-subject analysis to estimate risk of falls 
associated with prescribing exposures 
4.2.1 Self-controlled case series analysis 
The self-controlled case series method was developed to investigate the 
association between the incidence of an event in periods of time with and 
without exposure 195. The relevance of the method to this project is that it is 
not subject to the confounding which characterises classical case-control 
analysis and which arises from differences between cases and their controls 
which are fixed within individuals. 
Before describing the method and its application to these studies, it is helpful 
to set out some of the features of the method highlighted by Whitaker et a1195: 
• Case series analysis is an application of the cohort approach, and 
provides estimates of relative incidence only. 
• It requires only cases. As such, the estimates of incidence relate to 
different periods of exposure witl]in subjects. 
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• The method can control for confounders which remain constant within the 
observation period, and for age. 
• It works only when the overall risk of the event during the whole 
observation period is small 
• A key limitation of the method is that it requires that the probability of an 
exposure is not dependent on the occurrence of the outcome. 
4.2.2 Case definition 
In the case series analyses undertaken, the method was applied using the 
same case definition as that set out in 4.1.2. 
For the avoidance of any confusion, it should be noted that whereas the 
cases in the case control are considered to be exposed only when the 
exposure took place prior to the first recorded fall, in the self-controlled case 
series, cases are considered to be exposed if an exposure takes place at any 
point during the study period. For this reason, the number of cases in the 
case control and a corresponding case series analysis may be different: the 
difference is accounted for by the number of people whose first exposure 
occurs after their first fall. 
4.2.3 Episodes of exposure 
The prescribing record of individuals is punctuated by events on the Therapy 
table which record when a prescription was issued. In many instances the 
entries on the Therapy table recording prescribing for a particular patient are 
at fairly regular intervals of up to about two months duration. This is 
interpreted as the pattern of recording which arises where a patient requires 
a 'repeat prescription' at regul,ar intervals because they have used up their 
previous supply of medication. In some cases, the record may include much 
longer intervals between prescriptions. This is assumed to represent a 
period of time duringwhich the patient was not taking the medication and 
therefore was not currently exposed. 
Based on analyses of the elapsed time between prescriptions which shows 
that most prescriptions are issued at intervals of less than 60 days (see 
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Figure 4-1 to Figure 4-4 inclusive), we calculated episodes of continuous 
exposure, where an episode is defined as a series of consecutive 
prescriptions at intervals of not more than 60 days, and which ends 60 days 
after the last prescription in the series. 
Figure 4-1 Frequency distribution of the time interval between successive 
prescriptions of SNRls for cases 
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Figure 4-2 Frequency distribution of the time interval between successive 
prescriptions of 55Rls for cases 
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Figure 4-3 Frequency distribution of the time interval between successive 
prescriptions of thiazides for cases 
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Figure 4-4 Frequency distribution of the time interval between successive 
prescriptions of beta blockers for cases 
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Using this definition of episodic exposure, the exposure history of a study 
participant can be conceived in terms of one or more episodes of exposure, 
separated by periods of non-exposure as shown in Figure 4-5. 
Figure 4-5 Illustration of how series of prescriptions at intervals of not more than 60 
days are treated as discrete episodes of exposure 
Date of first prescription 
Interval of more than 60 days 
without prescription marks the end 
ofthe episode 
Subsequent prescriptions at 
intervals of not more than 60 days 
I 
4.2.4 Definition of risk periods 
The core of case series analysis is the estimation of relative incidence for 
different periods of exposure (risk periods). In the studies that follow, the 
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observation time for each person was divided into periods of non-exposure 
and exposure. Periods of exposure were sub-divided based on the risk 
profile determined in each of the respective case-control studies. As 
previously noted, the exposure period used in the case-control study of 
antidepressants was chosen to match that used in Hubbard et ai's study of 
SSRI prescribing and hip fracture. The same risk period was used in the 
corresponding case series study. This was a pragmatic choice: shorter risk 
periods would have led poor precision due to the relatively low frequency of 
SNRI prescribing. In the case series study of antihypertensives (most of 
which are more commonly prescribed than SNRls) a risk period was selected 
with reference to the periods of highest risk following first prescription 
observed in the corresponding case-control study. 
Accordingly, Figure 4-6 shows how, for the study of risk associated with 
SNRls, the periods of exposure were subdivided into the time immediately 
after the start of the episode of exposure (Days 1-28), and the time from Day 
29 until the end of the episode. Day 0 (Le. the same day as the start of the 
episode) was separated out to avoid ascertainment bias related to a greatly 
increased rate of falls recording at the time the first prescription is given (as 
described in Chapter 2). All remaining person-time was used as the baseline 
(unexposed) comparison period. 
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Figure 4-6 Illustration of how the entire observation time is divided into different risk 
periods 
Date of first prescription 
Interval of more than 60 days 
without prescription marks the end 
ofthe episode 
Subsequent prescriptions at 
intervals of not more than 60 days 
I 
\ 
Risk period 2 extends from Day 29 
to the end of the episode 
Risk period 1 extends from 
Day 1 to Day 28 
Risk period 0 is Day 0 only 
Baseline risk 
Baseline risk 
Computing the relative incidence of an event for each of the risk periods 
requires that the entire observation period for each individual is divided up 
and attributed to one of the risk periods. The method proposed by Whitaker 
et al for doing this involves setting "cutpoints" at the start and end of each risk 
period and at the start and end of the whole observation period, by which the 
whole period is divided into a series of "slices" of varying durations for which 
relative incidence can be calculated195. 
In the simplest case (no adjustment for age or confounders), these "slices" 
correspond exactly with the risk periods. This is the situation shown in Figure 
4-7. As will be seen below, the incorporation of adjustment for age or other 
confounders will require the introduction of additional cutpoints which will 
subdivide risk periods into smaller "slices". 
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Figure 4-7 Illustration of the risk periods defined in the case series analysis of 
antidepressant prescribing and the corresponding "cutpoints" required to divide the 
observation period into relevant "slices". 
Cutpoint to mark Cutpoint to mark 
end of Day 28 end of episode 
Cutpoint to mark end of Day 0 
Cutpoint to mark 
end of Day 28 
Cutpointto mark end of Day 0 
rk 
Cutpoint to mark start of episode Cutpoint to mark start of episode 
Cutpoint to mark start of 
observation period 
Cutpoint to mark end 
of observation period 
It should be noted that this represents an idealised version. In practice, there 
may be individuals where the first episode of exposure has started before the 
start of the observation period, and episodes of exposure may not end until 
after the end of the observation period. 
For simplicity, the initial analysis undertaken aggregated the respective risk 
periods from the various episodes (i.e. no distinction was made about 
whether the high risk period occurred in a first or subsequent episode of 
prescribing). As discussed below, this became the basis of what is described 
as the standard analysis. Subsequent analysis involved disaggregating first 
and subsequent episodes of prescribing, to assess whether any association 
that exists is primarily with the onset of prescribing in the very first episode 
only, or with the onset of prescribing in any episode. 
4.2.5 Adjusting for age 
Whitaker et al also describe how to include age effects in the model to 
correct for confounding by age 195. Based on our finding from the same 
dataset that the incidence rate of recorded falls in older people is strongly 
related to age (rate ratio of approximately 12 for people aged 90 years 
compared to people aged 60-64 years)196, we adjusted for likely age-related 
variation in the incidence of first fall using 1 year agebands. We did this by 
expanding the number of risk periods to allow for the full range of ages of 
study participants. 
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In sensitivity analysis we found that increasing the ageband intervals to 6-
monthly made negligible impact on the estimates of relative incidence. 
Figure 4-8 shows how incorporating adjustment for age in 1 year agebands 
increases the number of "slices" into which the observation period is divided. 
Figure 4-8 Illustration of how additional 'cutpoints' are incorporated in order to 
prepare the data for an age-adjusted analysis 
4 : .... 
Additional cutpoint to mark end of 
72nd year 
Additional cutpoint to mark end of 
73nd year 
4.2.6 Other possible sources of confounding in case series 
analysis 
The focus of analyses in the case series method is on the relative incidence 
of the event (first fall) for periods of risk which are defined relative to the 
exposure of interest. If there is a temporal association between the exposure 
of interest and exposure to some other factor which is known to be 
associated with falls in older people, then there is a possibility of 
confounding . . (For example, if the onset of antidepressant prescribing is 
associated with the onset of antipsychotic prescribing, say, for which there is 
an established association with falls). 
In such an instance, one way to address this is to adjust for the possible 
co.nfounding. The m ~ t h o d d for doing this involves identifying episodes of 
exposure to the confounding medication and the associated risk periods for 
which there is evidence of an effect on falls. Additional cutpoints are 
introduced to reflect the periods of increased risk which might be attributable 
to the confounding medication. In t h i ~ ~way the observation period is divided 
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into an increasing number of shorter "slices" (see Figure 4-9), each of which 
can be categorised in terms of its exposure to the confounder, and to age, as 
well as to the primary exposure of interest. The definition of these additional 
risk periods for the confounding prescribing is further complicated where the 
prescribing is recurrent. 
Figure 4-9 Illustration of how the observation time is further divided in order to 
prepare for adjustment for a confounding exposure to episodic prescribing 
Additional cutpoint to 
mark start of prescribing 
of confounding exposure 
4.2.7 Sample size 
Additional cutpoint to 
mark end of highest risk 
period of prescribing of 
confounding exposure 
4.2.7.1 Case series analysis of antidepressants 
Using the sampsLsccs utility in Stata it was estimated that with an average 
follow-up of 6 years, 1900 cases exposed to SNRls are required to provide 
85% power to detect a risk ratio of 1.7 for an increased risk of fall in the first 
28 days. 
Therefore, in order to achieve sufficient precision in the estimates of relative 
incidence in the case. series analysis of SNRls the study population was 
extended to cover the entire period 2001-8 inclusive. This was because of 
the relatively small numbers of participants exposed to SNRls in the period 
2003-2006. In other respects, the case definition described above remained 
unchanged. 
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4.2.8 Case series analysis of antihypertensives 
In contrast to this, the numbers of participants exposed to antidepressants or 
to antihypertensives in the period 2003-2006 were much higher and provided 
sufficient precision without any need for an extension of the study period. 
Based on an average follow-up of 3 years, 1100 exposed cases are required 
to provide 80% power to detect a risk ratio of 1.7 for an increased risk of fall 
in the first 21 days. 
4.2.9 Estimating relative incidence 
In case series analysis, the timing of events is treated as a random process . 
• Since the analysis depends on cases, the likelihood is conditional on an 
event having occurred during the period of observation, therefore the relative 
incidence of first fall in these different periods of exposure is estimated using 
conditional Poisson regression. 
The fact that first fall is a unique event means that it cannot be truly random. 
Nevertheless, Whitaker et al explain that the case series method remains 
valid for rare non-recurrent events because "the times of a first occurrence of 
a rare potentially recurrent event and the times of occurrence of a rare 
unique event cannot in practice be distinguished,,195. There is no formal 
definition of what constitutes a "rare event" in this context, but the judgement 
of Professor Farrington who was instrumental in the early exploitation and 
subsequent development of the method197, is that the incidence of recorded 
fall in THIN is sufficiently rare 196 to justify treating first fall as a random 
event198. 
4.2.10 Underlying assumptions and tests for breaches 
In each case series study, sensitivity analysis was undertaken to assess the 
possibility of a breach of the assumption on which the method depends: that 
the occurrence of an event does not alter the probability of subsequent 
exposure. The first of these analyses was to test whether there might be a 
short-term dependency between a fall and subsequent exposures (as a result 
of, say, a medication review leading to a change in prescribing). As 
explained by Whitaker et ai, in a situation such as this, a fall would be 
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unlikely to occur in the period immediately prior to an exposure (because the 
occurrence of the fall has led to a reduced probability of subsequent 
exposure) 195. This would result in an incidence rate for the baseline period 
which is artificially low, with the result that the rate in the period following 
exposure would be exaggerated. To test for this potential dependency, the 
standard analysis (described above) was amended to include an additional 
observation period corresponding to the 30 days prior to the start of an 
episode. Incidence rate ratios for the standard analysis were compared with 
the respective risk periods in the sensitivity analysis, on the basis that a large 
difference in rate ratios would be evidence that events influence the 
probability ~ o f f a subsequent exposure. 
A second sensitivity analysis was performed to test for a breach of the 
assumption: that mortality subsequent to a fall alters the probability of 
subsequent exposure. Whitaker et al state that case series analysis of 
deaths (an example of the most extreme situation, for which there would be 
an inevitable dependency for subsequent prescribing!) may be undertaken 
"by taking the observation period as the time from exposure to the end of the 
planned observation period", provided that the death events are rare. 
However, given the advanced age of the participants and their associated 
mortality196, it was decided that the second sensitivity analysis should 
comprise a test which removes from the standard analysis all people who 
died within 90 days of the recorded fall, to observe whether this resulted in a 
considerable change in the observed size of effect. Following consultation 
with Professor Farrington at the Open University, it was judged that the 
approach of excluding cases who died following a fall would be preferable to 
the alternative approach which itself rests on a further assumption (that 
mortality following a fall is rare) which it would be difficult to defend198. 
Whitaker at al set out a further test which, effectively, involved removing from 
the analysis all individuals whose fall was prior to exposure. (Their approach 
to achieving this is to redefine the observation period for each individual so 
that it starts at age at exposure. Since the analysis is conditioned on the 
number of events, an individual with no events will contribute nothing to the 
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estimation of the incidence rate). The purpose of this is to undertake an 
analysis in which there is no possibility of a prior fall event exerting an effect 
on the probability of a subsequent event. The analysis is now a comparison 
of incidence rates between different post-exposure periods. It no longer 
provides what the standard analysis does: a comparison of incidence rates 
before and after exposure. However the test requires that exposure for an 
individual is unique. This chapter has already described how recorded 
prescribing of the medications of interest in these studies are recurrent. This 
means that this test has limited utility in this study and therefore was set 
aside. 
In their early explanation of the method, Whitaker et al noted that "a general 
approach to the analysis of event-dependent exposures is a topic of ongoing 
research". More recently, Farrington et al published an extension to the 
method for rare non-recurrent events which circumvents the problem of the 
underlying assumption regarding the independence of events and the 
probability of subsequent exposure 199. Consideration is given to this in the 
final chapter 
4.3 Application of the method 
Initially, no distinction was made between risk periods occurring in different 
episodes of prescribing (Le. the period corresponding to the onset of first 
ever prescribing was aggregated with the periods relating to the onset of 
prescribing in subsequent episodes). Age was adjusted for in 1 year 
agebands. In each study this was the basis of what was considered to be 
standard analysis. 
Where the results of the earlier case control analysis indicated that the 
greatest effect would be found in the first episode of prescribing, the standard 
analysis was repeated, but separating out periods corresponding to first and 
subsequent episodes of exposure, and periods of non-exposure between 
episodes. This constituted an extension of the standard analysis. 
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Whitaker et al set out some of the Stata code to undertake these analyses2oo. 
In the following studies, their approaches have been combined and adapted 
to analyse relative incidence for exposures which may occur in a series of 
episodes of irregular duration and intervals, whilst adjusting for age and other 
possible confounders. 
In adapting the code it has been written to facilitate the 'flexing' of key 
assumptions about the length of time that may elapse between prescriptions 
before an episode is deemed to have ended, and the definition of alternative 
risk periods (e.g. to assist with some of the sensitivity tests described below). 
It has also ~ b e e n n written in such a way as to incorporate adjustment for other 
variables which may confound an observed association, as described in 
4.2.6. 
These methods were applied first of all to the study of SNRls. The reason for 
this is that it seemed prudent to start by applying the method to a class of 
medication for which the association with falls is already relatively well 
established (whereas it is less clear in the case of antihypertensives). In 
addition it seemed that the gap in the literature could be addressed with 
greater certainty than might be the case with antihypertensives. 
All of the following studies used the October 2008 version of THIN which 
became available since the earlier stUdies of incidence and mortality were 
completed (which used the October 2007 version). 
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5 Serotonin-norepinephrine reuptake inhibitors and 
falls 
This chapter addresses the third project aim which is: 
• to establish whether the falls risk profile of more recently introduced 
serotonin noradrenalin reuptake inhibitors is more favourable than that 
of selective serotonin reuptake inhibitors 
5.1 Introduction 
Antidepressant medications have been associated with an increased risk of 
falls and fracture in the elderly, and this increase in risk appears to be 
common to both the older tricyclic antidepressants (TeAs) and the more 
recent selective serotonin reuptake inhibitors (SSRls)129. It has been 
suggested that newer dual action serotonin-norepinephrine (noradrenaline) 
reuptake inhibitors (SNRls) may be safer in terms of fracture risk 159 and risk 
of falling in residential care and nursing homes 126 but there are no data on 
the risk of falls associated with the use of these drugs in older people in the 
community setting. Therefore the independent effect of SNRls on the risk of 
falls in older people was investigated using classical case-control analyses 
and case series analysis. The methods for these are set out in detail in the 
previous chapter. 
5.2 Results 
As described in the previous chapter, 9682 people were identified who were 
aged >60 years and who experienced a first fall, and 52 100 matched 
controls (Table 5-1). The mean age of cases was 77.5 years, and 76.4 years 
for controls. Thirty two percent of cases and controls were male. 
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Table 5-1 Characteristics of cases and controls in THIN 2003-6 
Cases % Controls % 
n= 9682 52100 
Age 
Mean age (years) 77.5 76.4 
Gender 
Females 6602 68% 35573 68% 
Males 3080 32% 16527 32% 
CHD ever 6974 72% 34051 65% 
~ ~
Diabetes or CVD ever 5425 56% 23559 45% 
Antipsychotic (current prescribing) 509 5% 1371 3% 
Hypnotic/anxiolytic (current prescribing) 1208 12% 3744 7% 
Diuretic prescription (current prescribing) 3657 38% 16459 32% 
Digoxin (current prescribing) 594 6% 2022 4% 
Type1a Anti-arrhythmics (current prescribing) 0 0% 0 0% 
CHD = corononary heart disease. CVD = cardiovascular disease. 
Results of the analyses of ever (previouslrecentlcurrent)/never prescribing 
are shown in Table 5-2. Prescribing of SNRls was uncommon compared 
with prescribing of TCAs and SSRls; of the controls, 806 (2%) had ever been 
prescribed an SNRI, and most of these (768) were prescribed venlafaxine, 
with small numbers having been prescribed reboxetine (41 ) or duloxetine 
(19). Cases who had experienced a first fall were more likely than controls to 
have ever been prescribed an SNRI (3%), and the unadjusted OR associated 
with having ever been prescribed an SNRI was 1.77 (1.53 - 2.05). The risk of 
first fall was highest in those currently prescribed an SNRI, with a 2.5-fold 
increase in risk compared with those who had never been prescribed an 
SNRI. 
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Table 5-2 Association between first recorded fall and prescribing of antidepressants 
in THIN 2003-6 
Exposure Cases Controls Odds ratio Odds ratio 
n=9682 n=52100 (95% confidence intervals) (95% confidence intervals) 
Adjusted for antipsychotics 
& hypnotics/anxiolytics 
SNRI 
NeYer prescribed 9426 ( 97% ) 51294 ( 98% ) 1.00 1.00 
EYer prescribed 256 ( 3% ) 806 ( 2%) 1.n ( 1.53 - 2.05 ) 1.30 (1.12- 1.51) 
Pre\1ously prescribed 135 ( 1%) 516 ( 1%) 1.47 ( 1.21 - 1.78 ) 1.09 ( 0.90 - 1.33 ) 
Recently prescribed 6 ( 0% ) 34 ( 0%) 0.98 ( 0.41 - 2.35 ) 0.79 ( 0.33 - 1.90 ) 
Currently prescribed 115 ( 1% ) 256 ( 0%) 2.49 ( 1.99 - 3.12 ) 1.79 ( 1.42 - 2.25 ) 
SSRI 
NeYer prescrilied n26 ( 80% ) 45750 ( 88% ) 1.00 1.00 
EYer prescribed 1956 ( 20%) 6350 ( 12% ) 1.88 ( 1.n - 1.99 ) 1.55 ( 1.46 - 1.65 ) 
Pre\1ously prescribed 1081 ( 11% ) 4208 ( 8%) 1.57 ( 1.46 - 1.69 ) 1.31 (1.21 - 1.41 ) 
Recently prescribed 111 ( 1% ) 297 ( 1% ) 2.24 ( 1.79 - 2.80 ) 1.85 ( 1.48 - 2.32 ) 
Currently prescribed 764 ( 8% ) 1845 ( 4%) 2.50 ( 2.29 - 2.74 ) 2.04 ( 1.86 - 2.24 ) 
Tricyclic 
NeYer prescribed 7067 ( 73% ) 42209 ( 81% ) 1.00 1.00 
EYer prescribed 2615 ( 27% ) 9891 ( 19%) 1.64 ( 1.56 - 1.72 ) 1.38 ( 1.30 - 1.46 ) 
Pre\1ously prescribed 1811 ( 19% ) 7313 ( 14%) 1.54 ( 1.45 - 1.63 ) 1.30 ( 1.23 - 1.39 ) 
Recently prescribed 106 ( 1% ) 390 ( 1%) 1.70 ( 1.36 - 2.11 ) 1.44 ( 1.16 - 1.80 ) 
Currently prescribed 698 ( 7% ) 2188 ( 4%) 1.96 ( 1.79 - 2.14 ) 1.61 ( 1.46 - 1.76 ) 
Of the potential confounders evaluated for inclusion in bivariate models, 
prescribing of anti psychotics and hypnotic-anxiolytic drugs altered the effect 
by 10%. In the final model, after adjustment for antipsychotic and hypnotic-
anxiolytic prescribing, the effect of current use of SNRls was reduced but still 
demonstrated an almost 80% increase in risk (adjusted OR 1.79; 1.42 -
2.25). The magnitude and significance of effects were very similar when 
prescriptions were limited specifically to venlafaxine. 
Evidence of an interaction with age for ever prescribed TeAs (p = 0.0003) 
was found, for which the size of the effect (i.e. risk of first fall) increased with 
age. For ever prescribed SNRls and SSRls, no evidence of interaction with 
age was found (p = 0.884 and p = 0.134 respectively). 
The risk of first fall was apparent within the first 28 days following first 
prescription of an SNRI (adjusted OR 3.42; 0.96 - 12.24) and was maintained 
in the subsequent 28 days (adjusted QR 4.40; 1.46 - 13.27) - see Table 5-3. 
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Table 5-3 Association between first recorded fall and first prescription of 
antidepressant in THIN 2003-6 
First prescription Cases Controls Odds ratio Odds ratio 
(Deys elapsed before first fall) n=9682 n=52100 (95% confidence intetVals) (95% confidence IntetVals) 
Unadjusted Adjusted for anti psychotics 
& hypnotlcs/anxiolytics 
SNRIs (Any) 
No prescriptions prior to index date 9426 ( 97.36% ) 51294 ( 98.45%) 1.00 1.00 
o days o ( 0.00% ) 1 ( 0.00% ) 
1-28 days 5 ( 0.05% ) 5 ( 0.01% ) 5.10 ( 1.45- 17.94 ) 3.42 ( 0.96 - 12.24 ) 
2 ~ d a y s s 7 ( 0.07% ) 6 ( 0.01% ) 6.91 (2.32- 20.58 ) 4.40 ( 1.46 - 13.27 ) 
>56 days 244 ( 2.52% ) 794 ( 1.52% ) 1.71 ( 1.48- 1.98 ) 1.26 ( 1.09 - 1.47 ) 
SSRls 
No prescriptions prior to index date 7726 ( 79.80% ) 45750 ( 87.81% ) 1.00 1.00 
o days 6 ( 0.06% ) o ( 0.00% ) 
1-28 days 31 ( 0.32% ) 67 ( 0.13% ) 2.74 ( 1.79- 4.22 ) 2.34 ( 1.52 - 3.62 ) 
28-56 days 36( 0.37% ) 54( 0.10% ) 3.62 (2.35- 5.58 ) 3.09 ( 2.00 - 4.78 ) 
>56 days 1883 ( 19.45% ) 6229 ( 11.96%) 1.85 ( 1.74- 1.96 ) 1.52 ( 1.43 - 1.62 ) 
¢ 
Tricycllcs 
No prescriptions prior to index date 7067 ( 72.99% ) 42209 ( 81.02% ) 1.00 1.00 
o days 8 ( 0.08% ) 7 ( 0.01% ) 7.38 ( 2.66- 20.45 ) 7.12 ( 2.56 - 19.82 ) 
1-28 days 29 ( 0.30% ) 52 ( 0.10% ) 3.51 (2.22- 5.57 ) 3.18 ( 2.00 - 5.07 ) 
28-58 days 21 ( 0.22% ) 65 ( 0.12% ) 1.91 ( 1.16- 3.15 ) 1.65 ( 9·99 - 2.73 ) 
>56 days 2557 ( 26.41% ) 9767 ( 18.75%) 1.62 ( 1.54- 1.71 ) 1.36 ( 1.29 - 1.44 ) 
When the analysis was validated by searching for the anticipated effects of 
other antidepressants, an increased risk of first fall with ever having been 
prescribed either a TeA (unadjusted OR 1.64) or an SSRI (unadjusted OR 
1.88) was found (see Table 5-2); these values were very similar in size to the 
effects on hip fracture previously described for a similar cohort158. The 
adjusted OR for first fall with current exposure to SSRls was 2.04 (1.86-
2.24), which was slightly greater than that for TeAs 1.61 (1.46 - 1.76) and 
similar to other findings for antidepressants 128. Both TeAs and SSRls were 
associated with an acute increase in risk in the first few weeks after the first 
prescription, which was more marked for TeAs than for SSRls. The effect of 
SNRls on the first fall in the analyses was very similar to that seen for SSRls 
and for TeAs. 
When the data were extended to cover the period 2001-8 (as described in 
the previous chapter in 1.1.3) there were 1916 fall cases exposed to SNRls. 
On conducting the self-controlled case-series analysis (Table 5-4) to 
compare the risk of falls in periods of exposure with baseline (unexposed) 
periods, the risk was found to be significantly increased in the period 1-28 
days after commencement of an e p i s ~ d e e of SNRI treatment (although 
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smaller than that seen in the case-control analyses) and in the period from 
day 57 to the end of treatment. Adjustment for the confounders used in the 
case-control model did not alter the effect by 10%. The results were also 
very similar when exposure was restricted to venlafaxine treatment alone. 
Table 5-4 Association between SNRI antidepressant exposure (any treatment 
episode) and first fall: case-series analysis in THIN 2001-8 
First Follo'IMJp time Incidence rate ratio 
Period of exposure falls (person years) (95% confidence intervals) 
(n) 
Any SNRI • 
Unexposed (pre/posUbetween episodes) 1308 8960.7 1.00 
Day 0 of episode 17 11.7 10.03 ( 6.15 - 16.36) 
Day 1 - 28 of episode 71 329.9 1.49 ( 1.15- 1.93 ) 
Day 29 - 56 of episode 56 330.5 1.18 ( 0.88'- 1.57 ) 
Day 57 - end of episode 464 2669.4 1.29 ( 1.08- 1.53 ) 
When this standard analysis was repeated on the same data but separating 
out periods of first and subsequent exposure, the risks of fall in the periods 
following first exposure were higher than in those following a subsequent 
exposure (see Table 5-5). 
Table 5-5 Association between first or subsequent episodes of SNRI prescribing and 
first fall: case series analysis in THIN 2001-8 
First Time at Incidence rate ratio 
Period of exposure falls risk (95% confidence 
(n) (Pyrs) intervals) 
Any SNRI 
Unexposed (time before first episode) 1223 8352.9 1.00 
Day 0 of first episode 9 3.9 13.41 (6.93 - 25.97 ) 
Day 1 - 28 of first episode 36 109.1 1.90 ( 1.35 - 2.68 ) 
Day 29 - 56 of first ~ p i s o d e e 28 110.4 1.48 ( 1.01 - 2.17 ) 
Day 57 - end of first episode 266 1320.6 1.43 ( 1.16 - 1.76 ) 
Unexposed (time between episodes) 85 611.7 1.00 ( 0.72 - 1.38 ) 
Day 0 of subsequent episode 8 7.9 6.86 ( 3.33 - 14.15) 
Day 1 - 28 of subsequent episode 35 220.8 1.07 ( 0.72 - 1.58 ) 
Day 29 - 56 of subsequent episode 28 220.2 0.86 ( 0.56 - 1.31 ) 
Day 57 - end of subsequent episode 198 1344.9 1.02 ( 0.78- 1.33 ) 
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Both of the analyses to test for a possible breach in the underlying 
assumption concerning the independence of falls and the probability of 
subsequent exposure resulted in only small changes in the estimated size of 
the effect (see Table 5-6 below). This was interpreted as there being only 
weak evidence for a breach of the assumption regarding independence of 
falls and probability of subsequent exposure, and that the effect of any bias 
related to mortality following a fall is small. 
Table 5-6 Sensitivity analysis to test dependence between fall event and risk of 
subsequent exposure to SNRI antidepressant in THIN 2003-8 
First Time Including a prlH1XPOSure First Time Excluding cases '1110 
Period 01 exposure fa/ls at risk period fa/ls at risk died v.ithin 90 days of 
(n) (pyrs) IRR(95% CI) (n) (pyrs) fa/l IRR(95% CI) 
Any SNRI 
Unexposed periods 1268 8722.9 1.00 1029 7317.5 1.00 
30 day period prior to any episode 40 237.7 1.11 (0.80- 1.55 ) 
Day 1 - 28 of episode 71 329.9 1.51 ( 1.16- 1.96 ) 52 266.2 1.41 (1.04- 1.91 ) 
Day 29 - 56 of episode 56 330.5 1.19 (0.89- 1.59 ) 44 267.1 1.19 (0.86- 1.65 ) 
Day 57 - end of episode 464 2669.4 1.30 ( 1.09- 1.55 ) 331 2060.5 1.23 ( 1.00- 1.50 ) 
5.3 Discussion 
The risk of first fall was increased almost 2-fold in people currently prescribed 
an SNRI, and this increase in risk was apparent in the first month after the 
first prescription. The sizes of effect were similar to those seen for SSRls and 
TeAs. Based on the prevalence in this population during the study period, 
the relative risk corresponds to a population attributable risk proportion in the 
region of 0.5%. In the within-person analysis, the effect of SNRls was slightly 
smaller than seen in the between-person analysis. This remained the case 
even when the analysis differentiated between risk periods associated with 
first ever and subsequent exposures. This suggests that the findings of the 
case-control analysis may have been overestimates. 
5.3.1 Study S t r ~ n g t h s s and Weaknesses 
The main strengths of the study include the large number of cases and the 
fact that the data were collected prospectively, which means that recall of 
medication exposures and of falls is not a source of bias. In the UK, 
antidepressant medications are available only on prescription, and previous 
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studies have shown these to be well documented where there is a 
computerized system201 . Therefore, in settings in which practices contribute 
to THIN, the data provide a reliable measure of prescribing. 
Medications were differentiated according to standard classifications in the 
British National Formulary191. The data and analysis were validated using 
other classes of antidepressants and these exhibited the expected pattern of 
risk, based on evidence from other studies. 
The main potential weaknesses of the study are the validity of the recording 
of fall events, and the incomplete control of confounding. As previously 
discussed, falls recorded in primary care are a subset of the falls self-
reported in surveys. Data are not available to describe which self-reported 
falls are more likely to be recorded in primary care, but the earlier study in 
this project found that patients with recorded falls are an important group who 
experience increased mortality compared with non-fallers (2-fold increase for 
recurrent fallers, and a more than 5-fold increase for recurrent fallers aged 
60-74 years), which suggests that recorded falls are more likely to be those 
for which medical attention was required196. Nevertheless, incomplete 
recording of falls raises the possibility of differential ascertainment of falls for 
patients receiving antidepressant medication. Such a bias would have led to 
overestimated ORs. However, the day of the prescription was excluded from 
the exposure time, which avoided ascertainment bias of falls recorded at the 
time of initial prescribing. Moreover, the sizes of effect found for TeAs and 
SSRls are very similar to those previously reported in this dataset for hip 
fracture, which is relatively unlikely to be under-recorded158. 
The possibility that these results are affected by confounding by co-morbidity 
was explored in several ways. In the case-control analysis, a number of 
potential confounders were controlled for and the final model was adjusted 
for prescription of antipsychotics and hypnotic-anxiolytics, which were the 
only potential confounders to reduce the OR for the effect of SNRls. The 
extent to which the effect was attributable to characteristics of the patients 
rather than to prescribing was explored by comparing the risk for people 
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currently and previously prescribed SNRls; this analysis revealed much 
stronger effects for current prescribing. 
Finally, further analysis was undertaken using the case series method, which 
controls for factors that vary between individuals, such as frailty and severity 
of depression. These factors may remain constant for long periods but the 
fact that they can and do vary over time within individuals means that there is 
some uncertainty about the extent to which the case series method fully 
adjusts for their effect. This applies particularly to depression, the symptoms 
of which may wax and wane, whereas underlying frailty tends to increase 
over the lorig term 
Two analyses were applied to test sensitivity to the assumption underlying 
the method: that the occurrence of a fall does not affect the risk of a 
subsequent exposure. These were judged to be reasonable assumptions 
because there was only weak evidence of 'depletion' in the incidence of falls 
in the period prior to exposure, or of significant bias due to mortality following 
a fall. 
The smaller size of effect in the case-series analysis (compared to the case 
control) suggests that the case-control analysis may have overestimated the 
true effect, because of bias. Nevertheless, the finding of increased fall risk in 
the first 28 days after the start of treatment with SNRls in the case-series 
analysis suggests an independent adverse effect of this drug on fall risk. 
The extent, if any, of non-compliance to medication, could not be assessed 
and both methods rely on the dates of prescriptions to approximate periods 
of exposure and non-exposure. However, it should be noted that 
misclassifications in exposure would result in underestimation of a true effect. 
5.3.2 Other Studies 
Several recent meta-analyses have demonstrated that antidepressant 
prescribing is associated with an increased incidence of falling, based on 
studies conducted in a variety of settiri'gs 128129202. However, these studies 
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did not evaluate falls risk for SNRls or the evaluation was not made for 
community dwelling older people. Coupland et ai's recent cohort study was 
published after this study was completed127. It includes more than 60,000 
patients in a similar dataset to THIN spanning an 11 year period, and 
provides estimates of the hazard of next fall for SSRls (irrespective of 
whether the event is a first or subsequent recorded event). The adjusted 
hazard ratio for SSRls is 1.66 (1.58 - 1.73). Their study also estimates a one 
year risk of falls for people prescribed Venlafaxine which is similar to their 
equivalent estimate for SSRls. In a large, case-control study in Denmark (n 
= 498617), Vestergaard et al investigated the effect of the full spectrum of 
antidepressant groups on fracture risk and found significant associations with 
fracture at specific sites for SNRls but no consistent increase in risk 159. A 
study of residential care and nursing care homes in Sweden (n = 3604) found 
no significant increase in risk of falls with SNRls, although the investigators 
did observe an effect with SSRls 126. Both of these studies suggested that 
SNRls may be a safer alternative for older people than TCAs or SSRls, 
which appear to be associated with both falls and fracture 126 128 129 158 160203. 
This study focuses specifically on the effect of SNRls on risk of falls in the 
community and suggests there is an increase in risk similar to that for SSRls, 
and an increased risk shortly after initiation of therapy. 
A recent review observed that the mechanisms by which antidepressants 
increase risk of falls and related fractures are complex and may include 
orthostatic hypotension, arrhythmias, sedation, insomnia, movement 
disorders and confusion 152. The specific mechanism by which SNRls cause 
falls is not clear, but venlafaxine, which is the most commonly prescribed 
SNRI, has adverse effects in common with SSRls and TCAs (e.g. 
drowsiness, confusion, insomnia, movement disorders, visual disturbance 
and hypotension), each of which are implicated as contributing to falls in 
older people 152. 
The evidence for the relative efficacy of SNRls compared with other 
antidepressants remains limited and inconsistent2°4-206. Nevertheless, SNRls 
have been suggested by some to be the antidepressant of choice for the 
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elderly because of their low potential for drug interactions and possible 
favourable effect on pain associated with depression205-207, although 
concerns about cardiotoxicity and toxicity in overdose have led the National 
Institute for Health and Clinical Excellence (NICE) to recommend that these 
drugs be used as second-line treatments. These results suggest that 
clinicians initiating prescribing of SNRls should also be alert to the increased 
risk of falls. 
5.3.3 Implications 
This study provides evidence that SNRls are associated with an increased 
risk of firstlalls in older people that is similar to that associated with other 
classes of antidepressants. Clinicians should be alert to these risks when 
prescribing SNRls in older people. 
In terms of methodology, the study shows how the application of the case 
series method described by Whitaker et al can be used to analyse the 
association between first fall and recurrent transient exposures in order to 
quantify the role of confounding in estimates derived from classical case 
control analysis. More specifically, it demonstrates the feasibility and value 
of applying classical case control and self -controlled case series analysis to 
address specific gaps in the evidence base for a specific subgroup of 
medications (SNRls), so that their falls risk profile can be compared to what 
is already known about the risk profile of SSRls and of antidepressants in 
general. 
Having applied these methods to address a specific gap (evidence about the 
risk profile of SNRls) in what is otherwise relatively well-evidenced literature 
(evidence about the falls risk profile of antidepressants in general), the focus 
of the next chapter turns to a study which seeks to apply the approach to a 
whole group of medications (antihypertensive medication and its subgroups) 
for which the evidence base concerning falls risk is less compelling. 
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6 Antihypertensives and falls 
This chapter addresses the fourth project aim which is: 
• to establish whether being prescribed antihypertensive medication 
modifies the risk of falling in older people, differentiating between 
specific sub-classes of medication, and assessing the extent of any 
confounding 
6.1 Introduction 
Antihypertensive medications have long been implicated as a potential cause 
of falls in ~ I d e r r people, via orthostatic hypotension 153. A meta-analysis of 
small studies found no overall association with falls for the main classes of 
cardiac and analgesic medications, including some of the main classes of 
antihypertensives. The review highlighted uncertainty about the extent to 
which the presence of a real effect may be obscured by the variable role of 
confounding by indication between pooled studies 129. Woolcott et ai's review 
included analysis of antihypertensives, for which they found a frequentist 
pooled estimate of 1.26 (1.08 - 1.46)128. However, as was noted by 
Cumming concerning many earlier studies13o, this more recent meta-analysis 
was not designed to differentiate between sub-classes of antihypertensive. 
Despite their widespread prescribing, there remains little recent data for 
class-specific effects on falls. Therefore the role of antihypertensive 
medications in older people with a recorded fall in primary care was 
investigated. 
The previous chapter set out how classical case control and case series 
methods were applied to a group of medications for which the falls risk profile 
is relatively well evidenced (as described in the previous chapter). This 
chapter describes how the same two methods were applied to quantify the 
association between subgroups of antihypertensive medication and first fall. 
The rationale and methods for the complementary use of these two study 
designs are set out in detail in the Methods chapter. 
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6.2 Results 
6.2.1 Case control analysis 
9682 people aged over 60 years who experienced a first fall were identified, 
and 52 100 controls (matched according to the criteria described in the 
methodology chapter). More than 88% of cases were matched to four or 
more controls; amongst the oldest cases fewer matched controls were 
secured for each case. Nevertheless each of the cases was successfully 
matched to at least one control of the exact same age, sex, and general 
practice. The mean age of cases was 77.5 years, and 76.4 years for 
controls. 32% of cases and controls were male (as shown in Table 5-1 in the 
previous chapter). 
Results of our analyses of ever/never and previous/current prescribing were 
recorded in Table 6-1. In unadjusted analysis there were significant odds 
ratios for all classes of medication, ranging from 1.10 (1.05 - 1.16) for beta 
blockers to 1.48 (1.37 - 1.61) for thiazides. After adjustment for prior 
diagnoses of CHD, co-morbidities and other antihypertensives there were 
significant associations for thiazides 1.25 (1.15 - 1.36), ACE inhibitors 1.15 
(1.05 - 1.25) and for beta blockers 0.90 (0.85 - 0.96). 
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Table 6-1 Association between first recorded fall and prescribing of 
antihypertensives, THIN 2003-6 
Exposure 
Thiazide 
Neier prescribed 
Eler prescribed 
PrelAously prescribed 
Recently prescribed 
Currently prescribed 
Beta bloc ker 
Neier p r e s c r i ~ ~
Eler prescribed 
PrelAously prescribed 
Recently prescribed 
Currently prescribed 
ACE inhibitor 
Neier prescribed 
Eler prescribed 
PrelAously prescribed 
Recently prescribed 
Currently prescribed 
Angiotensin-II receptor antagonist 
Neier prescribed 
Eler prescribed 
PrelAously prescribed 
Recently prescribed 
Currently prescribed 
Calcium channel blocker 
Neier prescribed 
Eler prescribed 
PrelAously prescribed 
Recently prescribed 
Currently prescribed 
Cases 
n=9682 
Controls 
n=52100 
8817 ( 91% ) 49066 ( 94%) 
865 ( 9% ) 3034 ( 6%) 
228 ( 2% ) 851 ( 2%) 
43( 0% ) 161 ( 0%) 
594 ( 6% ) 2022 ( 4%) 
6246 ( 65% ) 34562 ( 66%) 
3436 ( 35%) 17538 ( 34%) 
1463 ( 15% ) 7003 ( 13%) 
193 ( 2% ) 944 ( 2%) 
1780 ( 18% ) 9591 ( 18%) 
6437 ( 66% ) 37468 ( 72%) 
3245 ( 34%) 14632 ( 28%) 
1096 ( 11% ) 4841 ( 9%) 
169 ( 2% ) 740 ( 1% ) 
1980 ( 20% ) 9051 ( 17%) 
8770 ( 91% ) 47624 ( 91%) 
912 ( 9% ) 4476 ( 9%) 
184 ( 2% ) 915 ( 2%) 
62 ( 1% ) 275 ( 1%) 
666 ( 7% ) 3286 ( 6%) 
6517 ( 67% ) 36992 ( 71%) 
3165 ( 33%) 15108 ( 29%) 
1234 ( 13% ) 5456 ( 10%) 
173 ( 2% ) 834 ( 2%) 
1758 ( 18% ) 8818 ( 17%) 
Odds ratio 
(95% confidence 
intervals) 
Unadjusted 
1.00 
1.48 ( 1.37 - 1.61 ) 
1.41 ( 1.22 - 1.65) 
1.42 ( 1.01 - 1.99) 
1.52 ( 1.38 - 1.68) 
1.00 
1.10 (1.05- 1.16) 
1.18 (1.10- 1.25) 
1.15 (0.98 - 1.35) 
1.05 ( 0.99 - 1.11 ) 
1.00 
1.30 ( 1.24 - 1.36) 
1.32 (1.23 - 1.42) 
1.32 ( 1.11 - 1.56) 
1.28 ( 1.21 - 1.36) 
1.00 
1.12 (1.04- 1.21) 
1.09 (0.92 - 1.28) 
1.26 (0.95 - 1.67) 
1.12 (1.02- 1.22) 
1.00 
1.19 ( 1.14 - 1.25) 
1.28 (1.19- 1.37) 
1.18 ( 1.00 1.40 ) 
1.14 ( 1.07 - 1.21 ) 
Odds ratio 
(95% confidence intervals) 
Adjusted for CHD, Charlson, 
and other antihypertensives 
1.00 
1.25 ( 1.15 - 1.36) 
1.19 (1.02- 1.39) 
1.16 (0.82 - 1.64) 
1.28 ( 1.16 - 1.42) 
1.00 
0.95 (0.90 - 1.00) 
1.00 (0.94 - 1.07) 
1.01 (0.86- 1.19) 
0.90 ( 0.85 - 0.96 ) 
1.00 
1.09 (1.04- 1.16) 
1.15 (1.05- 1.25) 
1.09 ( 0.92 - 1.30) 
1.07 ( 1.01 - 1.14) 
1.00 
0.95 (0.87 - 1.03) 
0.89 (0.75 - 1.05) 
1.11 (0.83 - 1.47) 
0.95 (0.87 - 1.04) 
1.00 
1.01 (0.96 - 1.07) 
1.07 ( 0.99 - 1.15) 
0.99 (0.84 - 1.18) 
0.98 (0.92 - 1.04) 
For thiazides, the increased risk was significant for currently prescribed 1.28 
(1.16 - 1.42), and in those previously prescribed. In beta blockers, the 
protective effect was significant for currently prescribed 0.90 (0.85 - 0.96) but 
not previously prescribed. But for ACE inhibitors (the other class in which 
there was a significant association with first falls), the effect of current 
prescribing was we.aker than for previously prescribed 1.07 (1.01 - 1.14). 
In the adjusted analyses no evidence of interaction with age was found, 
except for calcium channel blockers, in which there was a stronger positive 
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association with first fall amongst those aged 60 to 75 years than in those 
aged over 75. 
Unadjusted and adjusted models of the risk of first fall after first prescription 
showed strong positive associations at 0 days for all classes of medication 
(except angiotensin-II receptor antagonists for which there were no cases in 
this subcategory) - see Table 6-2. But amongst antihypertensives for 
elapsed times of 1-7 days, 8-14 and 15-21 days, only thiazides showed 
significant odds ratios. In days 1-7 following a first prescription, the adjusted 
odds ratio offirstfall for thiazides was 5.41 (1.62 - 18.14), at 8-14 days was 
5.02 (1.63 -15.51), and at 15-21 days remained 4.28 (1.19 -15.42). 
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Table 6-2 Association between first recorded fall and first prescription for 
antihypertensive (or antidepressant). THIN 2003-6 
First prescription 
(Days elapsed before first fall) 
Thiazide 
No prescriptions prior to index date 
o days 
1-7 days 
8-14 days 
15-21 days 
22-28 days 
>28 days 
Beta blocker 
No prescriptions prior to index date 
o days 
1-7 days 
8-14 days ~ ~
15-21 days 
22-28 days 
>28 days 
ACE inhibitor 
No prescriptions prior to index date 
o days 
1-7 days 
8-14 days 
15-21 days 
22-28 days 
>28 days 
A n g i o t e n s i n ~ 1 1 receptor antagonist 
No prescriptions prior to index date 
o days 
1-7 days 
8-14 days 
15-21 days 
22-28 days 
>28 days 
Calcium channel blocker 
No prescriptions prior to index date 
o days 
1-7 days 
8-14 days 
15-21 days 
22-28 days 
>28 days 
Cases 
n=9682 
Controls 
n=52100 
8817 ( 91.07%) 49066 ( 94.18%) 
4 ( 0.04% ) 2 ( 0.00% ) 
6 ( 0.06% ) 5 ( 0.01% ) 
7 ( 0.07% ) 6 ( 0.01% ) 
5 ( 0.05% ) 5 ( 0.01% ) 
5 ( 0.05% ) 11 ( 0.02% ) 
838 ( 8.66% ) 3008 ( 5.77% ) 
6246 ( 64.51 %) 34562 ( 66.34%) 
8 ( 0.08% ) 3 ( 0.01% ) 
5 ( 0.05% ) 21 ( 0.04% ) 
6 ( 0.06% ) 19 ( 0.04% ) 
10 ( 0.10% ) 29 ( 0.06% ) 
1 ( 0.01% ) 22 ( 0.04% ) 
3406 ( 35.18%) 17444 ( 33.48% ) 
6437 ( 66.48%) 37468 ( 71.92%) 
13 ( 0.13% ) 7 ( 0.01% ) 
8 ( 0.08% ) 36 ( 0.07% ) 
10 ( 0.10% ) 47 ( 0.09% ) 
11 ( 0.11% ) 31 ( 0.06% ) 
14 ( 0.14% ) 41 ( 0.08% ) 
3189 ( 32.94%) 14470 ( 27.77% ) 
8770 ( 90.58%) 47624 ( 91.41 % ) 
o ( 0.00% ) 2 ( 0.00% ) 
4 ( 0.04% ) 13 ( 0.02% ) 
2 ( 0.02% ) 18 ( 0.03% ) 
3 ( 0.03% ) 21 ( 0.04% ) 
4 ( 0.04% ) 18 ( 0.03% ) 
899 ( 9.29% ) 4404 ( 8.45% ) 
6517 ( 67.31% ) 38992 ( 71.00%) 
16 ( 0.17% ) 3 ( 0.01% ) 
5 ( 0.05% ) 36 ( 0.07% ) 
2 ( 0.02% ) 31 ( 0.06% ) 
2 ( 0.02% ) 41 ( 0.08% ) 
1 ( 0.01% ) 35 ( 0.07% ) 
3139 ( 32.42% ) 14962 ( 28.72% ) 
6.2.2 Case series analysis 
Odds ratio 
(95% confidence intervals) 
Unadjusted 
1.00 
11.13 ( 2.02- 61.24 ) 
6.14 ( 1.84- 20.47 ) 
6.05 ( 1.98- 18.44 ) 
4.86 ( 1.38- 17.08 ) 
2.49 (0.84- 7.38 ) 
1.45 ( 1.34- 1.58 ) 
1.00 
15.59 (4.12- 58.99 ) 
1.28 (0.47- 3.46) 
1.80 (0.71 - 4.54 ) 
1.80 (0.86- 3.77 ) 
0.28 (0.04- 2.09 ) 
1.10 ( 1.05- 1.15 ) 
1.00 
11.20 (4.44- 28.22 ) 
1.38 (0.64- 2.99 ) 
1.29 (0.65- 2.56 ) 
2.14 ( 1.07- 4.30 ) 
2.08 ( 1.13- 3.85 ) 
1.29 ( 1.23- 1.35 ) 
1.00 
0.00 ( 0.00 - infinity ) 
1.85 (0.60- 5.68 ) 
0.64 ( 0.15- 2.75 ) 
0.78 ( 0.23 - 2.64 ) 
1.19 (0.40- 3.54 ) 
1.12 ( 1.04- 1.21 ) 
1.00 
33.89 ( 9.87 - 116.34) 
0.84 ( 0.33- 2.13 ) 
0.35 ( 0.08- 1.49 ) 
0.29 ( 0.07- 1.20 ) 
0.14 ( 0.02- 1.04 ) 
1.19 ( 1.14- 1.25 ) 
Odds retia 
(95% confidence intervals) 
Adjusted for CHD, Charlson, 
and other antihypertensives 
1.00 
9.96 ( 1.86 - 54.45 ) 
5.41 ( 1.62 - 18.14 ) 
5.02 ( 1.63 - 15.51 ) 
4.28 ( 1.19 - 15.42 ) 
2.27 ( 0.74 - 6.92 ) 
1.22 ( 1.12 - 1.33 ) 
1.00 
15.45 ( 4.07 - 58.58 ) 
1.34 ( 0.50 - 3.59 ) 
1.56 ( 0.61 - 3.99 ) 
1.59 ( 0.75 - 3.34 ) 
0.25 ( 0.03 - 1.86 ) 
0.94 ( 0.90 - 1.00 ) 
1.00 
10.47 4.14 - 26.48 ) 
1.17 0.54 - 2.54 ) 
1.18 ( 0.60 - 2.35 ) 
1.98 ( 0.98 - 4.00 ) 
1.86 ( 1.00 - 3.46 ) 
1.08 ( 1.03 - 1.15 ) 
1.00 
0.00 ( 0.00 - infinity ) 
1.45 ( 0.47 - 4.47 ) 
0.57 ( 0.13 - 2.48 ) 
0.71 ( 0.21 - 2.43 ) 
1.20 ( 0.40 - 3.56 ) 
0.95 ( 0.87 - 1.03 ) 
1.00 
36.54 ( 10.61 - 125.85) 
0.82 ( 0.32 - 2.10 ) 
0.32 ( 0.07 - 1.35 ) 
0.23 ( 0.06 - 0.96 ) 
0.14 ( 0.02 - 1.02 ) 
1.01 ( 0.96 - 1.07 ) 
In applying the case series method to the dataset, the analysis consisted of 
exposed patients only. There.fore the number of exposed cases and the 
amount of follow-up time varied between classes of antihypertensive. ranging 
from 1128 cases with 3785 person-years of follow-up time for participants 
with an exposure to thiazides, to 4293 cases with 15 700 person-years for 
those exposed to an ACE inhibitor (Table 6-3). 
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Table 6·3 Association between episodes of antihypertensive and first fall: case series 
analysis in THIN 2003·6 
Standard Analysis 
First Follow- Incidence rate ratio 
Period of exposure falls up (95% confidence 
recorded (Pyrs) intervals) 
Thiazide 
Unexposed periods 534 1931.7 1.00 
Day 1 - 21 of episode 62 144.6 1.63 ( 1.20 - 2.20 ) 
Day 22 - end of episode 522 1708.9 1.11 ( 0.91 - 1.37 ) 
Beta blocker 
Unexposed periods 2134 8132.7 1.00 
• Day 1 - 21 of episode 156 589.0 1.13 ( 0.94 - 1.36 ) 
Day 22 - end of episode 1565 5676.7 1.16 ( 1.04- 1.30 ) 
ACE inhibitor 
Unexposed periods 2313 8904.1 1.00 
Day 1 - 21 of episode 156 578.2 1.11 (0.92- 1.32 ) 
Day 22 - end of episode 1768 6217.5 1.15 ( 1.04- 1.28 ) 
Angiotensin-II receptor antagonist 
Unexposed periods 727 2844.9 1.00 
Day 1 - 21 of episode 51 217.3 0.92 ( 0.68 - 1.26 ) 
Day 22 - end of episode 604 2185.6 1.09 ( 0.91 - 1.29 ) 
Calcium channel blocker 
Unexposed periods 2179 8215.3 1.00 
Day 1 - 21 of episode 104 551.2 0.75 ( 0.60 - 0.92 ) 
Day 22 - end of episode 1588 5654.5 1.11 ( 0.99 - 1.23 ) 
The incidence of first fall was increased in the first 3 weeks of thiazide 
prescribing (IRR 1.63, 1.20 - 2.20), but was not significantly increased in 
subsequent exposed periods. After disaggregating first and subsequent 
episodes of prescribing, it was apparent that the increased risk of falls in Day 
1-21 was higher for the first episode of prescribing (IRR 2.80,1.72 - 4.57), 
and for all subsequent periods of exposure the rate ratio is positive, but lower 
and non-significant (Table 6-4). 
104 
Table 6-4 Association between first and subsequent episodes of antihypertensive 
prescribing and first fall: case series analysis in THIN 2003-6 
First Follow- Incidence rate ratio 
Period of exposure falls up (95% confidence 
recorded (Pyrs) intervals) 
Thiazide 
Pre-exposure period 462 1690.1 1.00 
Day 1 - 21 of first episode 18 21.5 2.80 ( 1.72 - 4.57 ) 
Day 22 - end of first episode 203 599.3 1.30 ( 0.99- 1.71 ) 
Between episodes 72 242.4 1.17 ( 0.79 - 1.73 ) 
Day 1 - 21 of subsequent episode 44 123.1 1.33 ( 0.88- 2.02 ) 
Day 22 - end of subsequent episode 319 1108.7 1.01 (0.74- 1.40 ) 
Beta blocker 
• 
Pre-exposure period 1778 6705.1 1.00 
Day 1 - 21 of first episode 21 51.0 1.64 ( 1.06- 2.56 ) 
Day 22 - end of first episode 375 1307.8 1.23 ( 1.02- 1.48 ) 
Between episodes 356 1428.4 1.13 ( 0.93- 1.37: ) 
Day 1 - 21 of subsequent episode 135 538.0 1.13(0.90- 1.41 ) 
Day 22 - end of subsequent episode 1190 4368.9 1.21 ( 1.02 - 1.42 ) 
ACE inhibitor 
Pre-exposure period 1998 7636.7 1.00 
Day 1 - 21 of first episode 29 85.3 1.27 ( 0.88- 1.84 ) 
Day 22 - end of first episode 561 1943.0 1.15 ( 0.99 - 1.33 ) 
Between episodes 315 1267.5 1.02 ( 0.84- 1.23 ) 
Day 1 - 21 of subsequent episode 127 492.9 1.07 ( 0.86 - 1.34 ) 
Day 22 - end of subsequent episode 1207 4274.5 1.16 ( 1.00 - 1.35 ) 
Angiotensin-II receptor antagonist 
Pre-exposure period 663 2534.9 1.00 
Day 1 - 21 of first episode 9 36.7 0.89 ( 0.46- 1.73 ) 
Day 22 - end of first episode 237 860.4 1.00 ( 0.80- 1.26 ) 
Between episodes 64 311.6 0.67 ( 0.48 - 0.96 ) 
Day 1 - 21 of subsequent episode 42 180.6 0.80 ( 0.55 - 1.17 ) 
Day 22 - end of subsequent episode 367 1323.5 0.96 ( 0.75 - 1.23 ) 
Calcium channel blocker 
Pre-exposure period 1776 6543.0 1.00 
Day 1 - 21 of first episode 9 62.1 0.53 ( 0.27 - 1.02 ) 
Day 22 - end of first episode 372 1339.9 0.98 ( 0.83 - 1.17 ) 
Between episodes 403 1675.2 0.89 { 0.75 - 1.08 ) 
Day 1 - 21 of subsequent episode 95 489.0 0.74 (0.58- 0.95 ) 
Day 22 - end of subsequent episode 1216 4311.7 1.08 ( 0.93- 1.27 ) 
For exposure to beta blockers, the incidence of first falls for the first 3 weeks 
of exposure was not significantly different to unexposed periods (IRR 1.13, 
0.94 -1.36). For Day 22 onwards, the incidence rate was higher than in 
unexposed periods (IRR 1.16, 1.04 ~ · 1 . 3 0 ) . . Having disaggregated first and 
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subsequent episodes, the rate ratio during the first 3 weeks of the very first 
episode of exposure was higher than in the baseline pre-exposed period 
(IRR 1.64,1.06 - 2.56). The incidence of falls remained increased, though 
with a smaller size of effect, for Day 22 until the end of first episode (IRR 
1.23, 1.02 - 1.48) and in subsequent episodes from Day 22 to the end of the 
end of episode (IRR 1.21, 1.02 - 1.42). 
Amongst the other classes of antihypertensive, the rate ratio for calcium 
channel blockers for the first 3 weeks of exposure was lower than the 
baseline period (IRR 0.75, 0.60 - 0.92), but this effect disappeared in the 
subsequent periods. For ACE Inhibitors there was an increased incidence 
rate for the period 22 days onward (lRR 1.15, 1.04 - 1.28) but not in the first 
3 weeks of exposure. For Angiotensin Inhibitors none of the periods had an 
incidence rate that was significantly different to the baseline period. 
Two further analyses were undertaken to test for a breach of the assumption 
underpinning the method: that fall events are independent of exposure to 
prescribing of antihypertensive medication. As described in the Methods 
chapter, the first analysis tests for the possibility that the incidence rate ratio 
for a fall in periods following exposure is overstated, as a result of a relative 
"depletion" of fall events in the period leading up to exposure. It achieved 
this by including a pre-exposure period to identify whether this would 
significantly impact the estimate of the incidence rate ratio in the period 
following exposure. In none of the subgroups of antihypertensive 
medications did the inclusion of the pre-exposure period impact the rate ratio 
by more than 4% (see Table 6-5). 
The second analysis to test for possible dependence between a fall event 
and subsequent mortality (and therefore with subsequent exposure) involved 
repeating the standard analysis for all cases apart from those who died 
following a fall. This resulted in only small changes in the estimated size of 
the effect (see Table 6-5 below). This was interpreted as there being only 
weak evidence for a breach of the assumption regarding independence of a 
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prior fall and the probability of subsequent exposure, and that the effect of 
any bias related to mortality following a fall is small. 
Table 6-5 Sensitivity analyses to test dependence between fall and probability of 
subsequent exposure to antihypertensive in THIN 2003-6 
Including a 30 day ( x ~ X P O S t r 9 9 period Excluding cases v.ho died wthin 90 days of a fall 
First Follow- Incidence rate ratio First Follow- Incidence rate ratio 
Period of exposure fa/ls up (95% confidence fa/ls up (95% confidence 
recorded (Pyrs) intervals) recorded (Pys) intervals) 
Thiazide 
Unexposed periods 498 1810.6 1.00 373 1394.8 1.00 
30 day period' prior to any episode 36 121.1 1.13 ( 0.78- 1.64 ) 
Day 1 - 21 of episode 62 144.6 1.68 ( 1.22- 2.29 ) 41 100.3 1.57 ( 1.08- 2.27 ) 
Day 22 - end of episode 522 1708.9 1.14 ( 0.92- 1.43 ) 336 1120.0 1.12 ( 0.88- 1.44 ) 
Beta blocker 
~ ~
Unexposed periods 2016 7662.1 1.00 1742 6797.5 1.00 
30 day period' prior to any episode 118 470.6 1.08 ( 0.88 - 1.33 ) 
Day 1 - 21 of episode 156 589.0 1.15 ( 0.95- 1.39 ) 128 5081.1 1.09 ( 0.89- 1.34 ) 
Day 22 - end of episode 1565 5676.7 1.18 ( 1.05- 1.34 ) 1301 4818.2 1.16 ( 1.02- 1.31 ) 
ACE inhibitor 
Unexposed periods 2192 8428.8 1.00 1921 7530.7 1.00 
30 day period' prior to any episode 121 475.4 1.03 ( 0.85- 1.26 ) 
Day 1 - 21 of episode 156 578.2 1.11 (0.93- 1.34 ) 129 486.3 1.09 ( 0.89- 1.32 ) 
Day 22 - end of episode 1766 6217.5 1.16 ( 1.04- 1.30 ) 1389 5053.0 1.11 (0.99- 1.25 ) 
Angiotensin-II receptor antagonist 
Unexposed periods 688 2667.1 1.00 650 2543.4 1.00 
30 day period' prior to any episode 39 177.8 0.83 ( 0.58- 1.17 ) 
Day 1 - 21 of episode 51 217.3 0.89 ( 0.64- 1.22 ) 45 192.9 0.88 ( 0.63- 1.22 ) 
Day 22 - end of episode 604 2185.6 1.05 ( 0.87- 1.26 ) 515 1916.6 1.00 ( 0.83- 1.21 ) 
calcium channel blocker 
Unexposed periods 2057 7766.4 1.00 1830 7086.6 1.00 
30 day period' prior to any episode 122 448.9 1.09 ( 0.89- 1.33 ) 
Day 1 - 21 of episode 104 551.2 0.76 ( 0.61 - 0.94 ) 89 22.1 0.76 ( 0.61 - 0.96 ) 
Day 22 - end of episode 1588 5654.5 1.12 ( 1.00- 1.26 ) 1269 4667.9 1.07 ( 0.95- 1.21 ) 
, may be less than 30 days for episodes separated by short InteNils 
Based on the case control analysis which found that the association with first 
falls is confounded by prescribing of other antihypertensives, further case 
series analyses were performed to assess possible confounding by anyone 
of the antihypertensives. The approach to this involved adding in tum each 
of the antihypertensives for which a statistically significant association had 
been found in the earlier analysis. In none of the analyses did the 
incorporation of a confounder result in anything more than tiny changes to 
the estimates of relative incidence. 
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6.3 Discussion 
6.3.1 Findings & interpretation 
In this large case-control study of older people using prospectively collected 
exposure data, the risk of first fall for people ever-prescribed thiazides was 
about 25% higher than for those never prescribed. This effect related to 
current prescribing, and was stronger in the 3 weeks after the first 
prescription in which period the odds ratio of a first fall was about 5. Based 
on the prevalence of current thiazide prescribing in this population during the 
study period, the relative risk corresponds to a population attributable risk 
p r o p o r t i o n ~ i n n the region of 1 %. Case series analysis also showed that the 
incidence risk ratio for this period is 2.80, and this suggests that the effect 
observed in the case-control study is real but may have been amplified by 
other differences between cases and controls. 
For beta blockers we found a small protective effect which related to current 
but not previous prescriptions. However, in case series analysis there was a 
weakly positive effect for beta blockers, which is evidence that the weak 
protective effect of the case control study arose due to confounding (or 
chance) rather than the real effect of beta blockers. 
The case control analysis found an increased risk of first fall for people ever 
prescribed ACE inhibitors, but this increase related equally to those who had 
discontinued prescriptions as those currently prescribed. There was weak 
evidence that the risk is higher around the third and fourth week after onset 
of prescribing. On their own, these findings do not suggest that ACE 
inhibitors cause falls, but that, the group given ACE inhibitors were at higher 
underlying risk offalls. The case series analysis provides weak, equivocal 
evidence on this point: there was no increase in incidence rate for the onset 
of prescribing, but ~ s l i g h t l y y increased rate beyond 22 days. 
In case series analysis, there was a lower incidence of first falls in the first 3 
weeks of exposure to calcium channel blockers, which closely reflects the 
non-significant decrease in risk of first fall within the first 3 weeks of first 
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prescription observed in the case control study. It is not possible to say 
whether this is a real effect of calcium channel blockers or by what 
mechanism such an effect might be produced. 
6.3.2 Strengths & weaknesses 
The main strength of the studies is the large number of cases, the 
completeness of the exposure data for prescribing, the fact that the data 
were collected prospectively which means that recall is not a source of bias, 
and the assessment of residual confounding by applying complementary 
methods to a single dataset. Medications were differentiated according to 
standard classifications. Previous studies have demonstrated the validity of 
the data in THIN for pharmacoepidemiological research 167168173. 
In the case control study, co-morbidity was controlled for in two ways. Firstly, 
possible confounding by a number of conditions and medications associated 
with falls was checked for and, as a result, adjustment was incorporated for 
diagnoses of CHD and for Charlson index which reduced the odds ratios in a 
way consistent with expectations. It should be noted that Charlson is 
designed as an index of one year mortality based on patients in a hospital 
setting, and may not correlate fully with comorbidity in a general population 
setting. Secondly, to explore the extent to which the effect was attributable to 
characteristics of the patients rather than the prescribing, the risk for people 
currently and previously prescribed was compared. 
The possibility of residual confounding which could account for some or all of 
the positive effect observed for thiazides is acknowledged. Nevertheless by 
applying the self-controlled case series analysis to the same group of cases, 
a way is provided of assessing the extent to which the findings of the case 
control study may have been subject to residual confounding by factors 
which remain constant within individuals. Application of the case series 
method, which is not subject to residual confounding by factors which remain 
constant within individuals, showed that in the first weeks of thiazide 
prescribing there is a positive association with falls. 
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The main potential weaknesses of the case control study is the validity of the 
recording of fall events, and the possibility of non-compliance to medications. 
Regarding the recording of fall events, the earlier study of incidence and 
mortality suggested that falls recorded in primary care are a subset of the 
falls self-reported in surveys 196. This raises the possibility of differential 
ascertainment for patients receiving antihypertensive medication. Such a 
bias, if it existed, would tend to increase the odds ratios. However, the fact 
that case control analysis found a mixture of positive, negative and non-
significant effects between medication classes suggests that the effect of any 
ascertainment bias is probably small overall. 
The extent of any non-compliance to medication cannot be assessed reliably. 
But it is noted that non-compliance would result in underestimation. of a true 
effect in the case control study. 
A limitation of the case series method relates to the requirement that events 
should not influence the probability of subsequent exposures. Whilst thiazide 
prescribing itself may be regarded as relatively safe (and therefore unlikely to 
be influenced by a fall), it could be an element in polypharmacy, which may 
be a risk factor for falls. As such, subsequent prescribing of thiazides may be 
influenced by a fall. Therefore this was tested for in a sensitivity analysis 
which included a 30 day observation period immediately prior to the 
exposure. This had little impact on the rate ratios, suggesting that any 
potential exaggeration of the incidence rate ratio in the period after exposure 
(due to there being fewer fall events in the period leading up to exposure) 
was minimal. In other words there was only weak evidence that exposure 
status is influenced by a prior recorded fall. 
The degree to which risk of exposure is influenced by falls-related mortality 
was also assessed, by excluding participants who died within 90 days of the 
fall. This resulted in little change to the risk ratios, indicating that the effect 
on any bias resulting from mortality subsequent to a fall is small. The study 
data also satisfy other assumptions underlying the method including: the 
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requirement that the risk of first fall in the observation period be small, and 
that the timing of first fall with respect to age is variable. 
The potential weaknesses of the case series analysis relate to uncertainty 
about what can be reliably inferred from prescribing records about actual 
exposure status. There are two possible aspects to this uncertainty. Each of 
them amounts to a misclassification of exposure period. Since either of 
these two misclassifications is non-differential, the most likely result would be 
a dilution of the true effect. 
• The first possible cause of misclassification relates to the assumption, based 
on the analysis of intervals between prescriptions, that prescriptions 
separated by not more than 60 days constitute a single c o n t i n u o u ~ ~ period of 
prescribing ending 60 days after the final prescription. The issue here is 
whether the prescribing history represents a complete record of what was 
actually prescribed. The rationale for this assumption is described in the 
Methods chapter, which also shows that relatively few prescriptions are 
recorded at intervals of more than 60 days. Therefore, it is likely that any 
error arising (from misclassifying intervals of more than 60 days as gaps in 
prescribing) would have a small diluting effect on the estimated size of the 
effect. 
Secondly it is also assumed that there is a high level of patient compliance 
with recorded prescriptions. The issue here is whether the prescribing 
history represents a complete record of the medication received by the 
patient. It is noted that this second assumption is more likely to have been 
breached208. Once again any resulting misclassification is likely to be non-
differential and therefore likely to result in a dilution of the true effect. 
Finally, applying these complementary analyses to assess a large number of 
possible associations necessarily involves making many estimates of effect. 
One implication of this is that it increases the likelihood that one of the 
observed effects does not reflect a real difference. 
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6.3.3 Other studies 
An association between antihypertensives and falls via orthostatic 
hypotension has been long-suspected153 but the relationship with drug-
related orthostatic hypotension is not clear154155. Leipzig et ai's 129 review of 
medications and falls included observational studies of antihypertensives and 
other cardiovascular medications. The meta-analysis found weak 
associations with one or more falls for digoxin (OR 1.22), type 1A anti-
arrhythmics (OR 1.59) and use of any diuretic (OR 1.08). Since 1999, 
studies have been inconsistent in their findings with regard to 
a n t i h y p e r t ~ n s i v e s s and risk offalls13914o, with many providing only an 
aggregated classification of antihypertensives 128137. Setting out to test the 
hypothesis that associations between medications and falls are confounded 
by medical conditions, Lee et al141 found no association with falls for most 
cardiovascular and non-cardiovascular medication groups (including 
psychotropics), except for nitrates. 
The association observed in this study between first recorded fall and 
prescribing of thiazides is consistent with the hypothesis that this class of 
antihypertensive medication is an independent risk factor for falls and that the 
risk is greatest in the first three weeks after the start of prescribing. The 
mechanism by which this occurs is not clear. However the literature 
indicates an initial hypotensive response to thiazide diuretics in the first few 
weeks of treatment, mediated by a reduction in plasma volume and cardiac 
output, and that these return to near baseline levels over several weeks with 
the longer term reduction in blood pressure driven by different underlying 
mechanisms20921o. This may explain the change in risk with time since 
initiation of treatment. Other' possible explanations for the decrease in risk in 
consecutive weeks include the development of biological tolerance or coping 
mechanisms, or a degree of survival bias in which patients reporting 
problems are taken off the medication in the first three weeks, leaving a 
group of cases who are less susceptible to further falls. 
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The size of the observed association with thiazides is small over the long 
term but represents an almost three-fold risk during the first three weeks of 
first exposure. The prevalence of thiazide prescribing in older people (9% 
amongst first fallers211 ), means that the public health impact could be 
significant. The HYVET (Hypertension in the Very Elderly) trial demonstrated 
the benefit of hypertensive treatment, based on a diuretic with or without an 
additional ACE inhibitor, in reducing the risk of death from stroke, death from 
any cause and heart failure in the very elderly. This study is a further 
reminder to clinicians initiating prescribing of thiazides in older people to be 
alert to the possibility of an increased risk of falls in the first three weeks of 
• prescribing. 
It is possible that the weakly protective effect of beta blockers observed in the 
case control analysiS could be causal. It has been suggested that if this 
reflects a true effect, it may be explained by a possible protective effect for 
vasovagal syncope, in which the beta blocker attenuates the raised levels of 
catecholamine preceding syncope212 but it is not clear what this mechanism 
could be. However, the fact that this effect was not observed in the 
complementary case series analysis suggests that the protective effect of 
beta blockers observed in the case control study was most likely to have 
been due to chance. 
With regard to the lower incidence of first falls in the first 3 weeks of exposure 
to calcium channel blockers, it is not possible to say whether this is a real 
effect of calcium channel blockers or by what mechanism such an effect 
might be produced but it is noted that calcium channel blockers used in the 
treatment of hypertension is Gommonly associated with headache, dizziness 
and oedema 191. Furthermore, following their introduction, the fear amongst 
doctors that they would increase the risk of falls was greater than for other 
ctasses of antihypertensive and could have led to stronger warnings about 
their possible effect than were given for other classes of antihypertensive. It 
is possible that the onset or anticipation of these side effects results in 
greater caution or less mobility on the part of the patient, leading to a lower 
incidence of recorded falls in the first"few weeks of medication. 
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More generally, whilst these findings provide evidence to support the 
warnings of an earlier meta-analysis 129 and a subsequent systematic 
review125 that the results of individual studies are subject to confounding, 
they also demonstrate how the complementary application of the case series 
method can be used to assess the extent of possible confounding in classic 
case control analyses. 
6.4 Implications 
These complementary studies provide evidence that thiazides are associated 
with an increased risk of first falls and that this persists for at least the first 
three weeks of exposure, which suggests that this class of medication may 
not be as safe as previously thought. There is weaker evidence for a 
protective effect of calcium channel blockers in the first three weeks of 
exposure. Considering the complementary analyses together, there was no 
increase in falls risk for other classes of antihypertensive medication. 
These studies also demonstrate that the case series method provides an 
effective way to assess the extent of residual confounding in case-control 
studies whose data include longitudinal information about exposure status 
and outcome. 
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7 Other medications and falls 
This chapter addresses the final project aim which is: 
• to identify any other classes or sub-classes of medication prescribed 
in primary care whose apparent falls risk warrants investigation in 
future studies 
7.1 Introduction 
A range of medications are associated with an increased risk of falls in older 
people 122128129. For some of these classes (e.g. NSAID) the mechanism by 
which they may predispose older people to fall "is far from clear,,121. 
Therefore in view of the lack of systematic studies of the falls profile of 
medications, a further hypothesis-generating study was performed "to identify 
other classes of medication prescribed to older people whose fall profile may 
warrant further investigation in subsequent studies. 
The methods for this are set out in detail in the chapter relating to the 
methods for the aetiological studies. This study uses the same nested case-
control approach on the same dataset, using the same definitions of cases 
and controls, matching ratio, and classification of exposure according to the 
elapsed time between the index event and final preceding prescription. 
However, since the purpose of the study described in this chapter is simply to 
highlight subgroups of medication whose risk profile may warrant further 
study (not to draw conclusions about independent effects), it makes no 
attempt to adjust for confounders other than age and sex (used for 
matching), nor to estimate the extent of any residual confounding or other 
bias through use of case series analysis. 
Classes of medication in the British National Formulary (BNF) which are not 
prescribed for olde"r people by general practitioners were excluded from the 
analysis, along with medications for which the number of cases with an 
exposure ever was fewer than 10. Classes of medication included in the 
meta-analyses reviewed in earlier chapters 122128129 were also excluded. 
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7.2 Results 
As described in previous chapters, 9682 people were identified who were 
aged >60 years and who experienced a first fall, and 52 100 matched 
controls. The mean age of cases was 77.5 years, and 76.4 years for 
controls. Thirty two percent of cases and co,ntrols were male. Their profile is 
described in Table 5-1. 
Estimates of the odds ratios for first fall for ever (previous Irecent Icurrent) 
Inever prescribing are summarised and presented in tables, by BNF chapter. 
Medication classes corresponding to treatment of the cardiovascular and 
~ ~
central nervous systems, and analgesics were excluded for the reasons 
described in the Methods, along with obstetric-related medications for which 
there were fewer than 10 cases recorded with exposures. In all instances, 
the odds ratios are adjusted for age and sex, but not for other confounders. 
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Table 7-1 Association between first recorded fall and prescribing of medications for 
the gastro-intestinal system, THIN 2003-6 
Odds ratio 
Exposure Cases Controls (95% confidence 
n=9682 n=52100 intervals) 
Unadjusted 
Dyspepsia & gastro-oesophageal disease 
Never prescribed 6721 ( 69% ) 39681 76% ) 1.00 
Ever prescribed 2961 ( 31% ) 12419 24% ) 1.42 ( 1.36 - 1.50 ) 
Pre\1ously prescribed 2187 ( 23% ) 9325 18% ) 1.40 ( 1.33 - 1.48) 
Recently prescribed 195 ( 2% ) 822 2% ) 1.42 ( 1.21 - 1.67 ) 
Currently prescribed 579 ( 6% ) 2272 4% ) 1.51 ( 1.37 - 1.69) 
c 
Antispasmodics & gut motility 
Never prescribed 7319 ( 76% ) 42206 81% ) 1.00 
Ever prescribed 2363 ( 24% ) 9894 19% ) 1.43 ( 1.35 - 1.50 ) 
Pre\1ously prescribed 1904 ( 20% ) 8314 16% ) 1.37 ( 1.29 - 1.45 ) 
Recently prescribed 109 ( 1% ) 433 1% ) 1.51 ( 1.22 - 1.86 ) 
Currently prescribed 350 ( 4% ) 1147 2% ) 1.79 ( 1.58 - 2.03 ) 
Ulcer healing 
Never prescribed 5380 ( 56% ) 33480 ( 64% ) 1.00 
Ever prescribed 4302 ( 44% ) 18620 ( 36% ) 1.46 ( 1.39 - 1.52 ) 
Pre\1ously prescribed 1941 ( 20% ) 9562 ( 18% ) 1.29 ( 1.22 - 1.36 ) 
Recently prescribed 251 ( 3% ) 1151 ( 2% ) 1.38 ( 1.20 - 1.59 ) 
Currently prescribed 2110 ( 22% ) 7907 ( 15% ) 1.67 ( 1.58 - 1.77 ) 
Acute diarrhoea 
Never prescribed 7560 ( 78% ) 44453 85% ) 1.00 
Ever prescribed 2122 ( 22% ) 7647 15% ) 1.67 ( 1.58 - 1.77 ) 
Pre\1ously prescribed 1641 ( 17%) 6401 12% ) 1.54 ( 1.45 - 1.64 ) 
Recently prescribed 116 ( 1% ) 356 1% ) 1.98 ( 1.59 - 2.45 ) 
Currently prescribed 365 ( 4% ) 890 2% ) 2.50 ( 2.21 - 2.84 ) 
Chronic bowel disorders 
Never prescribed 9472 ( . 98% ) 51233 98% ) 1.00 
Ever prescribed 210 ( 2% ) 867 2%) 1.35 ( 1.16 - 1.58 ) 
Pre\1ously prescribed 130 ( 1% ) 504 1% ) 1.44 ( 1.18 - 1.75 ) 
Recently prescribed 11 ( 0% ) 49 0% ) 1.33 ( 0.69 - 2.56 ) 
Currently prescribed 69 ( 1% ) 314 1% ) 1.22 (0.94 - 1.59 ) 
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Table 7-1 (continued) 
Laxatives 
Never prescribed 5632 ( 58% ) 37178 ( 71% ) 1.00 
Ever prescribed 4050 ( 42% ) 14922 ( 29% ) 1.76 ( 1.68 - 1.84 ) 
Pre"';ously prescribed 2255 ( 23% ) 9226 ( 18% ) 1.60 ( 1.52 - 1.70 ) 
Recently prescribed 364 ( 4% ) 1204 ( 2% ) 1.97 ( 1.74 - 2.23 ) 
Currently prescribed 1431 ( 15% ) 4492 ( 9% ) 2.02 ( 1.89 - 2.16 ) 
Anal & rectal preparations 
Never prescribed 8482 ( 88% ) 46770 ( 90%) 1.00 
Ever prescribed 1200 ( 12% ) 5330 ( 10% ) 1.27 ( 1.19 - 1.36 ) 
Pre"';ously prescribed 1047 ( 11% ) 4697 ( 9% ) 1.26 ( 1.17 - 1.35) 
Recently prescribed 59 ( 1% ) 233 ( 0% ) 1.44 ( 1.08 - 1.92 ) 
Currefltly prescribed 94 ( 1% ) 400 ( 1% ) 1.32 ( 1.05 - 1.65 ) 
Intestinal secretions 
Never prescribed 9610 ( 99% ) 51807 ( 99% ) 1.00 
Ever prescribed 72( 1% ) 293 ( 1% ) 1.38 ( 1.06 - 1.79 ) 
Pre"';ously prescribed 40 ( 0% ) 185 ( 0% ) 1.26 ( 0.89 - 1.78 ) 
Recently prescribed 2 ( 0% ) 18 ( 0% ) 0.66 ( 0.15 - 2.85 ) 
Currently prescribed 30 ( 0% ) 90 ( 0% ) 1.73 ( 1.14 - 2.64 ) 
With the exception of medications for chronic bowel disorders and intestinal 
secretions, between one tenth and one third of people aged over 60 years 
have been prescribed subclasses of gastro-intestinal medication in primary 
care. In each subclass, there is a significant positive association between 
first fall and ever-prescribed with odds ratios ranging from 1.27 (1.19 - 1.36) 
for anal and rectal preparations to 1.76 (1.68 - 1.84) for laxatives. The point 
estimates of odds ratios for currently prescribed are higher than for recently 
and previously prescribed for all subclasses, with the exception of 
medications for chronic bowel disorders. 
The highest unadjusted odds ratios for current prescribing were found in 
medications for acute diarrhoea OR 2.50 (2.21 - 2.84), laxatives OR 2.02 
(1.89 - 2.16), antispasmodics OR 1.79 (1.58 - 2.03) and intestinal secretions 
OR 1.73 (1.14 - 2.64). 
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Table 7-2 Association between recorded first fall and prescribing of medications in 
primary care for the respiratory system 
Odds ratio 
Exposure Cases Controls (95% confidence 
n=9682 n=52100 intervals) 
Unadjusted 
Bronchodilators 
Never prescribed 7060 ( 73% ) 40945 79% ) 1.00 
Ever prescribed 2622 ( 27% ) 11155 21% ) 1.39 ( 1.32 - 1.46 ) 
Previously prescribed 1319 ( 14% ) 5795 11% ) 1.35 ( 1.26 - 1.44 ) 
Recently prescribed 221 ( 2% ) 883 2% ) 1.51 ( 1.30 - 1.75 ) 
Curre'htly prescribed 1082 ( 11% ) 4477 9% ) 1.42 ( 1.32 - 1.52 ) 
Corticosteroids 
Never prescribed 8068 ( 83% ) 45323 87% ) 1.00 
Ever prescribed 1614 ( 17% ) 6777 13% ) 1.37 ( 1.29 - 1.45 ) 
Previously prescribed 681 ( 7% ) 2707 5% ) 1.45 ( 1.33 - 1.59 ) 
Recently prescribed 168 ( 2% ) 796 2% ) 1.23 ( 1.04 - 1.46 ) 
Currently prescribed 765 ( 8% ) 3274 6% ) 1.33 ( 1.23 - 1.45 ) 
Cromoglicate, related, & leukotriene receptor antagonists 
Never prescribed 9570 ( 99% ) 51645 99% ) 1.00 
Ever prescribed 112 ( 1% ) 455 1% ) 1.40 ( 1.14 - 1.73 ) 
Previously prescribed 86 ( 1% ) 310 1% ) 1.59 ( 1.25 - 2.02 ) 
Recently prescribed 2 ( 0% ) 21 0% ) 0.54 ( 0.13 - 2.32 ) 
Currently prescribed 24 ( 0% ) 124 0% ) 1.08 ( 0.69 - 1.68 ) 
Antihistmaines, hyposensitations, & allergic emergencies 
Never prescribed 6780 ( 70% ) 39267 75% ) 1.00 
Ever prescribed 2902 ( 30% ) 12833 25% ) 1.35 ( 1.28 - 1.41 ) 
Previously prescribed 2187 ( 23% ) 9325 18% ) 1.40 ( 1.33 - 1.48 ) 
Recently prescribed 195 ( 2% ) 822 2% ) 1.42 ( 1.21 - 1.67 ) 
Currently prescribed 579 ( 6% ) 2272 4% ) 1.51 ( 1.37 - 1.69 ) 
Oxygen 
Never prescribed 9551 ( 99% ) 51741 ( 99% ) 1.00 
Ever prescribed 131 ( 1% ) 359 ( 1% ) 1.94 ( 1.58 - 2.38 ) 
Previously prescribed 53 ( 1% ) 187 ( 0% ) 1.45 ( 1.06 - 1.98 ) 
Recently prescribed 13 ( 0% ) 42 ( 0% ) 1.84 ( 0.99 - 3.42 ) 
Currently prescribed 65 ( 1% ) 130 ( 0% ) 2.71 ( 2.00 - 3.68 ) 
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Table 7-2 (continued) 
Mucolytics 
Newr prescribed 9625 ( 99% ) 51926 ( 100%) 1.00 
Ewr prescribed 57 ( 1% ) 174 ( 0% ) 1.86 ( 1.37- 2.52 ) 
Pre",;ously prescribed 28 ( 0% ) 90 ( 0% ) 1.81 ( 1.18- 2.77 ) 
Recently prescribed 6 ( 0% ) 18 ( 0%) 1.81 ( 0.71 - 4.65 ) 
Currently prescribed 23 ( 0% ) 66 ( 0% ) 1.94 ( 1.20 - 3.15 ) 
Aromatic inhalations 
Newr prescribed 9596 ( 99% ) 51769 ( 99% ) 1.00 
Ewr prescribed 86 ( 1% ) 331 ( 1% ) 1.45 ( 1.13- 1.86 ) 
Pre",;ously prescribed 84( 1% ) 319 ( 1% ) 1.47 (1.14- 1.89 ) 
Recently prescribed 2 ( 0% ) 5 ( 0% ) 2.40 (0.47 - 12.37) 
Currently prescribed o ( 0% ) 7 ( 0%) ( ) 
Cough preparations 
Newr prescribed 7769 ( 80% ) 44369 ( 85% ) 1.00 
Ewr prescribed 1913 ( 20% ) 7731 ( 15% ) 1.46 ( 1.37- 1.55 ) 
Pre",;ously prescribed 1792 ( 19% ) 7245 ( 14% ) 1.46 ( 1.37- 1.55 ) 
Recently prescribed 39 ( 0% ) 187 ( 0% ) 1.16 ( 0.82 2.80 ) 
Currently prescribed 82 ( 1% ) 299 ( 1% ) 1.59 ( 1.24 - 2.04 ) 
Systemic nasal decongestants 
Newr prescribed 8784 ( 91% ) 48061 ( 92% ) 1.00 
Ewr prescribed 898 ( 9% ) 4039 ( 8%) 1.28 ( 1.18- 1.39 ) 
Pre",;ously prescribed 867 ( 9% ) 3915 ( 8%) 1.28 ( 1.18 - 1.39 ) 
Recently prescribed 15 ( 0% ) 55 ( 0%) 1.67 ( 0.93- 2.97 ) 
Currently prescribed 16 ( 0% ) 69 ( 0% ) 1.38 ( 0.80- 2.39 ) 
For some subclasses of respiratory medication, more than a quarter of 
people aged over 60 years have been prescribed them in primary care, e.g. 
bronchodilators, antihistamines and hyposensitisation. In all subclasses, 
there is a positive association between first fall and ever-prescribed with odds 
ratios ranging from 1.28 (1.18 - 1.39) for systemic nasal decongestants to 
1.94 (1.58 - 2.38) for oxygen. 
With the exception of oxygen, the point estimates of odds ratios for currently 
prescribed are similar to those for ever prescribed. The highest odds ratios 
for current prescribing were found in medications for oxygen 2.71 (2.00-
3.68), mucolytics 1.94 (1.20 - 3.15) and cough preparations 1.59 (1.24-
2.04). For the relatively large number of older people prescribed 
bronchodilators, corticosteroids, antihistamines and hyposensitisations, the 
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odds of first fall is between one third and one half greater compared to the 
odds for their matched controls. 
Table 7-3 Association between recorded first fall and prescribing of medications in 
primary care for infections, THIN 2003-6 
Odds ratio 
Exposure Cases Controls (95% confidence 
n=9682 n=52100 intervals) 
Unadjusted 
Antibacterials 
Newr prescribed 1415 ( 15% ) 11710 ( 22% ) 1.00 
Ewr pl'e$cribed 8267 ( 85% ) 40390 ( 78% ) 1.79 ( 1.68 - 1.91 ) 
Pre\oiously prescribed 5727. ( 59% ) 31444 ( 60% ) 1.60 ( 1.50 - 1.70 ) 
Recently prescribed 789 ( 8% ) 3449 ( 7% ) 1.96 ( 1.78- 2.16 ) 
Currently prescribed 1751 ( 18% ) 5497 ( 11% ) 2.75 ( 2.54- 2.98 ) 
Antifungals 
Newr prescribed 8579 ( 89% ) 47526 ( 91% ) 1.00 
Ewr prescribed 1103 ( 11% ) 4574 ( 9% ) 1.38 ( 1.29- 1.48 ) 
Pre\oiously prescribed 993 ( 10% ) 4208 ( 8% ) 1.35 ( 1.25- 1.46 ) 
Recently prescribed 36 ( 0% ) 136 ( 0% ) 1.49 ( 1.03- 2.16 ) 
Currently prescribed 74 ( 1% ) 230 ( 0% ) 1.86 ( 1.43- 2.43 ) 
Anti\oirals 
Newr prescribed 9106 ( 94% ) 49551 95% ) 1.00 
Ewr prescribed 576 ( 6% ) 2549 5% ) 1.23 ( 1.12 - 1.35 ) 
Pre\oiously prescribed 515 ( 5% ) 2401 ( 5% ) 1.16 ( 1.05- 1.28 ) 
Recently prescribed 20 ( 0% ) 70 ( 0% ) 1.58 ( 0.96- 2.61 ) 
Currently prescribed 41 ( 0% ) 78 ( 0% ) 3.03 ( 2.07- 4.42 ) 
Antiprotozoals 
Newr prescribed 7403 ( 76% ) 42743 ( 82% ) 1.00 
Ewr prescribed 2279 ( 24% ) 9357 ( 18% ) 1.43 ( 1.35 - 1.51 ) 
Pre\oiously prescribed 1743 ( 18% ) 7570 ( 15% ) 1.36 ( 1.28 - 1.44 ) 
Recently prescribed 105 ( 1% ) 412 ( 1% ) 1.45 ( 1.17 - 1.80 ) 
Currently prescribed 431 ( 4% ) 1375 ( 3% ) 1.80 ( 1.61 - 2.02 ) 
Anthelmintics 
Newr prescribed 9636 ( 100% ) 51908 ( 100%) 1.00 
Ewr prescribed 46 ( 0% ) 192 ( 0% ) 1.37 ( 0.99- 1.90 ) 
Pre\Aously prescribed 41 ( 0% ) 188 ( 0% ) 1.24 ( 0.88- 1.75 ) 
Recently prescribed 4 ( 0% ) 1 ( 0% ) 24.00 ( 2.68 - 214.72 ) 
Currently prescribed 1 ( 0% ) 3 ( 0% ) 2.00 ( 0.21 - 19.23 ) 
Amongst the subclasses of medication for infections (see Table 7-3), the 
prevalence of ever prescribing is highest in antibacterials (76%), then 
antiprotozoals (19%). 
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The odds ratios of first fall for ever prescribed ranges from not significantly 
different to 1 for antithelmintics through to antibacterials for which the odds 
ratio is 1.79 (1.68 - 1.91). 
The odds ratio of current prescribing for antibacterials is 2.75 (2.54 - 2.98), 
and significantly higher than the odds ratio for recent or previous prescribing. 
For antivirals, this gradient is even more pronounced: the odds ratio of 
current prescribing is 3.03 (2.07 - 4.42) compared to 1.16 (1.05 -1.28) for 
previous prescribing. For antifungals and antiprotozoals, the estimates for 
• 
current prescribing are 1.86 (1.43 - 2.43) and 1.80 (1.61 - 2.02) respectively. 
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Table 7-4 Association between recorded first fall and prescribing of medications in 
primary care for the endocrine system, THIN 2003-6 
Odds ratio 
Exposure Cases Controls (95% confidence 
n=9682 n=52100 intervals) 
Unadjusted 
Diabetes 
Newr prescribed 8496 ( 88% ) 47477 91% ) 1.00 
Ewr prescribed 1186 ( 12% ) 4623 9% ) 1.47 ( 1.37 - 1.58 ) 
Previously prescribed 149 ( 2% ) 693 1% ) 1.20 ( 1.00 - 1.44 ) 
Recently prescribed 56 ( 1% ) 291 1% ) 1.09 ( 0.82 - 1.46 ) 
Currently prescribed 981 ( 10% ) 3639 7% ) 1.55 ( 1.44 - 1.67 ) 
1 
Thyroid & antithyroid 
Newr prescribed 8577 ( 89% ) 47152 91% ) 1.00 
Ewr prescribed 1105 ( 11% ) 4948 9% ) 1.23 ( 1.15 - 1.32 ) 
Previously prescribed 84( 1% ) 430 1% ) 1.06 ( 0.84 - 1.35 ) 
Recently prescribed 94 ( 1% ) 459 1% ) 1.16 ( 0.92 - 1.45 ) 
Currently prescribed 927 ( 10% ) 4059 8% ) 1.26 ( 1.16 - 1.36 ) 
Corticosteroids 
Newr prescribed 7192 ( 74% ) 41993 81% ) 1.00 
Ewr prescribed 2490 ( 26% ) 10167 20% ) 1.46 ( 1.39 - 1.54 ) 
Previously prescribed 1784 ( 18% ) 7967 15% ) 1.33 ( 1.26 - 1.41 ) 
Recently prescribed 147 ( 2% ) 561 1% ) 1.56 ( 1.30 - 1.88 ) 
Currently prescribed 559 ( 6% ) 1639 3% ) 2.03 ( 1.84 - 2.25 ) 
Sex hormones 
Newr prescribed 8357 ( 86% ) 45547 87% ) 1.00 
Ewr prescribed 1325 ( 14% ) 6553 13% ) 1.24 (1.15-1.33) 
Previously prescribed 997 ( 10% ) 4998 10% ) 1.24 ( 1.14 - 1.35) 
Recently prescribed 68 ( 1% ) 423 1% ) 0.98 ( 0.75 - 1.28 ) 
Currently prescribed 260 ( 3% ) 1132 2% ) 1.31 ( 1.14 - 1.51 ) 
Hypothalmic & pituitary hormones, & anti-oestrogens 
Newr prescribed 9416 ( 97% ) 50839 98% ) 1.00 
Ewr prescribed 266 ( 3% ) 1261 2% ) 1.13 (0.98 - 1.29) 
Previously prescribed 166 ( 2% ) 804 2% ) 1.11 ( 0.93 - 1.32 ) 
Recently prescribed 11 ( 0% ) 52 0% ) 1.16 ( 0.60 - 2.22 ) 
Currently prescribed 89 ( 1% ) 405 1% ) 1.15 ( 0.91 - 1.46 ) 
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Table 7-4 (continued) 
Bone metabolism 
Ne-.er prescribed 8681 ( 90% ) 48389 ( 93% ) 1.00 
E-.er prescribed 1001 ( 10% ) 3711 ( 7% ) 1.52 ( 1.41 - 1.64 ) 
Pre'o1ously prescribed 316 ( 3% ) 1294 ( 2% ) 1.35 ( 1.19 - 1.54 ) 
Recently prescribed 82 ( 1% ) 347 ( 1% ) 1.38 ( 1.08 - 1.75 ) 
Currently prescribed 603 ( 6% ) 2070 ( 4% ) 1.65 ( 1.50 - 1.82 ) 
Other endocrine 
Ne-.er prescribed 9457 ( 98% ) 51379 ( 99% ) 1.00 
E-.er prescribed 225 ( 2% ) 721 ( 1% ) 1.79 ( 1.53 - 2.09 ) 
Pre'o1ously prescribed 168 ( 2% ) 587 ( 1% ) 1.66 ( 1.40 - 1.99 ) 
Recently prescribed 10 ( 0% ) 35 ( 0% ) 1.59 ( 0.78 - 3.24 ) 
Currently prescribed 47 ( 0% ) 99 ( 0% ) 2.58 ( 1.81 - 3.68 ) 
Approximately 10% of study participants have been prescribed medications 
for diabetes, thyroid conditions, and bone metabolism (see Table 7-3). 
Approximately 13% have ever been prescribed sex hormones, and more 
than 20% have been prescribed corticosteroids. The prevalence of ever 
prescribing of other endocrine, and of hypothalamic and pituitary hormones is 
approximately 1-2%. 
The odds ratios of first fall for ever prescribed ranges from not significantly 
different to 1 for hypothalamic and pituitary hormones through to 1.79 (1.53 -
2.09) for other endocrine medications. 
The odds ratio of current prescribing is highest for other endocrine 
medications OR 2.58 (1.81 - 3.68), and then for corticosteroids OR 2.03 (1.84 
- 2.25). With the exception of medications for hypothalamic and pituitary 
hormones, odds ratios among other subclasses are significant, ranging from 
OR 1.31 (1.14 - 1.51) for sex hormones to 1.65 (1.50 - 1.82) for medications 
related to bone metabolism. 
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Table 7·5 Association between recorded first fall and prescribing of medications in 
primary care for gynaeocology and urinary tract infection, THIN 2003·6 
Odds ratio 
Exposure Cases Controls (95% confidence 
n=9682 n=52100 intervals) 
Unadjusted 
Vaginal & wlval conditions 
Newr prescribed 8187 ( 85% ) 45427 ( 87% ) 1.00 
Ewr prescribed 1495 ( 15% ) 6673 ( 13% ) 1.31 ( 1.23 - 1.40 ) 
P r e ~ o u s l y y prescribed 1334 ( 14% ) 5964 ( 11% ) 1.31 ( 1.23 - 1.41 ) 
R e c ~ n t l y y prescribed 73 ( 1% ) 277 ( 1% ) 1.52 ( 1.17 - 1.98 ) 
Currently prescribed 88 ( 1% ) 432 ( 1% ) 1.19 ( 0.94 - 1.51 ) 
Genito-urinary 
Newr prescribed 7542 ( 78% ) 42885 ( 82% ) 1.00 
Ewr prescribed 2140 ( 22% ) 9215 ( 18% ) 1.34 ( 1.27 - 1.41 ) 
P r e ~ o u s l y y prescribed 1162 ( 12% ) 4850 9% ) 1.38 ( 1.29 - 1.48 ) 
Recently prescribed 115 ( 1% ) 501 1% ) 1.33 ( 1.08 - 1.63 ) 
Currently prescribed 863 ( 9% ) 3864 7% ) 1.29 ( 1.19 - 1.39 ) 
Almost one fifth of older people have ever been prescribed medications 
related to the genito-urinary system, and more than one tenth of older women 
have ever been prescribed medication for vaginal and vulval conditions (see 
Table 7-5). 
For people currently prescribed medication for the genitourinary system, the 
odds ratio for first fall is 1.29 (1.19 - 1.39), but this is not significantly different 
to the odds ratio for people recently or previously prescribed. The odds ratio 
for first fall among older women currently prescribed for vaginal or vulval 
conditions is not statistically significant. 
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Table 7-6 Association between recorded first fall and prescribing of medications in 
primary care for malignant disease and immunosuppression, THIN 2003-6 
Cases Controls Odds ratio Exposure 
n=9682 n=52100 
(95% confidence 
intervals) 
Cytotoxics 
Ne\er prescribed 9451 ( 98% ) 51112 98% ) 1.00 
E\er prescribed 231 ( 2% ) 988 2% ) 1.28 ( 1.10 - 1.48 ) 
Pre\1ously prescribed 149 ( 2% ) 612 1% ) 1.31 ( 1.09 - 1.57 ) 
Recently prescribed 17( 0% ) 78 0% ) 1.23 ( 0.73 - 2.09 ) 
Curr$f1t1y prescribed 65 ( 1% ) 298 1% ) 1.23 ( 0.94 - 1.61 ) 
Immune response 
Ne\er prescribed 9615 ( 99% ) 51868 ( 100%) 1.00 
E\er prescribed 67 ( 1% ) 232 ( 0% ) 1.63 ( 1.24 - 2.15 ) 
Pre\1ously prescribed 42 ( 0% ) 140 0% ) 1.71 ( 1.21 - 2.43 ) 
Recently prescribed 3 ( 0% ) 8 0% ) 2.25 ( 0.60 - 8.48 ) 
Currently prescribed 22 ( 0% ) 84 0% ) 1.44 ( 0.89 - 2.31 ) 
Sex hormones & hormone antagonists in malignant disease 
Ne\er prescribed 9192 ( 95% ) 49929 96% ) 1.00 
E\er prescribed 490 ( 5% ) 2171 4% ) 1.23 ( 1.11 - 1.37 ) 
Pre\1ously prescribed 226 ( 2% ) 1186 2% ) 1.08 ( 0.94 - 1.26 ) 
Recently prescribed 35 ( 0% ) 126 0% ) 1.48 ( 1.01 - 2.16 ) 
Currently prescribed 229 ( 2% ) 859 2% ) 1.39 ( 1.20 - 1.61 ) 
Compared to other classes of medication, the prevalence of ever prescribing 
of medications in primary care for malignant disease and 
immunosuppression is low (see Table 7-6). The prevalence of ever 
prescribed is highest for sex hormones and hormone antagonists (4%). 
The odds ratio of first fall for ever prescribing is highest for medications for 
immune response OR 1.63 (1.24 - 2.15). However, the odds ratio for current 
prescribing is not Significant. Only in medications related to sex hormones 
and hormone a n t ~ g o n i s t s s is the odds ratio of first fall significant OR 1.39 
(1.20 -1.61). 
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Table 7-7 Association between first fall and prescribing of medications in primary 
care for nutrition and blood, THIN 2003-6 
Odds ratio 
Exposure Cases Controls (95% confidence 
n=9682 n=52100 intervals) 
Unadjusted 
Aneamias & other blood disorders 
Ne-.er prescribed 7567 78% ) 44495 85% ) 1.00 
E-.er prescribed 2115 22% ) 7605 15% ) 1.59 ( 1.50 - 1.68 ) 
Previously prescribed 1266 ( 13% ) 4804 9%) 1.52 ( 1.42 - 1 .62 ) 
Recently prescribed 171 ( 2% ) 551 1% ) 1.79 ( 1.50 - 2.13 ) 
Currehtly prescribed 678 ( 7% ) 2250 4% ) 1.70 ( 1.55 - 1.86 ) 
Fluids & electrolytes 
Ne-.er prescribed 9077 ( 94% ) 49856 96% ) 1.00 
E-.er prescribed 605 ( 6% ) 2244 4% ) 1.45 ( 1.31 - 1.59 ) 
Previously prescribed 503 ( 5% ) 1908 4% ) 1.41 ( 1.27 - 1.56 ) 
Recently prescribed 33 ( 0% ) 81 0% ) 2.34 ( 1.56 - 3.53 ) 
Currently prescribed 69 ( 1% ) 255 0% ) 1.45 ( 1.11 - 1.90 ) 
Oral nutrition 
Ne-.er prescribed 9110 94% ) 50345 ( 97% ) 1.00 
E-.er prescribed 572 6% ) 1755 ( 3% ) 1.68 ( 1.52 - 1.86 ) 
Previously prescribed 314 ( 3% ) 1033 2% ) 1.57 ( 1.38 - 1.80 ) 
Recently prescribed 42 ( 0% ) 146 0% ) 1.48 ( 1.05 - 2.11 ) 
Currently prescribed 216 ( 2% ) 576 1% ) 1.93 ( 1.64 - 2.27 ) 
Minerals 
Ne-.er prescribed 8086 ( 84% ) 46298 89% ) 1.00 
E-.er prescribed 1596 ( 16% ) 5802 11% ) 1.58 ( 1.49 - 1.69 ) 
Previously prescribed 660 ( 7% ) 2625 5% ) 1.46 ( 1.33 - 1.60 ) 
Recently prescribed 155 ( 2% ) 620 1% ) 1.47 ( 1.22 - 1.76 ) 
Currently prescribed 781 ( 8% ) 2557 5% ) 1.74 ( 1.60 - 1.90 ) 
Vitamins 
Ne-.er prescribed 7920 ( 82% ) 45916 88% ) 1.00 
E-.er prescribed 1162 ( 18% ) 6184 12% ) 1.67 ( 1.57 - 1.77 ) 
Previously prescribed 784 ( 8% ) 3089 6% ) 1.49 ( 1.37 - 1.63 ) 
Recently prescribed 147 ( 2% ) 530 1% ) 1.66 ( 1.38 - 2.01 ) 
Currently prescribed 831 ( 9% ) 2565 5% ) 1.87 ( 1.72 - 2.04 ) 
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Table 7-7 (continued) 
Bitters & tonics 
Newr prescribed 9602 ( 99% ) 51813 ( 99% ) 1.00 
Ewr prescribed 80 ( 1% ) 287 ( 1% ) 1.45 ( 1.12 - 1.89 ) 
PrelAously prescribed 74 ( 1% ) 274 ( 1% ) 1.40 ( 1.06 - 1.83 ) 
Recently prescribed 2 ( 0% ) 3 ( 0% ) 3.75 ( 0.63 - ### ) 
Currently prescribed 4 ( 0% ) 10 ( 0% ) 2.31 (0.72 - 7.36 ) 
Metabolic disorders 
Newr prescribed 9660 ( 100% ) 52020 ( 100%) 1.00 
Ewr prescribed 22 ( 0% ) 80 ( 0% ) 1.57 ( 0.98 - 2.53 ) 
PrelAously prescribed 15 ( 0% ) 56 ( 0% ) 1.54 ( 0.87 - 2.72 ) 
Recehtly prescribed 1 ( 0% ) 6 ( 0% ) 0.97 ( 0.12 - 8.09 ) 
Currently prescribed 6 ( 0% ) 18 ( 0% ) 1.89 ( 0.75 - 4.80 ) 
Amongst the range of medications prescribed in primary care for Ilutrition and 
blood (see Table 7-7), approximately 5% of older people are currently 
prescribed medications for anaemia, minerals and vitamins, and for these 
subclasses as many as 15% of people have been ever-prescribed. In the 
other subclasses, the prevalence of prescribing is much lower. 
With the exception of medication for metabolic disorders OR 1.57 (0.98 -
2.53), in all other subclasses the odds ratios for ever prescribed reaches 
statistical significance, ranging from 1.45 (1.31 - 1.59) for fluids and 
electrolytes through to 1.67 (1.57 - 1.77) for vitamins and 1.68 (1.52 - 1.86) 
for oral nutrition. 
The odds ratio of current prescribing is highest for oral nutrition OR 1.93 
(1.64 - 2.27) and vitamins OR 1.87 (1.72 - 2.04) and, in the case of vitamins, 
this is higher than the odds ratio for people previously prescribed. For 
minerals, the odds ratio among people currently prescribed is also higher 
than amongst those previously prescribed: OR 1.74 (1.60 - 1.90) compared 
to 1.46 (1.33 - 1.60). The point estimate for the odds ratio of first fall among 
people currently prescribed fluids and electrolytes is lower, OR 1.45 (1.11 -
1.90), than that for people recently prescribed, OR 2.34 (1.56 - 3.53). 
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Table 7-8 Association between first fall and prescribing in primary care of medication 
for muskuloskeletal and joint diseases, THIN 2003-6 
Odds ratio 
Exposure Cases Controls (95% confidence 
n=9682 n=52100 intervals) 
Unadjusted 
Rheumatic diseases & gout 
Newr prescribed 1951 ( 20% ) 15412 30% ) 1.00 
Ewr prescribed 7731 ( 80% ) 36688 70% ) 1.71 ( 1.62 - 1.81 ) 
Previously prescribed 3505 ( 36% ) 19667 38% ) 1.45 ( 1.37 - 1.55 ) 
Recently prescribed 599 ( 6% ) 2631 5% ) 1.85 ( 1.67 - 2.05 ) 
C u r r ~ n t l y y prescribed 3627 ( 37% ) 14390 28% ) 2.04 ( 1.92 - 2.17 ) 
Neuromuscular disorders 
Newr prescribed 7179 ( 74% ) 42495 82% ) 1.00 
Ewr prescribed 2503 ( 26% ) 9605 18% ) 1.58 ( 1.50 - 1.66 ) 
Previously prescribed 1685 ( 17%) 7005 13% ) 1.46 ( 1.38 - 1.55 ) 
Recently prescribed 125 ( 1% ) 534 1% ) 1.42 ( 1.16 - 1.73 ) 
Currently prescribed 693 ( 7% ) 2066 4% ) 1.99 ( 1.82 - 2.18 ) 
Soft tissue inflammation 
Newr prescribed 5657 ( 58% ) 36384 ( 70% ) 1.00 
Ewr prescribed 4025 ( 42% ) 15716 ( 30% ) 1.70 ( 1.62 - 1.78 ) 
Previously prescribed 3011 ( 31% ) 12809 ( 25% ) 1.55 ( 1.48 - 1.64 ) 
Recently prescribed 231 ( 2% ) 893 ( 2% ) 1.76 ( 1.51 - 2.04 ) 
Currently prescribed 783 ( 8% ) 2014 ( 4% ) 2.59 ( 2.37 - 2.83 ) 
The prevalence of prescribing of medication in primary care for musculo-
skeletal and joint diseases is high (Table 7-8). More than 70% of older 
people have been ever-prescribed medication for rheumatic diseases and 
gout, and more than a quarter of older people are currently prescribed for 
this. More than 30% have ever been prescribed medication for soft tissue 
inflammation, and almost 20% have been ever been prescribed for 
neuromuscular disorders. 
For all three subclasses of medication, the odds ratio of first fall associated 
with ever-prescribed is positive and significant. Furthermore, the odds ratio 
for current prescribing is higher than for previously prescribed. It is highest 
for medication for soft tissue inflammation, OR 2.59 (2.37 - 2.83) then for 
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rheumatic diseases OR 2.04 (1.97 - 2.17), followed by neuromuscular 
disorders OR 1.99 (1.82 - 2.18). 
Table 7-9 Association between first fall and prescribing in primary care of 
medications for the eye, THIN 2003-6 
Odds ratio 
Exposure Cases Controls (95% confidence 
n=9682 n=52100 intervals) 
Unadjusted 
Anti-infectiw eye preparations 
Newr prescribed 7129 ( 74% ) 40777 78% ) 1.00 
Ewr p r ~ s c r i b e d d 2553 ( 26% ) 11323 22% ) 1.30 ( 1.24 - 1.37 ) 
Previously prescribed 2324 ( 24% ) 10399 20% ) 1.29 ( 1.23 - 1.36 ) 
Recently prescribed 86 ( 1% ) 391 1% ) 1.22 (0.96 - 1.55 ) 
Currently prescribed 143 ( 1% ) 533 1% ) 1.53 ( 1.27 - 1.85 ) 
Corticosteroids & other anti-inflammatory 
Newr prescribed 7823 ( 81% ) 43816 84% ) 1.00 
Ewr prescribed 1859 ( 19% ) 8284 16% ) 1.24 ( 1.17 - 1.31 ) 
Previously prescribed 1679 ( 17%) 7419 14% ) 1.25 ( 1.17 - 1.32 ) 
Recently prescribed 68 ( 1% ) 295 1% ) 1.29 ( 0.99 - 1.68 ) 
Currently prescribed 112 ( 1% ) 570 1% ) 1.11 (0.91 - 1.37) 
Mydriatics & cycloplegics 
Newr prescribed 9549 ( 99% ) 51619 99% ) 1.00 
Ewr prescribed 133 ( 1% ) 481 1% ) 1.44 ( 1.19 - 1.76 ) 
Previously prescribed 117 ( 1% ) 425 1% ) 1.44 ( 1.16 - 1.77 ) 
Recently prescribed 1 ( 0% ) 13 0% ) 0.43 ( 0.05 - 3.31 ) 
Currently prescribed 15 ( 0% ) 43 0% ) 1.83 ( 1.01 - 3.32 ) 
Glaucoma 
Newr prescribed 9057 ( 94% ) 49063 94% ) 1.00 
Ewr prescribed 625 ( 6% ) 3037 6% ) 1.04 ( 0.95 - 1.14 ) 
Previously prescribed 130 ( 1% ) 610 1% ) 1.09 ( 0.90 - 1.33 ) 
Recently prescribed 39 ( 0% ) 170 0% ) 1.18 ( 0.82 - 1.68 ) 
Currently prescribed 456 ( 5% ) 2257 4% ) 1.02 ( 0.92 - 1.13 ) 
Miscellaneous ophthalmic preparations 
Newr prescribed 7944 ( 82% ) 45364 87% ) 1.00 
Ewr prescribed 1738 ( 18% ) 6738 13% ) 1.46 ( 1.37 - 1.55 ) 
Previously prescribed 1100 ( 11% ) 4230 8% ) 1.47 ( 1.37 - 1.58 ) 
Recently prescribed 130 ( 1% ) 515 1% ) 1.43 ( 1.18 - 1.74 ) 
Currently prescribed 508 ( 5% ) 1991 4% ) 1.43 ( 1.29 - 1.59 ) 
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More than 20% of older people have ever been prescribed anti-infective eye 
preparations in primary care (Table 7-9). The corresponding prevalence for 
corticosteroids, for miscellaneous opthalmic preparations, and for glaucoma 
is 16% and 13% and 6% respectively. Only for glaucoma (4%) and 
miscellaneous ophthalmic preparations (4%) is current prescribing greater 
than 1%. 
The odds ratio of first fall for older people who have ever been prescribed 
medications for glaucoma or corticosteroids for eye conditions in primary 
care is not different to 1. For the other subclasses, the odds ratio of first fall 
~ ~
for people ever prescribed ranges from 1.24 (1.17 - 1 .31) for corticosteroids 
and other anti-inflammatory medication, to 1.44 (1.16 - 1.77) for mydriatics 
and cycloplegics, and 1.46 (1.37 - 1.55) for miscellaneous ophthalmic 
preparations. 
For people currently prescribed in primary care, the odds ratio of first fall for 
mydriatics and cycloplegics is highest OR 1.83 (1.01 - 3.32), then for anti-
infective eye preparations OR 1.53 (1.27 - 1.85). 
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Table 7-10 Association between first fall and prescribing in primary care of 
medications for ear, nose and oropharynx, THIN 2003-6 
Odds ratio 
Exposure Cases Controls (95% confidence 
n=9682 n=52100 intervals) 
Unadjusted 
Ear 
Newr prescribed 5727 ( 59% ) 34988 67% ) 1.00 
Ewr prescribed 3955 ( 41% ) 17112 33% ) 1.43 ( 1.36 - 1.49 ) 
Previously prescribed 3498 ( 36% ) 15329 29% ) 1.41 ( 1.34 - 1.48 ) 
Recently prescribed 193 ( 2% ) 726 1% ) 1.63 ( 1.39 - 1.92 ) 
Currl;lntly prescribed 264 ( 3% ) 1057 2% ) 1.51 ( 1.31 - 1.73 ) 
Nose 
Newr prescribed 7128 ( 74% ) 41058 79% ) 1.00 
Ewr prescribed 2554 ( 26% ) 11042 21% ) 1.38 ( 1.32 - 1.46 ) 
Previously prescribed 2056 ( 21% ) 8939 17% ) 1.38 ( 1.30 - 1.46 ) 
Recently prescribed 154 ( 2% ) 652 1% ) 1.41 (1.18 - 1.69) 
Currently prescribed 344 ( 4% ) 1451 3% ) 1.42 ( 1.26 - 1.60 ) 
Oropharynx 
Newr prescribed 7860 ( 81% ) 1822 3% ) 1.00 
Ewr prescribed 1822 ( 19% ) 7011 13% ) 1.52 ( 1.43 - 1.61 ) 
Previously prescribed 1543 ( 16% ) 6181 12% ) 1.46 ( 1.37 - 1.56 ) 
Recently prescribed 91 ( 1% ) 315 1% ) 1.71 ( 1.35 - 2.17 ) 
Currently prescribed 188 ( 2% ) 515 1% ) 2.11 ( 1.78 - 2.50 ) 
Although the prevalence of current prescribing of medications for ear, nose 
and oropharynx ranges from between 1 - 3 %, between 13% (medications 
for oropharynx) and about 33% (for ear) of older people have ever been 
prescribed. 
In all three subclasses the odds ratio of ever prescribed is positive and 
ranges between 1.38 (1.32 ., 1.46) for medications for the nose, to 1.52 (1.43 
• 1.61) for medications for the oropharynx. Amongst people currently 
prescribed medications for the oropharynx, the odds ratio is 2.11 (1.78·2.50) 
and is greater tha·n amongst those previously prescribed. For medications 
for the ear and nose, the point estimate of the odds ratio for current 
prescribing is close to that for ever prescribed. 
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Table 7-11 Association between first fall and prescribing in primary care of 
medications for the skin, THIN 2003-6 
Odds ratio 
Exposure Cases Controls (95% confidence 
n=9682 n=52100 intervals) 
Unadjusted 
Skin conditions 
Ne'A9r prescribed 9523 ( 98% ) 51474 99% ) 1.00 
E'A9r prescribed 159 ( 2% ) 626 1% ) 1.34 ( 1.12 - 1.60 ) 
PrelAously prescribed 140 ( 1% ) 535 1% ) 1.38 ( 1.14 - 1.67 ) 
Recently prescribed 8 ( 0% ) 37 0% ) 1.19 ( 0.55 - 2.59 ) 
CurrE!l1t1y prescribed 11 ( 0% ) 54 0% ) 1.03 ( 0.53 - 1.99 ) 
Emollient & barrier preparations 
Ne'A9r prescribed 6057 ( 63% ) 37740 72% ) 1.00 
E'A9r prescribed 3625 ( 37% ) 14360 28% ) 1.53 ( 1.46 - 1.61 ) 
PrelAously prescribed 2475 ( 26% ) 10252 20% ) 1.48 ( 1.41 - 1.57 ) 
Recently prescribed 340 ( 4% ) 1353 3% ) 1.52 ( 1.34 - 1.72 ) 
CUrrently prescribed 810 ( 8% ) 2755 5% ) 1.73 ( 1.59 - 1.88 ) 
Topical local anaesthetics & antipruritics 
Ne'A9r prescribed 9317 ( 96% ) 50692 97% ) 1.00 
E'A9r prescribed 365 ( 4% ) 1408 3% ) 1.38 ( 1.22 - 1.55 ) 
PrelAously prescribed 320 ( 3% ) 1273 2% ) 1.34 (1.18-1.53) 
Recently prescribed 15 ( 0% ) 54 0% ) 1.36 ( 0.76 - 2.44 ) 
Currently prescribed 30 ( 0% ) 81 0% ) 1.95 ( 1.27 - 2.99 ) 
Topical corticosteroids 
Ne'A9r prescribed 4073 ( 42% ) 26098 50% ) 1.00 
E'A9r prescribed 5609 ( 58% ) 26002 50% ) 1.41 ( 1.35 - 1.48 ) 
PrelAously prescribed 4464 ( 46% ) 21303 41% ) 1.38 ( 1.31 - 1.44 ) 
Recently prescribed 404 ( 4% ) 1825 4% ) 1.45 ( 1.29 - 1.62 ) 
Currently prescribed 741 ( 8% ) 2874 6% ) 1.64 ( 1.50 - 1.80 ) 
Eczema & psoriasis 
Ne'A9r prescribed 9015 ( 93% ) 49376 95% ) 1.00 
E'A9r prescribed ,667 ( 7% ) 2724 5% ) 1.38 ( 1.26 - 1.51 ) 
PrelAously prescribed 499 ( 5% ) 2067 4% ) 1.35 ( 1.22 - 1.49 ) 
Recently prescribed 38 ( 0% ) 156 0% ) 1.42 ( 0.99 - 2.02 ) 
Currently prescribed 130 ( 1% ) 501 1% ) 1.52 ( 1.25 - 1.85 ) 
. Acne & rosacea 
Ne'A9r prescribed 6324 ( 65% ) 36975 71% ) 1.00 
E'A9r prescribed 3358 ( 35% ) 15125 29% ) 1.36 ( 1.30 - 1.43 ) 
PrelAously prescribed 3011 ( 31% ) 13906 27% ) 1.33 ( 1.26 - 1.40 ) 
Recently prescribed 128 ( 1% ) 490 1% ) 1.59 ( 1.30 - 1.94 ) 
Currently prescribed 219 ( ,2% ) 729 1% ) 1.80 ( 1.54 - 2.11 ) 
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Table 7-11 (continued) 
Warts & calluses 
Ne-.er prescribed 9474 ( 98% ) 51321 99% ) 1.00 
E-.er prescribed 208 ( 2% ) 779 1% ) 1.48 ( 1.27 - 1.74) 
Previously prescribed 192 ( 2% ) 726 1% ) 1.47 ( 1.25 - 1.73 ) 
Recently prescribed 4 ( 0% ) 21 0% ) 1.00 ( 0.33 - 2.99 ) 
Currently prescribed 12 ( 0% ) 32 0% ) 2.03 ( 1.03 - 4.00 ) 
Sunscreens & camoflagers 
Ne-.er prescribed 9565 ( 99% ) 51683 99% ) 1.00 
E-.er prescribed 117 ( 1% ) 417 1% ) 1.53 ( 1.24 - 1.88 ) 
Previously prescribed 95 ( 1% ) 350 1% ) 1.48 ( 1.17 - 1.86 ) 
Recently prescribed 6 ( 0% ) 24 0% ) 1.31 ( 0.53 - 3.26 ) 
Curr.,ently prescribed 16 ( 0% ) 43 0% ) 2.10 ( 1.18 - 3.74) 
Shampoos & scalp preparations 
Ne-.er prescribed 8936 ( 92% ) 49070 94% ) 1.00 
E-.er prescribed 746 ( 8% ) 3030 6% ) 1.34 ( 1 :23 - 1.46 ) 
Previously prescribed 624 ( 6% ) 2550 5% ) 1.33 ( 1.21 - 1.45 ) 
Recently prescribed 38 ( 0% ) 176 0% ) 1.16 ( 0.82 - 1.66 ) 
Currently prescribed 84( 1% ) 304 1% ) 1.59 ( 1.25 - 2.03 ) 
Anti-infecti-.e skin preparations 
Ne-.er prescribed 5064 ( 52% ) 31891 61% ) 1.00 
E-.er prescribed 4618 ( 48% ) 20209 39% ) 1.48 ( 1.41 - 1.55 ) 
Previously prescribed 3902 ( 40% ) 17582 34% ) 1.44 ( 1.37 - 1.51 ) 
Recently prescribed 282 ( 3% ) 1067 2% ) 1.68 ( 1.47 - 1.93 ) 
Currently prescribed 434 ( 4% ) 1560 3% ) 1.78 ( 1.60 - 2.00 ) 
Skin cleansers & antiseptics 
Ne-.er prescribed 8508 ( 88% ) 48243 ( 93% ) 1.00 
E-.er prescribed 1174 ( 12% ) 3857 ( 7% ) 1.67 ( 1.55 - 1.79 ) 
Previously prescribed 972 ( 10% ) 3338 6%) 1.60 ( 1.48 - 1.74 ) 
Recently prescribed 68 ( 1% ) 187 0%) 2.00 ( 1.50 - 2.66 ) 
Currently prescribed 134 ( 1% ) 332 1% ) 2.09 ( 1.70 - 2.57 ) 
Antiperspirants 
Ne-.er prescribed 9664 ( 100% ) 52039 ( 100%) 1.00 
E-.er prescribed 18 ( 0% ) 61 ( 0% ) 1.69 ( 0.99 - 2.86 ) 
Previously prescribed 17( 0% ) 55 ( 0% ) 1.76 ( 1.02 - 3.04) 
Recently prescribed 1 ( 0% ) 4 ( 0% ) 1.50 (0.17- ###) 
Currently prescribed o ( 0% ) 2 ( 0% ) ( ) 
. Topical circulatory preparations 
Ne-.er prescribed 9320 ( 96% ) 50882 98% ) 1.00 
E-.er prescribed 362 ( 4% ) 1218 2% ) 1.66 ( 1.46 - 1.87 ) 
Previously prescribed 311 ( 3% ) 1129 2% ) 1.53 ( 1.35 - 1.75 ) 
Recently prescribed 9 ( 0% ) 32 0% ) 1.51 ( 0.71 - 3.22 ) 
Currently prescribed 42 ( 0% ) 57 0% ) 4.13 ( 2.76 - 6.19) 
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A large number of subclasses of medication for skin conditions are 
prescribed in primary care (Table 7-11). For some subclasses, large 
numbers of older people have ever been prescribed (e.g. about one half for 
topical corticosteroids; about one third for anti-infective skin preparations). In 
most subclasses, not more than about 1 % of older people are currently 
prescribed. Exceptions to this are topical corticosteroids (6%), emollient and 
barriers (5%), and anti-infective skin preparations (3%). 
With the exception of antiperspirants (which is borderline significant), the 
odds ratio of first fall for all subclasses of medication prescribed in primary 
• 
care is significant and positive for all patients who have been ever prescribed 
in primary care. The odds ratio of first fall for ever prescribed is highest for 
skin cleansers OR 1.67 (1.55 - 1.79) and topical circulatory preparations OR 
1.66 (1.46 - 1.87). It is lowest for shampoos and scalp preparations OR 1.34 
(1.23 - 1.46). 
For current prescribing, the risk of first fall is highest for topical circulatory 
preparations OR 4.13 (2.76 - 6.19), sunscreens and camouflages OR 2.10 
(1.18 - 2.74), skin cleansers and antiseptics OR 2.09 (1.70 - 2.57), and warts 
and calluses 2.03 (1.03 - 4.00). In most other subclasses the odds ratio is 
positive and significant and in the case of the following medications it is also 
higher than for the people previously prescribed: acne and rosacea 1.80 
(1.54 - 2.11), emollients 1.73 (1.59 - 1.88), topical corticosteroids 1.64 (1.50 -
1.80), and anti-infective skin preparations 1.78 (1.60 - 2.00). The odds ratio 
of first fall for current prescribing of medication for skin conditions is not 
significantly different from 1. 
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Table 7-12 Association between first fall and prescribing in primary care of 
immunological products and vaccines, THIN 2003-6 
Odds ratio 
Exposure Cases Controls (95% confidence 
n=9682 n=52100 intervals) 
Unadjusted 
Vaccines & antisera 
Ne-.er prescribed 4724 ( 49% ) 27173 ( 52% ) 1.00 
E-.er prescribed 4958 ( 51% ) 24927 ( 48% ) 1.26 ( 1.19 - 1.33 ) 
Pre\Aously prescribed 4303 ( 44% ) 21794 42% ) 1.24 ( 1.17 - 1.31 ) 
Recently prescribed 301 ( 3% ) 1485 3% ) 1.44 ( 1.20 - 1.72 ) 
Currently prescribed 354 ( 4% ) 1648 3% ) 1.55 ( 1.31 - 1.84 ) 
Immunoglobulins 
Ne-.er prescribed 9484 ( 98% ) 50856 98% ) 1.00 
E-.er prescribed 198 ( 2% ) 1244 2% ) 0.91 ( 0.78 - 1.06 ) 
Pre\Aously prescribed 198 ( 2% ) 1244 ( 2% ) 0.91 ( 0.78 - 1.06) 
Recently prescribed o ( 0% ) o ( 0% ) ( ) 
Currently prescribed o ( 0% ) o ( 0% ) ( ) 
About one half of the older people are recorded as having ever been 
prescribed vaccine or antisera in primary care. Amongst these only 3% are 
currently prescribed. 2% of older people have been prescribed 
immunoglobulins, but none of these are being currently prescribed. 
The odds ratio of first fall for immunoglobulins is not significantly different to 
1. For current prescribing of vaccines and sera the odds ratio of first fall is 
1.55 (1.31 -1.84). 
It should be noted that the pattern of prescribing and of concordance for a 
vaccine is very different to that of a medication for the management of a 
chronic condition. As a result, the universal definition of current prescribing 
used in this study.may not be relevant to vaccines. Therefore, despite the 
fact that odds ratio is nearer to one than it is in many other subclasses, the 
high prevalence of vaccine prescribing suggests that the risk profile is worthy 
of further study. 
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Table 7-13 Association between recorded first fall and prescribing in primary care of 
anaesthesia, THIN 2003-6 
Odds ratio 
Exposure Cases Controls (95% confidence 
n=9682 n=52100 intervals) 
Unadjusted 
General anaesthesia 
Never prescribed 8051 ( 83% ) 46235 ( 89% ) 1.00 
Ever prescribed 1631 ( 17%) 5865 ( 11% ) 1.58 ( 1.49 - 1.68 ) 
Pre"';ously prescribed 1112 ( 11% ) 4187 ( 8% ) 1.53 ( 1.42 - 1.64 ) 
Recently prescribed 67 ( 1% ) 214 ( 0% ) 1.86 ( 1.41 - 2.46 ) 
C u ~ n t l y y prescribed 452 ( 5% ) 1464 ( 3% ) 1.68 ( 1.51 - 1.88 ) 
Local anaesthesia 
Never prescribed 8397 ( 87% ) 46335 ( 89% ) 1.00 
Ever prescribed 1285 ( 13% ) 5765 ( 11% ) 1.29 ( 1;21 - 1.39 ) 
Pre"';ously prescribed 1151 ( 12% ) 5347 ( 10% ) 1.25 ( 1.16 - 1.34 ) 
Recently prescribed 57 ( 1% ) 181 ( 0% ) 1.80 ( 1.33 - 2.43 ) 
Currently prescribed 77 ( 1% ) 237 ( 0% ) 1.85 ( 1.42 - 2.41 ) 
12% of older people are recorded as having been prescribed general 
anaesthesia in primary care, and a similar proportion have been prescribed 
for local anaesthesia. The corresponding prevalence of current prescribing is 
about 3% and less than 1%, respectively. 
The odds ratio of first fall for older people currently prescribed local 
anaesthesia is 1.85 (1.42 - 2.41) which is higher than the risk among people 
previously prescribed. The odds ratio is also positive and significant for 
people currently prescribed general anaesthesia OR 1.68 (1.51 -1.88), and 
among people recently prescribed OR 1.86 (1.41 - 2.46). 
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7.3 Discussion 
In this hypothesis-generating study of medications which were not included in 
recent meta-analyses, for almost all subclasses of medication prescribed in 
primary care to older people, there was a significant positive association 
between ever-prescribed and first fall. Age and sex adjusted odds ratios for 
current prescribing ranged from not significantly different from 1, to 4.13 (2.76 
- 6.19). For most subclasses, the point estimate of the age-sex adjusted 
odds ratio was between 1.3 and 1.7. Subclasses in which there was a 
statisticqJly significant association and in which the point estimate of the odds 
ratio for current prescribing was higher than this include antispasmodics 1.79 
(1.58 - 2.03), acute diarrhoea 2.50 (2.21 - 2.84), laxatives 2.02 (1.89 - 2.16), 
intestinal secretions 1.73 (1.14 - 2.64), oxygen 2.71 (2.00 - 3.68), mucolytics 
1.94 (1.20 - 3.15), antibacterials 2.75 (2.54 - 2.98), antifungals 1.86 (1.43 -
2.43), antivirals 3.03 (2.07 - 4.42), antiprotozoals 1.80 (1.61 - 2.02), 
corticosteroids 2.03 (1.84 - 2.25), other endocrine 2.58 (1.81 - 3.68), oral 
nutrition 1.93 (1.64 - 2.27), minerals 1.74 (1.60 - 1.90), vitamins 1.87 (1.72-
2.04), rheumatic diseases and gout 2.04 (1.92 - 2.17), neuromuscular 
disorders 1.99 (1.82 - 2.18), soft tissue inflammation 2.59 (2.37 - 2.83), 
mydriatics and cycloplegics 1.83 (1.01 - 3.32), oropharynx 2.11 (1.78-
2.50), emollient and barrier preparations 1.73 (1.59 - 1.88), topical local 
anaesthetics 1.95 (1.27 - 2.99), acne and rosacea 1.80 (1.54 - 2.11), warts 
and calluses 2.03 (1.03 - 4.00), sunscreens and camouflages 2.10 (1.18 -
3.74), anti-infective skin preparations 1.78 (1.60 - 2.00), skin cleansers 2.09 
(1.70 - 2.57), topical circulatory preparations 4.13 (2.76 - 6.19), and local 
anaesthesia 1.85 (1.42 - 2.41). 
7.3.1 Study strengths and weaknesses 
The main strengths and weaknesses of the study are similar to those already 
documented in preceeding chapters. Strengths include the large number of 
cases and the fact that the data were collected prospectively, which means 
that recall of medication exposures and of falls is not a source of bias. 
Medications were differentiated accc>rding to standard classifications in the 
British National Formulary191. 
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The main potential weakness of the study is the validity of the reporting and 
recording of fall events, which are a subset of the falls self-reported in 
surveys. The significance of falls recorded in primary care in terms of 
subsequent mortality has been evidenced in earlier chapters of the thesis. 
Nevertheless, it is acknowledged that incomplete recording of falls raises the 
possibility of differential ascertainment of falls for patients receiving 
prescribed medication. Such a bias would have led to an overestimation of 
odds ratios. However, it should be noted that the day of the prescription was 
excluded from the exposure time, which avoided ascertainment bias of falls 
~ ~
recorded at the time of initial prescribing. 
As this study is intended to generate hypotheses across a wide range of 
medications, no attempt has been made to assess the impact of or to control 
for confounding by other specific medications, polypharmacy in general, or 
co-morbidity. For the same reason, no attempt has been made to correct for 
the likelihood that in a study like this which involves a high number of 
comparisons, some of the observed associations will be attributable to 
chance. 
In the following sections, limitations speCific to certain subclasses of 
medications are described. As a general point, it should be noted that a 
single definition of current, recent and previous prescribing has been applied 
universally across all subclasses of medication. However there may be 
some medications for which a different definition might be more appropriate. 
For example, it might be that for vaccines requiring a single dose a different 
definition of current is required because the pattern of prescribing and 
delivery of the medication is different to that for medications prescribed in the 
management of chronic disease. This has not been addressed in this study. 
the implication of this is that for some subclasses the definitions of current 
and recent prescribing lack specificity. 
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Furthermore, there are some medications which can be purchased "over the 
counter", i.e. without prescription. Where this applies, it is documented in the 
following sections. It should be noted that in such instances THIN may 
represent an incomplete record of exposure for some or all cases and that 
there may be an under-representation of people in paid employment and 
others whose socio-economic status means that they do not qualify to have 
prescription charges waived (Le. it may be more attractive to such groups to 
purchase certain medications "over the counter"). 
7.3.2 Interpretation and consideration of other studies 
• Before turning to the interpretation of results for individual classes and 
subclasses of medication, it should be noted that for almost all medications 
the age and sex adjusted odds ratio of first fall is statistically signjficant and 
positive. This is interpreted as evidence of an association between the 
medication prescribed and first falls in older people. 
Nevertheless, it could also be evidence of a general bias in ascertainment of 
falls amongst people who, by virtue of receiving prescribed medication, are 
under the management of a clinician. Such a bias could arise because 
increased consulting provided more opportunities to be asked about or to 
report previous falls, or because patients consulting a doctor for any 
condition are more likely to report falls or to recall them when asked 
(because they are readier to associate a fall with a health condition, say). It 
could also arise as a result of increased vigilance on the part of the clinician 
whose threshold for enquiring about falls may be lower for patients who are 
receiving any kind of prescribed medication, Any combination of these could 
be invoked as explanation for general association between medications 
prescribed and first falls. However, another hypothesis generating study of 
the association between hip fracture and a wide range of medication 
'subclasses found a similar general association213• It is unlikely that a highly 
specific diagnosis like hip fracture, with its attendant implications and 
management, is subject to a generalised ascertainment bias. What seems 
more plausible is that a prescription of almost any subclass of medication is a 
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marker of frailty, which will be positively associated with a subsequent first 
fall. 
7.3.2.1 Medications for the gastro-intestinal system 
In this class of medication, the subclasses with the highest age and sex 
adjusted odds ratios are those for the treatment of acute diarrhoea, OR 2.50 
(2.21 - 2.84), and irritable bowel disease and diverticular disease OR 1.79 
(1.58 - 2.03), or medications which are known to cause griping or abdominal 
cramps, e.g. laxatives OR 2.02 (1.89 - 2.16). In these cases, an increased 
urge to void associated with the medication or the underlying condition 
p r o v i d e s ~ ~a plausible explanation for the observed association. For some 
subclasses (e.g. laxatives) it has been argued that the medication may lead 
to dehydration, orthostatic hypotension or confusion leading to a .greater 
propensity to fa1l214• Side effects of antimuscarinics include urinary urgency, 
confusion (particularly in the elderly), and giddiness 191. 
In their recent meta-analysis of laxatives and falls in older people, Bloch et al 
found evidence of publication bias but, on the basis of a pooled odds ratio of 
2.03 (1.52 - 2.72) concluded that there is also strong evidence for an 
association between laxative prescribing and falls in older people214. They 
also noted that it is probably not directly attributable to the medication itself 
but rather to co-morbidities such as Parkinsonism which confine patients to 
bed and are associated with constipation, and which themselves represent 
both a risk factor for falls and for laxative prescribing. Whilst this provides a 
plausible explanation, they cite no direct evidence for this from the studies in 
their meta-analysis. The potential role of underlying conditions such as this 
could be tested in THIN by·undertaking self-controlled case series analysis of 
a group of fallers exposed to laxatives who have a diagnosis of 
Parkinsonism. 
A search for literature relating to possible effects of anti-diarrhoeals or drugs 
for chronic bowel disorders and falls yielded no studies, as did searches for 
studies of antacids, antispasmodics, or proton pump inhibitors. 
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These findings suggest the need for further research to investigate the 
relationship between these medications and falls. Such studies would need 
to test for the role of confounding by indication. The high prevalence of ulcer-
healing drugs in older people (more than 15%) means that it is important to 
understand their falls profile. 
7.3.2.2 Medications for the respiratory system 
The medication subclasses with the highest age and sex adjusted odds ratios 
are oxygen (OR 2.74) and mucolytics (OR 1.94), both of which are 
prescribed to patients living with Chronic Obstructive Pulmonary Disease 
• (COPD) 191. Roig et ai's review concludes that most of the risk factors for falls 
in older people are common in people with COPO, and that there is evidence 
that lower limb weakness and impaired activities of daily living are well-
established risk factors for falls in people with COP0215. However, the review 
notes the lack of epidemiological stUdies assessing the prevalence of falls in 
people with COPD which is only partially addressed in a subsequent study of 
101 people with COP0216. The lack of larger scale epidemiological studies 
indicates a specific gap that can be addressed by further studies in THIN. A 
challenge of assessing the independent role of these medications in falls will 
be to differentiate the effect of newly prescribed medication from the possible 
impact of an exacerbation of the disease they are intended to treat. A further 
complication in the case of oxygen is that where this is accessed through a 
home-based oxygen service this may not be recorded in the patient's 
prescribing records. The extent of this would need to be assessed. 
Other subclasses worthy of further study include antihistamines, of which the 
older examples are attributed with side effects including drowsiness and 
psychomotor impairment, blurred vision, and gastro-intestinal 
disturbances 191. Other side effects include hypotension, and dizziness. 
Newer and non-sedating antihistamines are said to have milder side effects. 
There is a high prevalence of current prescribing which, together with the 
association observed in this study and the lack of evidence in the literature 
indicates the opportunity for further study. The study design would need to 
take account of the fact that some of these medications may be bought over 
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the counter, therefore primary care records may not fully reflect a patient's 
exposure. 
7.3.2.3 Medications for infections 
Acute illness is commonly cited as a medical risk factor for falls217• Some 
infections directly impact a physiological system relating to balance and 
stability (e.g. infection impacting vestibular functioning), but the association 
with falls is not strong 119. In some (e.g. urinary tract infection) the effect may 
relate to an increase in activity which carries a risk of falling (mobilising to 
walk to the bathroom). In others, the infections may be more difficult to 
classify in terms of falls pathology other than that it results in a further deficit 
of the balance system to a point that results in instability. 
The subclass with the highest adjusted odds ratio is antivirals, OR 3.03 (2.07 
- 4.42). Indications for this prescribing include a range of acute and chronic 
infections, and for patients who are immunocompromised or considered to be 
at risk as a result of other co-morbidities 191. The odds ratio for current 
prescribing is much higher than that for previous prescribing, and suggests 
that the association is not exclusively attributable to underlying co-
morbidities. However, further investigation of this association will be 
complicated by the need to differentiate the respective possible effects of the 
medication itself from the indication. 
Similar considerations arise for antibacterials, in which first fall is strongly 
associated with current prescribing, OR is 2.75 (2.54 - 2.98), but which are 
much more commonly prescribed than antivirals. The prevalence of 
antifungals is less than for antibacterials, but the association with first falls is 
also relatively strong, OR 1.86 (1.43 - 2.43). In this subclass, some of the 
indications relate to immunocompromised patients in which the association 
. may be confounded by the condition being treated191 . However, indications 
also include conditions which are less likely to represent a confounding factor 
(e.g. mild skin and nail infection). A study of the odds of first fall amongst 
older people with this diagnosis, could help establish the plausibility of the 
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hypothesis that this subclass of medication is independently associated with 
first fall in older people. 
Antiprotozoal prescribing, which is also associated with first falls, OR 1.80 
(1.61 - 2.02), is prescribed for the treatment for a range of infections. These 
include gastro-intestinal infection for which the symptoms and possible 
explanations are the same as those for subclasses prescribed for diarrhoea. 
Amongst a range of other indications, it is notable that antiprotozoals are also 
prescribed for prophylaxis against anti-malaria. It might be argued that the 
prevalence of co-morbidities in the group of older people prescribed 
. 
prophylaxis for travel purposes is unlikely to be greater than that in their age-
specific general population. On this basis, there may be scope for a study of 
the effects of the initiation of malarial prophylaxis on first fall. 
7.3.2.4 Medications for the endocrine system 
Amongst medications prescribed for the endocrine system, the subclass 
called "other endocrine drugs" has the strongest association between current 
prescribing and first fall OR 2.58 (1.81 - 3.68). However, the prevalence of 
prescribing is relatively low. Furthermore, the British National Formulary 
carries highlighted warnings for some drugs within this subclass regarding 
the sudden onset of sleepiness and other side-effects which could explain an 
association with first fall191 . 
In comparison, more than a fifth of older people have been ever-prescribed 
corticosteroid, which is used as replacement therapy or for long-term 
suppression of a range of diseases. In many cases, the drug treats the 
symptoms only, and the underlying condition is not cured. The patients 
receiving this group of medications may be heterogeneous, and have a 
greater burden of disease compared to the general population comparators . 
. In view of the heterogeneity of this group of patients, for the further 
exploration of the possible effect of corticosteroids it would be preferable to 
use a case definition which identifies a more homogeneous subset of 
patients and whose condition, ideally, remains fairly constant over time. 
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Several studies in the literature have reported an association between 
diabetes and falls or recurrent falls, but there is disagreement over the extent 
to which this may be partly or entirely attributable to insulin prescribing, 
polypharmacy in general, or an effect of the disease itself18-220. THIN 
provides an opportunity to study the effects of the medication itself or its 
initiation, using similar methods to those employed in this project. 
7.3.2.5 Medications for gynaecology and urinary-tract disorders 
The strength of association between each of these two subclasses and falls 
is weaker than for a number of classes. Nevertheless, the prevalence of 
. 
prescribing (up to one fifth, in the case of medications for the genito-urinary 
system) warrants further consideration of their falls profile. 
The subclass containing drugs for genito-urinary tract disorders includes 
medications for a range of conditions, including some (e.g. urinary 
incontinence, enuresis) for which a possible association with falls risk is 
alreadyestablished119. For some medications, documented side-effects 
include blurred vision, diarrhoea and central nervous system stimulation 
leading to restlessness, disorientation or hallucination. Therefore any further 
study of their falls profile would need to address specific medications and 
conditions, and to address the potentially confounding effect of the indication. 
7.3.2.6 Medications for malignant disease and immuno-suppression 
The associations with subclasses of medication in this group are relatively 
weak, involve relatively small numbers of people, many of whom are likely to 
be subject to serious co-morbidities and may be receiving a range of other 
medication. Therefore developing a more detailed understanding of their 
falls profile will be more complex, and is less likely to be of utility compared to 
other groups of medication. 
7.3.2.7 Medications for nutrition and blood disorders 
More than 5% of older people are currently prescribed vitamins or minerals, 
and there is an association with subsequent first fall, and in both subclasses 
the association amongst people curtently prescribed is stronger than 
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amongst those previously prescribed. Further study of their falls risk profile 
would need to adjust for possible confounding by indication (indications 
include a wide range of deficiencies arising directly from other treatments, 
diet, or underlying disease) and to consider whether the effect varies 
between different minerals and supplements. For example, vitamin 
supplements are more prevalent amongst residents in institutional settings 
who are prescribed corticosteroid therapy221. 
Vitamin and minerals are available "over the counter", therefore the 
prescribing record may not represent a complete record of exposure. The 
. 
likely impact of this is that the size of any effect attributable to the exposure 
will be diluted. 
There is weak evidence that the falls risk for people recently prescribed fluids 
and electrolytes is less than that for people currently prescribed suggesting 
that the first fall might be associated with the discontinuation of the 
medication rather than by the medication itself. It is not clear from the data in 
this study how much of this medication is prescribed to people who have 
diarrhoeal symptoms which may be independently associated with an 
increased falls risk (as discussed earlier). 
7.3.2.8 Medications for musculoskeletal and joint disorders 
Lord et al summarise evidence of an association between arthritis and other 
markers of musculoskeletal disease (e.g. restricted mobility, walking aid use) 
and falls 119, therefore it is unsurprising that this study finds a clear 
association with prescribing of medications for these and similar disorders. 
Similarly, there is an established association with deficits in neuromuscular 
functioning119 which explains, fully or in part, the observed association 
between prescribing for neuromuscular disorders and falls. 
Given, the large number of people who are prescribed the medications it 
would be valuable to understand their falls risk profile. However, this will be 
confounded by the underlying diseases and this may be difficult to separate 
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out due to the progressive nature of the diseases for which one would wish to 
control. 
7.3.2.9 Medications for the eye 
There is evidence of a strong association with falls in older people for several 
measures of vision including poor visual contrast sensitivity, decreased depth 
perception and poor visual acuity119, and evidence of weaker associations for 
some other indicators. However, the indications for the medications 
prescribed in primary care appear not to be closely associated with these 
measures of vision 191. Furthermore, for the more commonly prescribed 
• 
subclasses of medication the association with falls is weak or absent. 
In comparison with anti-infective and anti-inflammatory medications, fewer 
older people are prescribed mydriatics and cycloplegics (which are used to 
dilate the pupil prior to refractive procedures). It is possible that the 
increased risk of falls in people recently prescribed this subclass is a result of 
temporary impairment of vision following an eye procedure. However, as 
antimuscarinics, their side effects may include urinary urgency, confusion 
(particularly in the elderly), and giddiness 191. 
7.3.2.10 Medications for the ear, nose and oropharynx 
Many of the medications in this group are for the treatment of infection and 
also exhibit a relatively high odds ratio for first fall, e.g. current prescribing for 
oropharynx, OR 2.11 (1.78 - 2.50). As noted earlier, acute illness is 
commonly cited as a medical risk factor for falls217 • Therefore investigation of 
the extent to which these are due to the independent effect of the medication 
itself may be confounded by the indication. 
7.3.2.11 Medications for skin 
. This subclass includes a wide range of medications for skin conditions; for 
some of these the prevalence of prescribing is high and there is evidence of 
an association with first fall. This is strongest for topical circulatory 
preparations, sunscreens and camouflages, skin cleansers and antiseptics, 
and warts and calluses. Searches 'in the literature failed to identify any 
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studies looking at an association between these medications and falls. 
Neither were any studies identified for other medications such as emollients, 
and shampoos and scalp preparations. 
There is evidence of a higher risk of falls for patients with psoriatic arthritis222. 
Evidence of the association between arthritis and falls has already been 
noted119 and it may be this which accounts for the observed association with 
psoriasis. 
Within the subclass of medications for the treatment of acne, there is at least 
. 
one medication (isotretinoin) which has severe side-effects including joint 
pain 191. However, this would normally be prescribed only under the 
supervision of a dermatologist and it seems unlikely that a medication for this 
indication explains the very high prevalence of prescribing of the subclass. It 
should also be noted that acne is a documented side-effect of potent topical 
corticosteroids 191, which itself may be associated with falls. 
These observed associations suggests the need for further investigation, 
especially in medications where the prevalence of prescribing is high. It 
should be noted that shampoos are available "over the counter", therefore 
the prescribing record may not represent a complete record of exposure. 
The likely impact of this is that the size of any effect attributable to the 
exposure will be diluted. 
7.3.2.12 Immunological products and vaccines 
In this class of medication, only vaccines and sera have a positive 
association with first fall. -It should be noted that in the UK there is an annual 
influenza vaccine campaign. It is likely that this comprises a large part of the 
prescribing. The campaign is targeted towards at-risk groups who, by 
definition, will have co-morbidities not shared by their general population 
controls. Further investigation is required to differentiate the falls risk profile 
of the most commonly prescribed vaccines. 
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7.3.2.13 Anaesthesia 
This study was not designed to determine the indication for which a 
medication was used but, given the high prevalence of prescribing, it seems 
likely that at least some of the prescribing ascribed to this subclass will have 
been for pain relief, perhaps post-operatively. To the extent that this is the 
case, the group receiving this medication have a burden of morbidity beyond 
that of their general population controls. This would need to be taken into 
account in any further investigation of the observed association. 
7.4 • Implications 
The results of this hypothesis-generating study, together with the lack of 
evidence regarding their falls profile, indicate that further study.is warranted 
across a range of medication subclasses. Those which, on the basis of their 
indications and side-effects, are thought to be most easily addressed in THIN 
are listed below. In each case, further study should address the possibility 
that any association with falls may be confounded by the indication or other 
comorbidity. 
Subclass of medication Rationale for further study and other 
considerations 
Gap in the evidence regarding the possible 
Laxatives 
confounding effect of comorbidities which cause 
constipation, esp. Parkinson's disease 
The lack of an obvious causal link between the 
Antifungals indication (mild skin and nail infection) and falls 
provides an opportunity for studying the possible 
effect of the medication itself. 
About one tenth of older people have ever been 
prescribed antifungals (but current prescribing is 
less than 1 %) 
Corticosteroids are used in the treatment of a 
Corticosteroids 
wide range of disease. Differentiating the risk 
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associated with the drug itself requires a case 
definition which includes only patients whose 
condition is similar and for which the symptoms 
are fairly constant over time 
Disagreement in the literature about the extent 
Insulin 
to which the known association of diabetes with 
falls is due to insulin prescribing, polypharmacy, 
or an effect of the disease itself. 
High and increasing prevalence of insulin 
prescribing 
~ ~
Antibiotics for mild to 
Opportunity to study effect of treatment in a 
condition which is less likely to be associated 
moderate acne 
with falls than many acute bacterial Infections. 
In general, acute bacterial infection is 
associated with falls, and it is difficult to 
separate the effect of infections from the effect 
of their treatment. 
High prevalence of prescribing. 
Influenza or other Prevalence will be highest in groups at risk due 
vaccines 
to underlying disease. Making allowance for 
this is essential. Definition of current prescribing 
needs to be specific to how vaccine is 
administered. 
Sparsity of evidence about the incidence of falls 
Cohort study of the in people with COPD 
incidence of falls in 
people with COPD 
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8 Conclusions and recommendations 
This chapter brings together the implications arising out of the studies 
described in previous chapters into a set of conclusions and 
recommendations. These are organised according to the specific aims of 
each study in the project, and some more general recommendations about 
the utility and potential of the methods used in this project. 
8.1 The overall incidence of recorded falls among older 
people in primary care in the UK, and its variation over 
recent years and by socio-demographic attributes 
The crude incidence rate of falls recorded in primary care was approximately 
3.6 per 100 person years which, in a typical general practice with an all-age 
population of 10,000, represents about 78 recorded fall events per year 
amongst its 2113 people aged 60 or over. The rate remained unchanged in 
period 2003-2006. This rate is considerably lower than the incidence of 
primary care consultations amongst older people. The public health 
implication of this is that the National Institute for Health and Clinical 
Excellence's guideline that health professionals should routinely ask patients 
if they have fallen in the last year appears not to have been followed during 
the study period. Furthermore, the gap between the falls incidence observed 
in this study and the actual number of people attending falls clinics in 2006 
suggests that opportunities to intervene were being missed. 
The rate of falls is higher in women and in older age groups. The fact that it 
is also strongly associated with social disadvantage suggests the need to 
target the design and delivery of interventions accordingly. 
Given the potentially costly consequences of falls for individuals, their carers 
and family, and the wider health and social care system, greater priority 
should be given to systematically identify older people who fall, to apply 
interventions, and to target these according to need. 
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8.2 The risk of death associated with falls in older people 
in primary care 
People who fell experienced a substantial increase in mortality (two-fold 
increase for recurrent fallers, and more than five-fold for those aged 60-74 
years) which was independent of fractures recorded at the time of the fall or 
subsequently. Furthermore people who fall have an increased rate of 
subsequent fracture (approximately three-fold and, for recurrent fallers aged 
60-74 years more than eight-fold). 
~ ~
The public health implication of this is that older people with a recorded fall 
represent a group who are at increased risk of death. Furthermore these 
results suggest that this vulnerability is not simply a function of subsequent 
risk of fracture. Identifying people who fall, and especially those who fall 
recurrently, provides an opportunity to intervene on a group who are 
vulnerable irrespective of whether they have a subsequent fracture. 
8.3 The falls risk profile of serotonin noradrenalin reuptake 
inhibitors compared to selective serotonin reuptake 
inhibitors 
The risk of first fall was increased almost 2-fold in people currently prescribed 
an SNRI, and this increase in risk was apparent in the first month after the 
first prescription. The sizes of effect were similar to those seen for SSRls and 
TeAs. The clinical and public health implications of this relate to the 
suggestion by some that SNRls should be regarded as the antidepressant of 
choice for the elderly because of their low potential for drug interactions and 
possible favourable effect on' pain associated with depression. The results of 
this study show that clinicians initiating prescribing of SNRls should also be 
alert to the increased risk of falls. 
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8.4 The extent to which prescribing of antihypertensive 
medication modifies the risk of falling in older people 
Prescribing of thiazides is associated with an increased risk of first falls. The 
size of the observed association with thiazides is small over the long term but 
represents an almost three-fold risk during the first three weeks of first 
exposure. The study is a further reminder to clinicians initiating prescribing of 
thiazides in older people, which has generally been considered a 'safe' option 
for older patients, to be alert to the possibility of an increased risk of falls in 
the first three weeks of prescribing. 
There is weaker evidence for a protective effect of calcium channel blockers 
in the first three weeks of exposure, and the observed effect coutd have 
arisen by chance or as a result of clinician or patient responses to concerns 
about the effect of these medications. Considering the complementary 
analyses together (and contrary to what might have been expected from 
some classes regarded as more likely to undermine homeostasis), there was 
no increase in falls risk for other classes of antihypertensive medication. 
8.5 Identifying other medication prescribed in primary care 
whose falls risk warrants investigation in future 
studies 
Further study is needed to address gaps in the evidence base regarding the 
falls profile of a number of medication subclasses including: laxatives, 
antifungals, corticosteroids, insulin, antibiotics for mild to moderate acne, and 
vaccines for influenza and other infections. 
8.6 Utility and potential of the methods 
The preceding chapters have described the methods and the results 
obtained, including proper consideration of specific strengths and 
weaknesses of each study. It is proposed that these accounts, together with 
the four resulting publications 196211 223224 in peer-reviewed journals, 
successfully demonstrate that the research questions have been addressed 
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using methods which are appropriately rigorous in their design and 
execution. Nevertheless, in this final chapter, some broader reflection is 
warranted of the overall suitability of the methods and the potential for their 
future application in addressing questions about falls and the role of 
medications. 
8.6.1 THIN as a data source for falls 
THIN has provided a readily available source of longitudinal information 
about diagnoses and medical management of older people in the community, 
including comprehensive records of prescribing history on which to base 
reliable analyses of exposure to medications. This much is in common with a 
growing number of studies in pharmacoepidemiology which have used data 
from THIN or other primary care datasets. What is more unusual in this 
project is the use of recorded fall as an outcome measure which, as noted in 
the Introduction, may occur as a random event or may be the result of a 
complex interaction between an individual's physical capability and a range 
of environmental factors. 
Early observations included the fact that the number of falls recorded in 
primary care is much lower than the number of self-reported falls reported in 
a range of other studies, and that amongst older people who are recorded as 
having fallen there is an increased incidence rate of mortality and of fracture. 
These are important findings in their own right, provide a baseline against 
which to measure future changes, and justify the use of this outcome in the 
subsequent studies. Whilst care should be taken to avoid unwarranted 
inferences about falls in general based only on data relating to recorded falls, 
it should also be noted that currently (aside from primary care databases like 
THIN) other individual sources of data about falls in the general population 
are too small or too imprecise in their measurement of exposure to 
medications and potential confounders to provide a conclusive evidence 
about medications and falls in general129. Therefore, findings based on 
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analyses of falls recorded in primary care represent an important addition to 
the evidence base. 
Another point addressed in the hypothesis generating chapter but which 
warrants consideration here is that in almost all medications the risk of first 
fall was found to be positive and statistically significant. It has been noted 
earlier that this could be evidence of a general bias in ascertainment. 
However it was also argued that the association found (for example) between 
hip fracture (the management of which makes it unlikely to be subject to 
• 
ascertainment bias) and a wide range of medications suggests that a 
different explanation is more plausible; namely, that prescribing of almost any 
subclass of medication in older people provides a marker of frailty. The 
additional reflection warranted here is that the possible role of bias is 
commented on in the literature and few studies address this directly125. 
However, self-controlled case series does provide a means by which the role 
of bias may be assessed and, in the studies of antidepressants and 
antihypertensives described in this thesis, it has been applied for exactly that 
purpose. Considerations relating to its application are addressed in the 
following section. 
8.6.2 Considerations relating to study design 
The application of a cohort design to measure incidence and risk of mortality 
followed classic approaches, as did the nested case-control design. The 
complementary application of the case series method demonstrated the 
value of applying more than one method to an epidemiological problem, 
because it provided an indication of the extent of possible bias in the 
estimates. 
One reflection on'the future application of these methods relates to the 
selection of first fall as the event of interest (not subsequent or recurrent 
falling), which was critical both in the case-control study and the 
complementary case series analysis. In the case-control study the choice of 
1 
first fall was indicated by prior findings about the temporality of falls after first 
exposure and was made essential because of the possibility that prescribing 
behaviour is changed after a first fall (which would have been difficult to deal 
with if the event of interest was a recurrent fall). The case series studies 
were used to provide complementary analyses, so that findings arising from 
the case-control and case series methods could be compared directly. 
Therefore, it was essential that first fall remained the event of interest in the 
case series method. In point of fact, even if the event of interest in the case-
control study had been recurrent falls, it would have been problematic to 
adopt jhis in the case series studies because the method requires that 
occurrence of an event should not affect the rate at which subsequent events 
occur. In these studies, it is quite probable that ascertainment and recording 
will increase subsequent to a first fall; indeed, regular review of people who 
are known to have fallen is very much the intention of published guidance 163. 
Since completion of the analysis, Farrington et al have published an 
extension to the case series method to address within-individual dependence 
between recurrent events225• Further work on falls in this dataset should 
consider whether this extension could be applied in the case of recurrent 
falls. 
Whitaker et al have previously identified, and provided access to Stata code 
for the case-series models addressed in their tutorial195 (e.g. single and 
multiple periods of risk). The periodic and recurrent nature of exposures in 
these studies (a single period was deemed to continue until there was a 
break in prescribing, and this might be followed by one or more subsequent 
periods at a later date) required further development of these models and 
code to address this new combination of exposure characteristics, including 
the incorporation of logic to handle prevalent exposure, to ensure that risk 
periods are always consecutive but not overlapping, and to execute the 
sensitivity analyses needed to test for possible breaches of key assumptions. 
These will be valuable for future studies, including those needed to explore 
further the effects of some of the medications identified in the hypothesis-
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generating study (e.g. insulin, corticosteroids) which are used in the 
management of long term conditions and are likely to be characterised by a 
prescribing history comprising periodic, recurrent exposure. 
One aspect of the method which would require consideration in any future 
study using this design relates to the approach for dealing with the possibility 
that the occurrence of a fall affects the probability of subsequent exposure. If 
true, it would represent a violation of one of the assumptions underpinning 
the method: that probability of exposure is not affected by the occurrence of 
an outcome event. In the case of medications and falls in older people, there 
are two hypothetical situations in which this may be violated. The violations 
relate either to "disruption" of the exposure process or to the observation 
period. An example of the former is where the medication is thought to be 
contraindicated for falls, in which case prescribing may be modified 
subsequent to the fall. An example of the second is where follow-up is 
curtailed as a result of the event, thereby curtailing the exposure history. The 
most extreme example of this would be where patients die following a fall. 
The methods chapter describes the sensitivity analyses undertaken to test for 
each of these violations. In 2009, Farrington et al published methods for 
dealing with the possible impact of such "interferent" events (Le. events on 
which subsequent exposure is in some way dependent)199. However, this 
extension to the method is intended for analysis of transient point exposures. 
This suggests that it has little potential for analysing the effect of the periodic 
recurrent exposures found in the prescribing histories for medications used to 
treat long term conditions, such as antihypertensives and antidepressants. 
Furthermore, the method involves ignoring post-event exposures so tends to 
be less efficient in situations where the event merely increases the risk of 
death (Le. less curtailment) compared to those where the event often or 
always leads to d ~ a t h h (Le. frequent curtailment). 
As recently as 2011, Farrington et al published a further extension of the 
method to deal with situations in which rare nonrecurrent events increase 
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mortality in the medium and longer term226• This latest extension addresses 
the possible non-random curtailment which may be associated with a critical 
event, but not the possibility of a shorter term disruption of exposure. 
Notwithstanding the special assumptions underlying each of these 
extensions to the standard method, it is recommended that, in future case 
series analysis of a rare non-recurrent event like first fall, consideration is 
given to their suitability for addressing the possible impact of interferent 
events. 
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Appendix A • Search criteria used in literature 
reviews 
The initial search of the literature was completed using the following 
parameters which were applied in Ovid Medline. This yielded a large number 
of papers which were manually sorted to identify those of most immediate 
relevance to the topic. These were supplemented with relevant chapters 
from a recently published textbook3 7115121 and with key current policy 
documents and guidelines published in the UK. From April 2008 the same 
search criteria were applied on a monthly basis to new content added to 
Medline. 
~ ~
1. Accidental FaUs/ 
2. 'Wounds and Injuries"/ep [Epidemiology] 
3. 1 or 2 
4. faUs.ab,ti. 
5.3 and 4 
6. incidence.ab,ti. 
7. prevalence.ab,ti. 
8. mortality.ab,ti. 
9. survival.ab, ti. 
10. rate$.ab,ti. 
11.older.ab,ti. 
12. senior.ab,ti. 
13. elder$.ab,ti. 
14. geriatric$.ab,nw,ti. 
15. 11 or 12 or 13 or 14 
16. 6 or 7 or 8 or 9 or 10 
17. 5 and 15 and 16 
18. epidemiology of faUs.m_titl. 
19. 17 or 18 
20. remove duplicates from 19 
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A different set of parameters were applied for the review of literature relating 
to medications (see below for example). This also required sorting to identify 
a small number of studies of immediate relevance to the topics 
1. medication.mp. 
2. drug.mp. or Pharmaceutical Preparations/ 
3. 1 or 2 
4. Accidental Falls/ or falls.mp. 
5.3 and 4 
6. Heart Diseases/ 
7. Hypertension/ 
• 
8.6 or 7 
9.8 and 5 
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Appendix B - Read codes used to identify 
incident falls 
160 .. 00 
1601.00 
1602.00 
8BIG.00 
R200.12 
T040.00 
T040000 
T040100 
T040yOO 
T040z00 
T041.00 
T041 000 
T 0 4 1 ~ 0 0 0
T041200 
T041300 
T041yOO 
T041 zOO 
T042.00 
T042000 
T042100 
T042yOO 
T042z00 
T04z.00 
T04z000 
T04z100 
T04z200 
T04z300 
T04zyOO 
T04zz00 
T420000 
T420100 
T420200 
T420300 
T420400 
T420500 
T420600 
T420yOO 
T420z00 
T421.00 
T421 000 
T421100 
T421200 
T421300 
T421400 
T421500 
T421600 
T421yOO 
T421 zOO 
T43 .. 00 
T430.00 
T430000 
T430100 
T430200 
T430300 
T430400 
Falls 
Recurrent falls 
Number of falls in last year 
Falls caused by medication 
[0] Geriatric fall 
Fall in train 
Fall in train, railway employee injured 
Fall in train, passenger injured 
Fall in train, other specified person injured 
Fall in train, unspecified person injured 
Fall on train 
Fall on train, railway employee injured 
Fall on train, passenger injured 
Fall on train, pedestrian injured 
Fall on train, pedal cyclist injured 
Fall on train, other specified person injured 
Fall on train, unspecified person injured 
Fall from train 
Fall from train, railway employee injured 
Fall from train, passenger injured 
Fall from train, other specified person injured 
Fall from train, unspecified person injured 
Fall in, on or from train NOS 
Fall in, on or from train NOS, railway employee injured 
Fall in, on or from train NOS, passenger injured 
Fall in, on or from train NOS, pedestrian injured 
Fall in, on or from train NOS, pedal cyclist injured 
Fall in, on or from train NOS, other spec person injured 
Fall in, on or from train NOS, unspecified person injured 
Submersion-fall from gangplank- occ small unpowered boat inj 
Submersion-fall from gangplank- occ small powered boat inj 
Submersion-fall from gangplank- crew other watercraft inj 
Submersion-fall from gangplank- passenger oth watercraft inj 
Submersion-fall from gangplank- water skier injured 
Submersion-fall from gangplank- swimmer injured 
Submersion-fall from gangplank- docker or stevedore injured 
Submersion-fall from gangplank- other specified person inj 
Submersion-fall from gangplank- unspecified person injured 
Submersion or drowning due to fall overboard 
Submersion-fall overboard - occ small unpowered boat inj 
Submersion-fall overboard - occupant small powered boat inj 
Submersion-fall overboard - crew other watercraft injured 
Submersion-fall overboard - passenger other watercraft inj 
Submersion-fall overboard - water skier injured 
Submersion-fall overboard - swimmer injured 
Submersion-fall overboard - docker or stevedore injured 
Submersion-fall overboard - other specified person injured 
Submersion-fall overboard - unspecified person injured 
Fall on stairs or ladders in water transport 
Fall on stairs in water transport (WT) 
Fall-stairs water transport - occ small unpowered boat inj 
Fall-stairs water transport - occ small powered boat injured 
Fall-stairs water transport - crew other watercraft injured 
Fall-stairs water transP9rt - passenger other watercraft inj 
Fall-stairs water transport - water skier injured 
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T430500 
T430600 
T430yOO 
T430z00 
T431.00 
T431 000 
T431100 
T431200 
T431300 
T431400 
T431500 
T431600 
T431yOO 
T431 zOO 
T43z.00 
T43z000 
T43z100 
T43z200 
T43zjOO 
T43z400 
T43zS00 
T43z600 
T43zyOO 
T43zz00 
T44 .. 00 
T440.00 
T440000 
T440100 
T440200 
T440300 
T440400 
T440S00 
T440600 
T440yOO 
T440z00 
T44z.00 
T44z000 
T44z100 
T44z200 
T44z300 
T44z400 
T44zS00 
T44z600 
T44zyOO 
T44zz00 
T477.00 
T477000 
T4771 00 
T477200 
T477300 
T477400 
T477S00 
T477600 
T477yOO 
T477z00 
TS3 .. 00 
TS32.00 
TS32000 
TS32100 
TS32200 
Fall-stairs water transport - swimmer injured 
Fall-stairs water transport - docker or stevedore injured 
Fall-stairs water transport - other specified person injured 
Fall-stairs water transport - unspecified person injured 
Fall on ladder in water transport 
Fall-ladder water transport - occ small unpowered boat inj 
Fall-ladder water transport - occ small powered boat injured 
Fall-ladder water transport - crew other watercraft injured 
Fall-ladder water transport - passenger other watercraft inj 
Fall-ladder water transport - water skier injured 
Fall-ladder water transport - swimmer injured 
Fall-ladder water transport - docker or stevedore injured 
Fall-ladder water transport - other specified person injured 
Fall-ladder water transport - unspecified person injured 
Fall on stairs or ladders in water transport, NOS 
Fall-stairs/ladders-WT NOS - occ small unpowered boat inj 
Fall-stairs/ladders-WT NOS - occupant small powered boat inj 
Fall-stairs/ladders-WT NOS - crew other watercraft injured 
Fall-stairs/ladders-WT NOS - passenger other watercraft inj 
Fall-stairs/ladders-WT NOS - water skier injured 
Fall-stairs/ladders-WT NOS - swimmer injured 
Fall-stairs/ladders-WT NOS - docker or stevedore injured 
Fall-stairs/ladders-WT NOS - other specified person injured 
Fall-stairs/ladders-WT NOS - unspecified person injured 
Other falls in water transport (WT) 
Fall from one level to another NEe in water transport 
Fall to other level NEe in WT - occ small unpowered boat inj 
Fall to other level NEe in WT - occ small powered boat inj 
Fall to other level NEe in WT - crew other watercraft inj 
Fall to other level NEe in WT - passenger oth watercraft inj 
Fall to other level NEe in WT - water skier injured 
Fall to other level NEe in WT - swimmer injured 
Fall to other level NEe in WT - docker or stevedore injured 
Fall to other level NEe in WT - other specified person inj 
Fall to other level NEe in WT - unspecified person injured 
Fall in water transport NOS 
Fall in water transport NOS - occ small unpowered boat inj 
Fall in water transport NOS - occ small powered boat injured 
Fall in water transport NOS - crew other watercraft injured 
Fall in water transport NOS - passenger other watercraft inj 
Fall in water transport NOS - water skier injured 
Fall in water transport NOS - swimmer injured 
Fall in water transport NOS - docker or stevedore injured 
Fall in water transport NOS - other specified person injured 
Fall in water transport NOS - unspecified person injured 
Hit by boat, or part thereof, after fall from boat 
Hit boat after fall from boat- occ small unpowered boat inj 
Hit boat after -fall from boat- occ small powered boat inj 
Hit boat after fall from boat- crew other watercraft injured 
Hit boat after fall from boat- passenger oth watercraft inj 
Hit boat after fall from boat- water skier injured 
Hit boat after fall from boat- swimmer injured 
~ i t t boat after fall from boat- docker or stevedore injured 
Hit boat after fall from boat- other specified person inj 
Hit boat after fall from boat- unspecified person injured 
Fall in, on, or from aircraft 
Fall in aircraft 
Fall in aircraft - occupant of spacecraft injured 
Fall in aircraft - occupant of military aircraft injured 
Fall in aircraft - crew commercial aircraft surface/surf inj 
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T532300 
T532400 
T532500 
T532600 
T532700 
T532800 
T532z00 
T533.00 
T533000 
T533100 
T533200 
T533300 
T533400 
T533500 
T533600 
T533700 
T533800 
T533z00 
T534.bo 
T534000 
T534100 
T534200 
T534300 
T534400 
T534500 
T534600 
T534700 
T534800 
T534z00 
T53z.00 
T53z000 
T53z100 
T53z200 
T53z300 
T53z400 
T53z500 
T53z600 
T53z700 
T53z800 
T53zz00 
T60E.OO 
T613.00 
TC ... OO 
TC ... 11 
TCO .. OO 
TCOO.OO 
TCOOOOO 
TC00100 
TCOOzOO 
TC01.00 
TC01000 
TC01100 
TC01z00 
TC02.00 
TC02000 
TC02100 
TC02z00 
TCOz.OO 
TC1 .. 00 
TC10.00 
Fall in aircraft - other occ comm aircraft surf/surf injured 
Fall in aircraft - occupant comm surf/air aircraft injured 
Fall in aircraft - occupant other powered aircraft injured 
Fall in aircraft - occupant unpowered aircraft injured 
Fall in aircraft - parachutist injured 
Fall in aircraft - ground crew or airline employee injured 
Fall in aircraft - other person injured 
Fall on aircraft 
Fall on aircraft - occupant of spacecraft injured 
Fall on aircraft - occupant of military aircraft injured 
Fall on aircraft - crew commercial aircraft surface/surf inj 
Fall on aircraft - other occupant comm aircraft surf/s inj 
Fall on aircraft - occupant comm surf/air aircraft injured 
Fall on aircraft - occupant other powered aircraft injured 
Fall on aircraft - occupant unpowered aircraft injured 
Fall on aircraft - parachutist injured 
Fall on aircraft - ground crew/airline employee injured 
Fall on aircraft - other person injured 
Fall from aircraft 
Fall from aircraft - occupant of spacecraft injured 
Fall from aircraft - occupant of military aircraft injured 
Fall from aircraft - crew commercial aircraft surf/surf inj 
Fall from aircraft - other occupant comm aircraft surf/s inj' 
Fall from aircraft - occupant comm surf/air aircraft injured 
Fall from aircraft - occupant other powered aircraft injured 
Fall from aircraft - occupant unpowered aircraft injured 
Fall from aircraft - parachutist injured 
Fall from aircraft - ground crew or airline employee injured 
Fall from aircraft - other person injured 
Fall in, on or from aircraft NOS 
Aircraft fall NOS - occupant of spacecraft injured 
Aircraft fall NOS - occupant of military aircraft injured 
Aircraft fall NOS - crew comm aircraft surf/surf injured 
Aircraft fall NOS - other occ comm aircraft surf/surf inj 
Aircraft fall NOS - occupant comm surf/air aircraft injured 
Aircraft fall NOS - occupant other powered aircraft injured 
Aircraft fall NOS - occupant unpowered aircraft injured 
Aircraft fall NOS - parachutist injured 
Aircraft fall NOS - ground crew/airline employee injured 
Aircraft fall NOS - other person injured 
Fall from powered vehicle, industrial or commercial 
Accident involving fall from cable car, not on rails 
Accidental falls 
Fall - accidental 
Fall on or from stairs or steps 
Fall on or from escalator 
Fall on escalator 
Fall from escalator 
Fall on or from escalator NOS 
Fall on or from stairs 
Fall on stairs 
Fall from stairs 
Fall on or from stairs NOS 
Fall on or from steps 
Fall on steps 
Fall from steps 
Fall on or from steps NOS 
Fall on or from stairs or steps NOS 
Fall on or from ladders or scaffolding 
Fall from ladder 
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TC11.00 
TC1z.00 
TC2 .. 00 
TC20.00 
TC21.00 
TC22.00 
TC23.00 
TC24.00 
TC25.00 
TC26.00 
TC27.00 
TC28.00 
TC29.00 
TC2z.00 
TC3 .. 00 
TC30500 
TC31.00 
TC32.00 
TC32'OOO 
TC32100 
TC32z00 
TC3y.OO 
TC3yOOO 
TC3y100 
TC3y200 
TC3y300 
TC3y400 
TC3y500 
TC3y600 
TC3yzOO 
TC3z.00 
TC4 .. 00 
TC40.00 
TC41.00 
TC42.00 
TC42000 
TC42100 
TC42z00 
TC4y.OO 
TC4yOOO 
TC4y100 
TC4y200 
TC4y300 
TC4yzOO 
TC4z.00 
TC5 .. 00 
TC50.00 
TC51.00 
TC52.00 
TC53.00 
TC5z.00 
TCy .. OO 
TCyO.OO 
TCyz.OO 
TCz .. OO 
TG30700 
TG30800 
TH03.00 
TN7 .. 00 
TN70.00 
Fall from scaffolding 
Fall from ladder or scaffolding NOS 
Fall from or out of building or other structure 
Fall from balcony 
Fall from bridge 
Fall from building 
Fall from flagpole 
Fall from tower 
Fall from turret 
Fall from viaduct 
Fall from wall 
Fall from window 
Fall through roof 
Fall from or out of building or other structure NOS 
Fall into hole or other opening in surface 
Accident caused by fall into swimming pool 
Accidental fall into well 
Accidental fall into manhole 
Accidental fall into manhole, unspecified 
Accidental fall·.into storm drain 
Accidental fall into manhole NOS 
Fall into other hole or other opening in surface 
Fall into cavity, unspecified 
Fall into dock 
Fall into hole 
Fall into pit 
Fall into quarry 
Fall into shaft 
Fall into tank 
Fall into other hole, unspecified 
Fall into hole NOS 
Other fall from one level to another 
Fall from playground equipment 
Fall from cliff 
Fall from chair or bed 
Fall from chair 
Fall from bed 
Fall from chair or bed NOS 
Other fall from one level to another 
Fall from embankment 
Fall from haystack 
Fall from stationary vehicle 
Fall from tree 
Other fall from one level to another NOS 
Fall from one level to another NOS 
Fall on same level from slipping, tripping or stumbling 
Fall on same level from slipping 
Fall on same· level from tripping 
Fall on same level from stumbling 
Fall on moving sidewalk 
Fall on same level from Slipping, tripping or stumbling NOS 
Other falls 
Fall from bump against object 
Other accidental fall NOS 
Accidental falls NOS 
Accident caused by fall into moving part of machinery 
Accident caused by fall from moving part of machinery 
Late effects of accidental fall 
Injury ?accidental, fall from high place 
Injury ?accidental, fall from residential premises 
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TN71.00 
TN72.00 
TN7z.00 
U018411 
U10 .. 00 
U100.00 
U100000 
U100100 
U100200 
U100300 
U100400 
U100500 
U100600 
U100700 
U100yOO 
U100z00 
U101.00 
U101QOO 
U101100 
U101200 
U101300 
U101400 
U101500 
U101600 
U101700 
U101yOO 
U101z00 
U102.00 
U102000 
U102100 
U102200 
U102300 
U102400 
U102500 
U102600 
U102700 
U102yOO 
U102z00 
U105.00 
U105000 
U105100 
U105200 
U105300 
U105400 
U105500 
U105600 
U105700 
U105yOO 
U105z00 
U106.00 
U106000 
U106100 
U106200 
U106300 
U106400 
U106500 
U106600 
U106700 
U106yOO 
U106z00 
Injury ?accidental, fall from other man-made structure 
Injury ?accidental, fall from natural site 
Injury ?accidental, fall from high place NOS 
[X]Fall from pedal cycle without collision 
[X]Falls 
[X]Fall on same level involving ice and snow 
[X]Fall on same level involving ice and snow occurrn home 
[X] Fa II same level involv ice / snow occurrn resid instit'n 
[X]Fall sam Ivl inv ice/snw occ sch oth instlpub admin area 
[X]Fall same levi involv ice/snow, occ sport/athlet area 
[X]Fall same levi inv ice and snow, occ street / highway 
[X]Fall same levi inv ice / snow, occ trade / service area 
[X]Fall same levi inv ice/snow, occ indust / construct area 
[X]Fall on same levi involving ice and snow occurrn on farm 
[X]Fall same levi inv ice / snow, occ at other specif place 
[X]Fall same levi inv ice / snow, occ at unspecified place 
[X]Fall on same level from slipping, tripping and stumbling 
[X]Fall same levi frm slip trip + stumb, occurrence at home 
[X]Fall same level from slip trip + stumb occ resid instit 
[X]Fall sme levi sip trp+stmb occ sch, oth instlpub adm area 
[X]Fall sme levi frm slip trip+stumb, occ sport/athlet area 
[X]Fall same level from slip trip+stumb, occ streetlhighway 
[X]Fall sme Ivl frm slip trip+stumb, occ trade/service area 
[X]Fall same levi, slip trip+stumb occ industlconstruct area 
[X]Fall same level from slip trip+stumbling, occur on farm 
[X]Fall same level, slip trip+stumb, occ other specif place 
[X]Fall same levi frm slip trip+stumbling, occ unspec place 
[X]Fall involv ice-skates skis roller-skates or skateboards 
[X]Fall inv ice-skate skis roll-skate/skateboard, occ home 
[X]Fali inv ice-skat ski roll-skatlskateboard occ resid inst 
[X] Fall , ice-skt ski rol-sktlskbd, sch oth instlpub adm area 
[X]Fali inv ice-skt ski rol-sktlskbrd occ sport/athlet area 
[X]Fali inv ice-skat ski roll-skatlskbrd occ streetlhighway 
[X]Fali inv ice-skt ski rol-sktlskbrd occ trade/servce area 
[X]Fali inv ice-skt ski rol-sktlskbrd industlconstruct area 
[X]Fali inv ice-skat ski roll-skatlskatebrd, occur on farm 
[X]Fali inv ice-skt ski roll-sktlskbrd, occ oth spec place 
[X]Fali inv ice-skat ski roll-skatlskbrd occ unspecif place 
[X]Fali involving wheelchair 
[X]Fali involving wheelchair, occurrence at home 
[X]Fali involvng wheelchair occurrence residential instit'n 
[X]Fali invlv w'chair occ school oth institlpub admin area 
[X]Fali involving wheelchair, occurm at sport/athlet area 
[X]Fali involving wheelchair, occurrence on streetlhighway 
[X]Fali involvng wheelchair occurrnce at trade/service area 
[X]Fali involv wheelchair, occurrnce at industlconstr area 
[X]Fali involving wheelchair, occurrence on farm 
[X]Fali involv wheelchair, occurrnce at other specif place 
[X]Fali involving wheelchair occurrnce at unspecified place 
[X]Fali involving bed 
[X]Fali involving bed, occurrence at home 
[X]Fall involving bed occurrence in residential institution 
[X]Fali involv bed occurrn school oth institlpub admin area 
[X]Fall involving bed occurrence at sports / athletics area 
[X]Fali involving bed, occurrence on street and highway 
[X]Fali involving bed, occurrence at trade and service area 
[X]Fali involv bed occurrn at industrial/construction area 
[X]Fall involving bed, occurrence on farm 
[X]Fali involving bed, occurrence at other specified place 
[X]Fali involving bed, occurrence at unspecified place 
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U107.00 
U107000 
U107100 
U107200 
U107300 
U107400 
U107500 
U107600 
U107700 
U107yOO 
U107z00 
U108.00 
U108000 
U108100 
U108200 
U108300 
U108400 
U108&OO 
U108600 
U108700 
U108yOO 
U108z00 
U109.00 
U109000 
U109100 
U109200 
U109300 
U109400 
U109500 
U109600 
U109700 
U109yOO 
U109z00 
U10A.OO 
U10AOOO 
U10A100 
U10A200 
U10A300 
U10A400 
U10A500 
U10A511 
U10A600 
U10A700 
U10AyOO 
U10AzOO 
U10B.OO 
U10BOOO 
U10B100 
U10B200 
U10B300 
U10B400 
U10B500 
U10B600 
U10B700 
U10ByOO 
U10BzOO 
U10C.OO 
U10COOO 
U10C100 
U10C200 
[X]Fall involving chair 
[X]Fall involving chair, occurrence at home 
[X]Fall involving chair occurrence in residential instit'n 
[X]Fall invlv chair occ at school oth institlpub admin area 
[X]Fall involving chair occurrence at sports/athletics area 
[X]Fall involving chair, occurrence on street and highway 
[X]Fall involv chair, occurrence at trade and service area 
[X]Fall involving chair occurrence at industlconstruct area 
[X]Fall involving chair, occurrence on farm 
[X]Fall involving chair occurrence at other specified place 
[X]Fall involving chair, occurrence at unspecified place 
[X]Fall involving other furniture 
[X]Fall involving other furniture, occurrence at home 
[X]Fall involv other furniture occurrn resident institut'n 
[X]Fall inv oth furnitur occ schl oth institlpub admin area 
[X]Fall involv oth furniture occurrnce at sport/athlet area 
[X]Fall involv other furniture occurrnce on streetlhighway 
[X]Fall involv oth furniture occurrnce at trade/serv area 
[X]Fall involv oth furnitre occurrnce at industlconstr area 
[X]Fall involving other furniture, occurrence on farm 
[X]Fall involv oth furnitur occurrnce at other specif place 
[X]Fall involv oth furniture, occurrnce at unspecif place 
[X]Fall involving playground equipment 
[X]Fall involving playground equipment, occurrence at home 
[X]Fall involv playgrnd equipm occurr in resident instit'n 
[X]Fall inv playgrnd equip occ sch oth instlpub admin area 
[X]Fall involv playgrnd equipm occurrn at sport/athlet area 
[X]Fall involv playgrnd equipm occurrnce on streetlhighway 
[X]Fall involv playgrnd equipm occurrnce trade/service area 
[X]Fall involv playgrnd equipm occurrnce industlconstr area 
[X]Fall involving playground equipment, occurrence on farm 
[X]Fall involv playgrnd equip occurrnce other specif place 
[X]Fall involv playgrnd equipm occurrnce at unspecif place 
[X]Fall on and from stairs and steps 
[X]Fall on and from stairs and steps, occurrence at home 
[X]Fall on + from stair + step occurrnce resident instit'n 
[X]Fall on + frm stair + step occ sch oth instlpub adm area 
[X]Fall on + from stair + step occurrn at sport/athlet area 
[X]Fall on + from stairs + steps occurrn on streetlhighway 
[X]Fall on + from stair + step occurrn at trade/servce area 
[X]Fall on or from escalator 
[X]Fall on + from stair + step occurrnce industlconstr area 
[X]Fall on and from stairs and steps, occurrence on farm 
[X]Fall on + from stair + step occurrn at oth specif place 
[X]Fall on + from stair + step occurrnce at unspecif place 
[X]Fall on/from ladder 
[X]Fall on and from ladder, occurrence at home 
[X]Fall on + from ladder occurrn in residential institution 
[X]Fall on + from ladder, occ sch oth instlpub admin area 
[X]Fall on + from ladder occurrnce at sports/athletics area 
[X]Fall on and from ladder occurrence on street and highway 
[X]Fall on and from ladder occurrence at trade/service area 
[X]Fall on + from ladder occurrn at industr/constructn area 
[X]Fall on and from ladder, occurrence on farm 
[X]Fall on+from ladder, occurrence at other specified place 
[X]Fall on and from ladder, occurrence at unspecified place 
[X]Fall on and from scaffolding 
[X]Fall on and from scaffolding, occurrence at home 
[X]Fall on+from scaffold OGcurrn in residential institution 
[X]Fall on + from scaffold occ sch, oth instlpub admin area 
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U10C300 
U10C400 
U10C500 
U10C600 
U10C700 
U10CyOO 
U10CzOO 
U10D.OO 
U10DOOO 
U10D100 
U10D200 
U10D300 
U10D400 
U10D500 
U10D600 
U10D700 
U10DyOO 
U 1 0 D ~ O O
U10E.OO 
U10EOOO 
U10E100 
U10E200 
U10E300 
U10E400 
U10E500 
U10E600 
U10E700 
U10EyOO 
U10EzOO 
U10F.OO 
U10FOOO 
U10F100 
U10F200 
U10F300 
U10F400 
U10F500 
U10F600 
U10F700 
U10FyOO 
U10FzOO 
U10H.OO 
U10HOOO 
U10H100 
U10H200 
U10H300 
U10H400 
U10H500 
U10H600 
U10H700 
U10HyOO 
U10HzOO 
U10J.OO 
U10JOOO 
U10J100 
U10J200 
U10J300 
U10J400 
U10J500 
U10J600 
U10J700 
[X]Fall on+from scaffold occurrnce at sports/athletics area 
[X]Fall on + from scaffolding, occurrence on street/highway 
[X]Fall on + from scaffold occurrence at trade/service area 
[X]Fall on+from scaffold occurrn at industr/constructn area 
[X]Fall on and from scaffolding, occurrence on farm 
[X]Fall on+from scaffold occurrnce at other specified place 
[X]Fall on + from scaffold, occurrence at unspecified place 
[X]Fall from, out of or through building or structure 
[X]Fall from out of/through building/structur occurn home 
[X]Fall from out of/thro buildng/struct occ resid instit'n 
[X]Fall frm outlthr bldng/strct occ sch oth ins/pub adm area 
[X]Fall frm outlthro bldng/struct occ at sportiathlet area 
[X]Fall from outlthro buildng/struct occ on streetlhighway 
[X]Fall from outlthro buildng/struct occ at trade/serv area 
[X]Fall from outlthro buildng/struct occ industlconstr area 
[X]Fall from out of/through building/structur occumce farm 
[X]Fall from outlthro buildng/struct occ other specif place 
[X]Fall from outlthro buildng/struct occurrn unspecif place 
[X]Fall from tree 
[X]Fall from tree, occurrence at home 
[X]Fall from tree, occurrence in residential institution 
[X]Fall from tree occurrn school oth institlpub admin area· 
[X]Fall from tree, occurrence at sports and athletics area 
[X]Fall from tree, occurrence on street and highway 
[X]Fall from tree, occurrence at trade and service area 
[X]Fall from tree occurrnce at industrial/construction area 
[X]Fall from tree, occurrence on farm 
[X]Fall from tree, occurrence at other specified place 
[X]Fall from tree, occurrence at unspecified place 
[X]Fall from cliff 
[X]Fall from cliff, occurrence at home 
[X]Fall from cliff, occurrence in residential institution 
[X]Fall from cliff occurrn school oth institlpub admin area 
[X]Fall from cliff, occurrence at sports and athletics area 
[X]Fall from cliff, occurrence on street and highway 
[X]Fall from cliff, occurrence at trade and service area 
[X]Fall from cliff occurrn at industrial/construction area 
[X]Fall from cliff, occurrence on farm 
[X]Fall from cliff, occurrence at other specified place 
[X]Fall from cliff, occurrence at unspecified place 
[X]Other fall from one level to another 
[X]Other fall from one level to another, occurrence at home 
[X]Othr fall frm one level to anothr occurrn in resid inst 
[X]Othr fall frm one level to anothr, sch instlpub adm area 
[X]Othr fall from one level to anothr occ sportiathlet area 
[X]Othr fall from one level to anothr occurm streetlh'way 
[X]Other fall frmone level to anothr occ at trde/serv area 
[Xl0ther fall frm one level to anoth occ industlconstr area 
[X]Other fall from one level to another, occurrence on farm 
[X]Other fall frm one levi to anothr occ at oth specif pice 
[X]Othr fall frm one level to anothr occurrn at unspec pice 
[X]Other fall on same level 
[X]Other fall on same level, occurrence at home 
[X]Other fall on same level, occurrnce in resident instit'n 
[X]Other fall on same levi occ schl oth instlpub admin area 
[X]Other fall on same level occurm at sports/athletic area 
[X]Other fall on same level, occurrence on street / highway 
[X]Other fall on same level occurmce at trade/service area 
[X]Other fall on same levi, accurrn at industlconstuct area 
. [X]Other fall on same level, occurrence on farm 
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U10JyOO 
U10JzOO 
U10z.00 
U10Z000 
U10z100 
U10z200 
U10z300 
U10z400 
U10z500 
U10z600 
U10z700 
U10zyOO 
U10zz00 
U131.00 
U131000 
U131100 
U131200 
U131300 
U131400 
U131500 
U131600 
U131700 
U131yOO 
U131z00 
U133.00 
U133000 
U133100 
U133200 
U133300 
U133400 
U133500 
U133600 
U133700 
U133yOO 
U133z00 
U135000 
U135100 
U135200 
U135300 
U135400 
U135500 
U135600 
U135700 
U135yOO 
U135z00 
U46 .. 00 
U460.00 
U461.00 
U462.00 
U463.00 
U464.00 
U465.00 
. U466.00 
U467.00 
U46y.00 
U46z.00 
U4C .. 00 
U4CO.00 
U4C1.00 
U4C2.00 
[X]Other fall on same level occurm at oth specified place 
[X]Other fall on same level occurrence at unspecified place 
[X]Unspecified fall 
[X]Unspecified fall, occurrence at home 
[X]Unspecified fall, occurrence in residential institution 
[X]Unspecif fall occurmce school oth instiUpub admin area 
[X]Unspecified fall, occurrence at sports / athletics area 
[X]Unspecified fall, occurrence on street and highway 
[X]Unspecified fall, occurrence at trade and service area 
[X]Unspecified fall occurm at industrial/construction area 
[X]Unspecified fall, occurrence on farm 
[X]Unspecified fall, occurrence at other specified place 
[X]Unspecified fall, occurrence at unspecified place 
[X]Orowning and submersion following fall into bath-tub 
[X]Orowning+submersn follow fall into bath-tub occ at home 
[X]Orowng+submersn foil fall into bath-tub occ resid instit 
[X]Orown+subm foil fall into bath-tub sch ins/pub adm area 
[X]Orown+subm foil fall into bath-tub occ sporUathlet area 
[X]Orowng+submersn foil fall into bath-tub occ streeUh'way 
[X]Orown+subm foil fall into bath-tub occ trade/servce area 
[X]Orown+subm foil fall into bth-tub occ indusUconstr area 
[X]Orowning+submersn follow fall into bath-tub occ on farm 
[X]Orown+subm foil fall into bath-tub occ oth specif place 
[X]Orown+subm foil fall into bath-tub occ at unspecif place 
[X]Orowning + submersion following fall into swimming-pool 
[X]Orowning+submer follow fall into swim-pool occurm home 
[X]Orown+submersn foil fall into swim-pool occ resid instit 
[X]Orown+subm foil fall into swim-pool sch ins/pub adm area 
[X]Orown+subm foil fall into swim-pool occ sport area 
[X]Orown+submersn foil fall into swim-pool occ streeUh'way 
[X]Orown+subm foil fall into swim-pool occ trade/serv area 
[X]Orown+sub foil fall into swim-pool occ indusUconstr area 
[X]Orowning+submer follow fall into swim-pool occurm farm 
[X]Orown+subm foil fall into swim-pool occ oth specif place 
[X]Orown+subm foil fall into swim-pool occ unspecif place 
[X]Orowng+submersn follow fall into natural water occ home 
[X]Orown+submr foil fall into naturl water occ resid instit 
[X]Orown+subm foil fall into natrl watr sch ins/pub adm area 
[X]Orown+subm foil fall into natrl watr occ sporUathl area 
[X]Orown+submr foil fall into naturl water occ streeUh'way 
[X]Orown+sub foil fall into naturl watr occ trade/serv area 
[X]Orwn+sub foil fall into natrl watr occ indusUconstr area 
[X]Orowng+submersn follow fall into natural water occ farm 
[X]Orown+sub foil fall into naturl watr occ oth specif place 
[X]Orown+subm foil fall into naturl watr occ unspecif place 
[X]Falling jumping/pushed from high place undeterm intent 
[X]Faling jumpl)g/push frm high place undet intent occ home 
[X]Fali jump/push frm high place undet intent occ resid inst 
[X]Fall jump/push high pice undet intnt sch/ins/pub adm area 
[X]Fall jump/push frm high pice undt intnt sporUathlet area 
[X]Fall jump/push frm high place undt intnt occ streeUh'way 
[X]Fall jump/push frm high pice undt intnt trade/servce area 
[X}Fall jump/push frm high pice undt intn indusUconstr area 
[X]Fallng jumpng/push frm high place undet intent occ farm 
[X]Fall jump/push frm high pice undt intnt occ oth spec pice 
[X]Fali jump/push frm high pice undt intnt occ unspecif pice 
[X]Fallinglying running befor/into moving obj undet intent 
[X]Fallng Iyng run befr/into mov obj undet intent occ home 
[X]Fallly run befr/into moy obj undet intent resid instit'n 
[X]Fall Iy run bef/into mov obj und int sch/ins/pub adm area 
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U4C3.00 
U4C4.00 
U4C5.00 
U4C6.00 
U4C7.00 
U4Cy.OO 
U4Cz.OO 
[X]Fali Iy run befr/into mov obj undet intent sprt/athl area 
[X]Fali Iy run befr/into mov obj undet intent street/highway 
[X]Fali Iy run befr/into mov obj undet intent trad/serv area 
[X]Fali Iy run befr/into mov obj undet intent industr area 
[X]Faling Iyng run befr/into mov obj undet intent occ farm 
[X]Falily run befr/into mov obj undet intent oth spec place 
[X]Fali Iy run befr/into mov obj undet intent unspecif place 
188 
Appendix C - Publications arising from PhD 
studies 
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